<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?properties open_access?>
  <?properties manuscript?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">0413066</journal-id>
      <journal-id journal-id-type="pubmed-jr-id">2830</journal-id>
      <journal-id journal-id-type="nlm-ta">Cell</journal-id>
      <journal-id journal-id-type="iso-abbrev">Cell</journal-id>
      <journal-title-group>
        <journal-title>Cell</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0092-8674</issn>
      <issn pub-type="epub">1097-4172</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">37875108</article-id>
      <article-id pub-id-type="pmc">10841658</article-id>
      <article-id pub-id-type="doi">10.1016/j.cell.2023.09.024</article-id>
      <article-id pub-id-type="manuscript">NIHMS1935775</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Human MCTS1-dependent translation of JAK2 is essential for IFN-&#x3B3; immunity to mycobacteria</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Bohlen</surname>
            <given-names>Jonathan</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
          <xref rid="A3" ref-type="aff">3</xref>
          <xref rid="A4" ref-type="aff">4</xref>
          <xref rid="CR1" ref-type="corresp">@</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>Qinhua</given-names>
          </name>
          <xref rid="A5" ref-type="aff">5</xref>
          <xref rid="A6" ref-type="aff">6</xref>
          <xref rid="FN1" ref-type="author-notes">#</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Philippot</surname>
            <given-names>Quentin</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
          <xref rid="FN1" ref-type="author-notes">#</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ogishi</surname>
            <given-names>Masato</given-names>
          </name>
          <xref rid="A5" ref-type="aff">5</xref>
          <xref rid="FN1" ref-type="author-notes">#</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rinchai</surname>
            <given-names>Darawan</given-names>
          </name>
          <xref rid="A5" ref-type="aff">5</xref>
          <xref rid="FN1" ref-type="author-notes">&#xB0;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nieminen</surname>
            <given-names>Tea</given-names>
          </name>
          <xref rid="A7" ref-type="aff">7</xref>
          <xref rid="FN1" ref-type="author-notes">&#xB0;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Seyedpour</surname>
            <given-names>Simin</given-names>
          </name>
          <xref rid="A8" ref-type="aff">8</xref>
          <xref rid="A9" ref-type="aff">9</xref>
          <xref rid="FN1" ref-type="author-notes">&#xB0;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Parvaneh</surname>
            <given-names>Nima</given-names>
          </name>
          <xref rid="A8" ref-type="aff">8</xref>
          <xref rid="A10" ref-type="aff">10</xref>
          <xref rid="A11" ref-type="aff">11</xref>
          <xref rid="FN1" ref-type="author-notes">&#xB0;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rezaei</surname>
            <given-names>Nima</given-names>
          </name>
          <xref rid="A8" ref-type="aff">8</xref>
          <xref rid="A12" ref-type="aff">12</xref>
          <xref rid="FN1" ref-type="author-notes">&#xB0;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yazdanpanah</surname>
            <given-names>Niloufar</given-names>
          </name>
          <xref rid="A8" ref-type="aff">8</xref>
          <xref rid="A12" ref-type="aff">12</xref>
          <xref rid="FN1" ref-type="author-notes">&#xB0;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Momenilandi</surname>
            <given-names>Mana</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
          <xref rid="FN1" ref-type="author-notes">&#xB0;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Conil</surname>
            <given-names>Cl&#xE9;ment</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
          <xref rid="FN1" ref-type="author-notes">&#xB0;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Neehus</surname>
            <given-names>Anna-Lena</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
          <xref rid="FN1" ref-type="author-notes">&#xB0;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schmidt</surname>
            <given-names>Carltin</given-names>
          </name>
          <xref rid="A5" ref-type="aff">5</xref>
          <xref rid="A13" ref-type="aff">13</xref>
          <xref rid="FN1" ref-type="author-notes">&#xB0;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Franco</surname>
            <given-names>Carlos Andres Arango</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
          <xref rid="FN1" ref-type="author-notes">&#xB0;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Le Voyer</surname>
            <given-names>Tom</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Khan</surname>
            <given-names>Taushif</given-names>
          </name>
          <xref rid="A14" ref-type="aff">14</xref>
          <xref rid="A15" ref-type="aff">15</xref>
          <xref rid="A16" ref-type="aff">16</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yang</surname>
            <given-names>Rui</given-names>
          </name>
          <xref rid="A5" ref-type="aff">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Puchan</surname>
            <given-names>Julia</given-names>
          </name>
          <xref rid="A17" ref-type="aff">17</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Erazo</surname>
            <given-names>Lucia</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Roiuk</surname>
            <given-names>Mykola</given-names>
          </name>
          <xref rid="A3" ref-type="aff">3</xref>
          <xref rid="A4" ref-type="aff">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vatovec</surname>
            <given-names>Taja</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
          <xref rid="A4" ref-type="aff">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Janda</surname>
            <given-names>Zarah</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
          <xref rid="A4" ref-type="aff">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bagaric</surname>
            <given-names>Ivan</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
          <xref rid="A4" ref-type="aff">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Materna</surname>
            <given-names>Marie</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gervais</surname>
            <given-names>Adrian</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Hailun</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rosain</surname>
            <given-names>J&#xE9;r&#xE9;mie</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Peel</surname>
            <given-names>Jessica</given-names>
          </name>
          <xref rid="A5" ref-type="aff">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Seeleuthner</surname>
            <given-names>Yoann</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Han</surname>
            <given-names>Ji Eun</given-names>
          </name>
          <xref rid="A5" ref-type="aff">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>L&#x2019;Honneur</surname>
            <given-names>Anne-Sophie</given-names>
          </name>
          <xref rid="A18" ref-type="aff">18</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moncada-V&#xE9;lez</surname>
            <given-names>Marcela</given-names>
          </name>
          <xref rid="A5" ref-type="aff">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Martin-Fernandez</surname>
            <given-names>Marta</given-names>
          </name>
          <xref rid="A19" ref-type="aff">19</xref>
          <xref rid="A20" ref-type="aff">20</xref>
          <xref rid="A21" ref-type="aff">21</xref>
          <xref rid="A22" ref-type="aff">22</xref>
          <xref rid="A23" ref-type="aff">23</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Horesh</surname>
            <given-names>Michael Espino</given-names>
          </name>
          <xref rid="A19" ref-type="aff">19</xref>
          <xref rid="A20" ref-type="aff">20</xref>
          <xref rid="A21" ref-type="aff">21</xref>
          <xref rid="A22" ref-type="aff">22</xref>
          <xref rid="A23" ref-type="aff">23</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kochetkov</surname>
            <given-names>Tatiana</given-names>
          </name>
          <xref rid="A5" ref-type="aff">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schmidt</surname>
            <given-names>Monika</given-names>
          </name>
          <xref rid="A24" ref-type="aff">24</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>AlShehri</surname>
            <given-names>Mohammed A.</given-names>
          </name>
          <xref rid="A25" ref-type="aff">25</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Salo</surname>
            <given-names>Eeva</given-names>
          </name>
          <xref rid="A7" ref-type="aff">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Harri</surname>
            <given-names>Saxen</given-names>
          </name>
          <xref rid="A7" ref-type="aff">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>ElGhazali</surname>
            <given-names>Gehad</given-names>
          </name>
          <xref rid="A26" ref-type="aff">26</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yatim</surname>
            <given-names>Ahmad</given-names>
          </name>
          <xref rid="A5" ref-type="aff">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Soud&#xE9;e</surname>
            <given-names>Camille</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sallusto</surname>
            <given-names>Federica</given-names>
          </name>
          <xref rid="A17" ref-type="aff">17</xref>
          <xref rid="A27" ref-type="aff">27</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ensser</surname>
            <given-names>Armin</given-names>
          </name>
          <xref rid="A24" ref-type="aff">24</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Marr</surname>
            <given-names>Nico</given-names>
          </name>
          <xref rid="A14" ref-type="aff">14</xref>
          <xref rid="A15" ref-type="aff">15</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Peng</given-names>
          </name>
          <xref rid="A5" ref-type="aff">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bogunovic</surname>
            <given-names>Dusan</given-names>
          </name>
          <xref rid="A19" ref-type="aff">19</xref>
          <xref rid="A20" ref-type="aff">20</xref>
          <xref rid="A21" ref-type="aff">21</xref>
          <xref rid="A22" ref-type="aff">22</xref>
          <xref rid="A23" ref-type="aff">23</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cobat</surname>
            <given-names>Aur&#xE9;lie</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shahrooei</surname>
            <given-names>Mohammad</given-names>
          </name>
          <xref rid="A28" ref-type="aff">28</xref>
          <xref rid="A29" ref-type="aff">29</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>B&#xE9;ziat</surname>
            <given-names>Vivien</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
          <xref rid="A5" ref-type="aff">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Abel</surname>
            <given-names>Laurent</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
          <xref rid="A5" ref-type="aff">5</xref>
          <xref rid="FN1" ref-type="author-notes">&#xA7;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Xiaochuan</given-names>
          </name>
          <xref rid="A6" ref-type="aff">6</xref>
          <xref rid="FN1" ref-type="author-notes">&#xA7;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Boisson-Dupuis</surname>
            <given-names>St&#xE9;phanie</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
          <xref rid="A5" ref-type="aff">5</xref>
          <xref rid="FN1" ref-type="author-notes">&#xA7;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Teleman</surname>
            <given-names>Aurelio A.</given-names>
          </name>
          <xref rid="A3" ref-type="aff">3</xref>
          <xref rid="A4" ref-type="aff">4</xref>
          <xref rid="FN1" ref-type="author-notes">&#xA7;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bustamante</surname>
            <given-names>Jacinta</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
          <xref rid="A5" ref-type="aff">5</xref>
          <xref rid="A30" ref-type="aff">30</xref>
          <xref rid="FN1" ref-type="author-notes">*</xref>
          <xref rid="CR1" ref-type="corresp">@</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Qian</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
          <xref rid="A5" ref-type="aff">5</xref>
          <xref rid="FN1" ref-type="author-notes">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Casanova</surname>
            <given-names>Jean-Laurent</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
          <xref rid="A5" ref-type="aff">5</xref>
          <xref rid="A31" ref-type="aff">31</xref>
          <xref rid="A32" ref-type="aff">32</xref>
          <xref rid="FN1" ref-type="author-notes">*</xref>
          <xref rid="CR1" ref-type="corresp">@</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Laboratory of Human Genetics of Infectious Diseases, Necker Hospital for Sick Children, 75015 Paris, France</aff>
      <aff id="A2"><label>2</label>Paris Cit&#xE9; University, Imagine Institute, 75015 Paris, France</aff>
      <aff id="A3"><label>3</label>German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany</aff>
      <aff id="A4"><label>4</label>Heidelberg University, 69120 Heidelberg, Germany</aff>
      <aff id="A5"><label>5</label>St. Giles Laboratory of Human Genetics of Infectious Diseases, The Rockefeller University, 10065 NY, USA</aff>
      <aff id="A6"><label>6</label>Children&#x2019;s Hospital of Fudan University, 201102 Shanghai, China</aff>
      <aff id="A7"><label>7</label>New Children&#x2019;s Hospital, 00290 Helsinki, Finland</aff>
      <aff id="A8"><label>8</label>Research Center for Immunodeficiencies, University of Medical Sciences, P94V+8MF Tehran, Iran</aff>
      <aff id="A9"><label>9</label>Nanomedicine Research Association (NRA), P94V+8MF Tehran, Iran</aff>
      <aff id="A10"><label>10</label>Department of Pediatrics, Tehran University of Medical Sciences, P94V+8MF Tehran, Iran</aff>
      <aff id="A11"><label>11</label>Children&#x2019;s Medical Center, P94V+8MF Tehran, Iran</aff>
      <aff id="A12"><label>12</label>Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), P94V+8MF Tehran, Iran</aff>
      <aff id="A13"><label>13</label>Faculty of Medicine, Heinrich Heine University D&#xFC;sseldorf, 40225 D&#xFC;sseldorf, Germany</aff>
      <aff id="A14"><label>14</label>College of Health and Life Sciences, Hamad Bin Khalifa University, 8C8M+6Q Doha, Qatar</aff>
      <aff id="A15"><label>15</label>Department of Immunology, Sidra Medicine, 8C8M+6Q Doha, Qatar</aff>
      <aff id="A16"><label>16</label>The Jackson Laboratory, Farmington, CT-USA</aff>
      <aff id="A17"><label>17</label>Institute of Microbiology, ETH Z&#xFC;rich, 8049 Z&#xFC;rich, Switzerland</aff>
      <aff id="A18"><label>18</label>Department of Virology, Cochin Hospital, 75015 Paris, France, EU</aff>
      <aff id="A19"><label>19</label>Center for Inborn Errors of Immunity, Icahn School of Medicine at Mount Sinai, 10029 NY, USA</aff>
      <aff id="A20"><label>20</label>Precision Immunology Institute, Icahn School, 10029New York, NY, USA</aff>
      <aff id="A21"><label>21</label>Mindich Child Health and Development Institute, Icahn School, 10029 New York, NY, USA</aff>
      <aff id="A22"><label>22</label>Department of Pediatrics, Icahn School, 10029 New York, NY, USA</aff>
      <aff id="A23"><label>23</label>Department of Microbiology, Icahn School, 10029 New York, NY, USA</aff>
      <aff id="A24"><label>24</label>Institute of Clinical and Molecular Virology, Universit&#xE4;tsklinikum Erlangen, 91054 Erlangen, Germany</aff>
      <aff id="A25"><label>25</label>King Fahad Medical City, Children&#x2019;s Specialized Hospital, 12231 Riyadh, Saudi-Arabia</aff>
      <aff id="A26"><label>26</label>Sheikh Khalifa Medical City, Union71-Purehealth, United Arab Emirates University, Al Ain, United Arab Emirates</aff>
      <aff id="A27"><label>27</label>Institute for Research in Biomedicine, Universit&#xE0; della Svizzera Italiana, 6500 Bellinzona, Switzerland</aff>
      <aff id="A28"><label>28</label>Clinical and Diagnostic Immunology, KU Leuven, 3000 Leuven, Belgium</aff>
      <aff id="A29"><label>29</label>Dr. Shahrooei Laboratory, 22 Bahman St., Ashrafi Esfahani Blvd, Tehran, Iran</aff>
      <aff id="A30"><label>30</label>Study Center for Primary Immunodeficiencies, AP-HP, 75015 Paris, France</aff>
      <aff id="A31"><label>31</label>Howard Hughes Medical Institute, 10032 New York, NY, USA</aff>
      <aff id="A32"><label>32</label>Department of Pediatrics, Necker Hospital, 75015 Paris, France, EU</aff>
      <author-notes>
        <fn fn-type="equal" id="FN1">
          <label>#,&#xB0;,&#xA7;,*</label>
          <p id="P1">Equal contributions</p>
        </fn>
        <fn fn-type="con" id="FN2">
          <p id="P2">Author Contributions</p>
          <p id="P3">J.Bo., J.Bu., Q.Zha. and J.-L.C. conceived the study, designed the experiments, interpreted the data, and drafted the manuscript. J.Bo., Q.Zho., Q.Zha., C.C., Y.S., A.C., and L.A. analyzed WES data. J.Bo, Q.Zho., M.R. Q.P., J.R., M.O., A.-L.N., C.A.A.F., A.S.LH., L.E., J.E.H., C.Sc., C.So., T.L.-V., M.E., M.M., M.R., M.S., N.M., T.K., T.V., D.B., A.E., R.Y., A.Y., J.Pe., J.Pu., M.M.-V., M.M.-F., F.S., V.B., S.B-D., and Z.J., performed experiments and generated figures. S.S., E.S., M.A-S., G.E.G., N.Y., T.N., S.H., M.S., N.P., N.R., X.W., Q.Zha., and J.Bu. recruited patients and coordinated the clinical study protocol and sample collection. J.Bo., M.O., P.Z., and D.R. analyzed RNA-seq experiments. S.B.-D., A.T., J-.L.C., Q.Zha., and J.Bu. supervised experiments or analyses. All the authors discussed, revised, and approved the manuscript.</p>
        </fn>
        <corresp id="CR1"><label>@</label>Correspondence: <email>jonathan.bohlen@institutimagine.org</email> (lead author), correspondence can also be directed to <email>jacinta.bustamante@inserm.fr</email> or <email>casanova@rockefeller.edu</email></corresp>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
        <day>14</day>
        <month>10</month>
        <year>2023</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <day>09</day>
        <month>11</month>
        <year>2023</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>23</day>
        <month>10</month>
        <year>2023</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>05</day>
        <month>2</month>
        <year>2024</year>
      </pub-date>
      <volume>186</volume>
      <issue>23</issue>
      <fpage>5114</fpage>
      <lpage>5134.e27</lpage>
      <permissions>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
          <license-p>This work is licensed under a <uri xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International License</uri>, which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.</license-p>
        </license>
      </permissions>
      <abstract id="ABS1">
        <p id="P4">Human inherited disorders of IFN-&#x3B3; immunity underlie severe mycobacterial diseases. We report X-linked recessive MCTS1 deficiency in men with mycobacterial disease from kindreds of different ancestries (from China, Finland, Iran, and Saudi Arabia). Complete deficiency of this translation re-initiation factor impairs the translation of a subset of proteins, including the kinase JAK2 in all cell types tested, including T lymphocytes and phagocytes. JAK2 expression is sufficiently low to impair cellular responses to IL-23 and partially IL-12, but not other JAK2-dependent cytokines. Defective responses to IL-23 preferentially impair the production of IFN-&#x3B3; by innate-like adaptive MAIT and &#x3B3;&#x3B4; T lymphocytes upon mycobacterial challenge. Surprisingly, the lack of MCTS1-dependent translation re-initiation and ribosome recycling seems to be otherwise physiologically redundant in these patients. These findings suggest that X-linked recessive human MCTS1 deficiency underlies isolated mycobacterial disease by impairing JAK2 translation in innate-like adaptive T lymphocytes, thereby impairing the IL-23-dependent induction of IFN-&#x3B3;.</p>
      </abstract>
      <abstract id="ABS2" abstract-type="summary">
        <title>One-Sentence Summary:</title>
        <p id="P5">X-linked recessive human MCTS1 deficiency underlies mycobacterial disease by impairing JAK2 translation in innate-like T lymphocytes, thereby decreasing the IL-23-dependent production of IFN-&#x3B3; by these cells upon mycobacterial challenge.</p>
      </abstract>
      <abstract id="ABS3" abstract-type="graphical">
        <title>Graphical Abstract</title>
        <p id="P199">
<graphic xlink:href="nihms-1935775-f0008.jpg" position="anchor"/>
</p>
      </abstract>
      <kwd-group>
        <kwd>MCTS1</kwd>
        <kwd>translation reinitiation</kwd>
        <kwd>JAK2</kwd>
        <kwd>IL-23</kwd>
        <kwd>mycobacterium</kwd>
        <kwd>MSMD</kwd>
        <kwd>inborn error of immunity</kwd>
        <kwd>X-linked disease</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="S1">
      <title>Introduction</title>
      <p id="P6">The clinical outcome of any infection varies considerably between individuals, ranging from silent infection in most, to lethal disease in a few<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup>. Tuberculosis (TB), caused by <italic toggle="yes">Mycobacterium tuberculosis</italic>, has been a deadly infectious disease, with at least one billion deaths in the last 2,000 years<sup><xref rid="R3" ref-type="bibr">3</xref></sup>. However, infection with <italic toggle="yes">M. tuberculosis</italic> is silent or benign in &gt;90% of infected individuals<sup><xref rid="R3" ref-type="bibr">3</xref></sup>. Forward genetics studies of rare patients with clinical disease due to the weakly virulent Bacillus Calmette&#x2013;Gu&#xE9;rin (BCG) live-attenuated vaccine against TB, or atypical environmental mycobacteria (EM) led to the discovery of human genetic and immunological determinants of TB<sup><xref rid="R4" ref-type="bibr">4</xref>&#x2013;<xref rid="R8" ref-type="bibr">8</xref></sup>. Severe disease due to BCG or EM<sup><xref rid="R9" ref-type="bibr">9</xref></sup> in otherwise healthy individuals, particularly those without HIV infection or immunosuppression, is referred to as Mendelian susceptibility to mycobacterial disease (MSMD) because of the frequent occurrence of multiplex families and parental consanguinity<sup><xref rid="R10" ref-type="bibr">10</xref></sup>. MSMD is relatively rare, occurring in ~1 in 50,000 individuals<sup><xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R12" ref-type="bibr">12</xref></sup>, and is typically &#x2018;isolated&#x2019; (~75% of cases) or, rarely, &#x2018;syndromic&#x2019; (~25%)<sup><xref rid="R12" ref-type="bibr">12</xref>&#x2013;<xref rid="R14" ref-type="bibr">14</xref></sup>. Patients with isolated MSMD are otherwise healthy and normally resistant to most common microbes, except, occasionally, other intramacrophagic pathogens, including some bacteria (e.g. <italic toggle="yes">Salmonella</italic>), fungi (e.g. <italic toggle="yes">Coccidioidomyces</italic>), and parasites (e.g. <italic toggle="yes">Leishmania</italic>)<xref rid="R12" ref-type="bibr">12</xref>.</p>
      <p id="P7">Over the last 25 years, the discovery of inborn errors of interferon-gamma (IFN-&#x3B3;) immunity has defined the root cause and immunological mechanism of MSMD and TB<sup><xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R16" ref-type="bibr">16</xref></sup>. With one possible exception (ZNFX1 deficiency), all genetic defects underlying both isolated and syndromic MSMD perturb IFN-&#x3B3; immunity (germline mutations of genes encoding IFN-&#x3B3;R1, IFN-&#x3B3;R2, IFN-&#x3B3;, STAT1, IRF1, JAK1, IL-12R&#xDF;1, IL-12R&#xDF;2, IL-23R, IL-12p40, TYK2, SPPL2A, IRF8, NEMO, CYBB, ISG15, USP18, ROR&#x3B3;T, and T-bet)<sup><xref rid="R4" ref-type="bibr">4</xref>&#x2013;<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R17" ref-type="bibr">17</xref>&#x2013;<xref rid="R37" ref-type="bibr">37</xref></sup>. Many genetic defects directly impair the production of IFN-&#x3B3;, or the response to this cytokine (IFN-&#x3B3;R1, IFN-&#x3B3;R2, JAK1, STAT1, IRF1), whereas others affect the production of, or response to the IFN-&#x3B3;-inducing cytokines IL-12, IL-23, and ISG15 (IL-12R&#xDF;1, IL-12R&#xDF;2, IL-23R, IL-12p40, TYK2, ISG15). Deficiencies of the IL-12-specific IL-12R&#xDF;2<sup>30</sup> and IL-23-specific IL-23R<sup><xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R41" ref-type="bibr">41</xref>,<xref rid="R42" ref-type="bibr">42</xref></sup> also underlie MSMD, suggesting that neither of these two IFN-&#x3B3;-inducing cytokines is dispensable for antimycobacterial immunity.</p>
      <p id="P8">Human genetic studies of MSMD have, thus, revealed that IL-12- and IL-23-dependent IFN-&#x3B3; immunity is essential for host defense against weakly virulent mycobacteria. Upon infection with mycobacteria<sup><xref rid="R43" ref-type="bibr">43</xref></sup>, macrophages produce IL-12 and IL-23, which stimulate natural killer (NK) and T lymphocytes to produce IFN-&#x3B3;. Several lymphocyte subsets have been identified as critical producers of IFN-&#x3B3; and mediators of antimycobacterial immunity: patients with autosomal recessive (AR) SPPL2A or ROR&#x3B3;T deficiency, or with autosomal dominant (AD) IRF8 deficiency suffer from MSMD due to a lack of T-helper (T<sub>H</sub>) 1* cells<sup><xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R31" ref-type="bibr">31</xref></sup>, whereas AR T-bet deficiency impairs the development and IFN-&#x3B3; production of NK cells, innate-like adaptive lymphocyte subsets (mucosal-associated invariant T cells [MAIT], V&#x3B4;2<sup>+</sup> &#x3B3;&#x3B4; T, and invariant natural killer [iNKT] cells), and T<sub>H</sub>1 cells<sup><xref rid="R34" ref-type="bibr">34</xref></sup>. In IL-12R&#xDF;1-, IL-12R&#xDF;2-, and IL-23R-deficient patients, these subsets (NK, MAIT, V&#x3B4;2<sup>+</sup> &#x3B3;&#x3B4; T, iNKT, T<sub>H</sub>1 and T<sub>H</sub>1*) also fail to produce IFN-&#x3B3; in response to IL-12 and/or IL-23<sup><xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R42" ref-type="bibr">42</xref></sup>. IFN-&#x3B3; can stimulate most cell types, but is crucial for the killing of mycobacteria within phagocytes<sup><xref rid="R43" ref-type="bibr">43</xref>,<xref rid="R44" ref-type="bibr">44</xref></sup>, and it also boosts the production of IL-12 and IL-23 by these cells, forming a positive feedback loop<sup><xref rid="R45" ref-type="bibr">45</xref>&#x2013;<xref rid="R48" ref-type="bibr">48</xref></sup>.</p>
      <p id="P9">Molecular genetics studies of MSMD have revealed the mechanisms of antimycobacterial immunity in humans <italic toggle="yes">in natura</italic><sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R49" ref-type="bibr">49</xref>,<xref rid="R50" ref-type="bibr">50</xref></sup>, demonstrating that IFN-&#x3B3; acts as a key antimycobacterial cytokine rather than an antiviral interferon. Severe viral diseases are rare in patients with MSMD, occurring mostly in patients with syndromic MSMD who also have impaired IFN-&#x3B1;/&#x3B2; immunity (mutations of <italic toggle="yes">JAK1, STAT1</italic>, <italic toggle="yes">TYK2</italic>)<sup><xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R52" ref-type="bibr">52</xref></sup>. Moreover, the study of MSMD has led to the discovery of both rare and common determinants of clinical TB, which is caused by <italic toggle="yes">M. tuberculosis</italic>, a bacterium 1,000 times more virulent than those implicated in MSMD<sup><xref rid="R2" ref-type="bibr">2</xref></sup>. Most genetic etiologies of MSMD have incomplete penetrance for MSMD and can manifest as genetic etiologies of TB<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R35" ref-type="bibr">35</xref></sup>. Moreover, homozygosity for the common P1104A allele of TYK2 selectively impairs the IL-23-dependent induction of IFN-&#x3B3; and accounts for about 1% of cases of TB in patients of European descent<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R54" ref-type="bibr">54</xref></sup>. The study of MSMD has, therefore, had both biological and medical implications. However, a clear genetic etiology has yet to be found for about half the MSMD patients identified to date, implying that our understanding of antimycobacterial immunity is incomplete. In this context, we searched for new genetic causes and immunological mechanisms of MSMD.</p>
    </sec>
    <sec id="S2">
      <title>Results</title>
      <sec id="S3">
        <title>Hemizygosity for pLOF variants of MCTS1 in five unrelated men with MSMD</title>
        <p id="P10">We hypothesized that MSMD might be due to the X-linked recessive (XR) inheritance of a single genetic defect in at least some patients in a cohort of patients with unexplained MSMD, as men outnumber women in this cohort (422 men, 359 women). We used whole-exome sequencing (WES) to search for rare predicted loss-of-function (pLOF, meaning stop-gain, frameshift, essential splice-site and large insertion/deletion) variants present on the X chromosome. We identified five independent, private (detected only in these kindreds) pLOF variants of the <italic toggle="yes">MCTS1</italic> gene in male patients from five kindreds (<xref rid="F1" ref-type="fig">Figure 1A</xref>&#x2013;<xref rid="F1" ref-type="fig">B</xref>). Sanger sequencing confirmed the presence and familial segregation of these variants, consistent with the XR inheritance of MSMD (<xref rid="F1" ref-type="fig">Figure 1A</xref>, <xref rid="SD1" ref-type="supplementary-material">Figure S1A</xref>&#x2013;<xref rid="SD1" ref-type="supplementary-material">E</xref>). The enrichment of these <italic toggle="yes">MCTS1</italic> pLOF variants in our male MSMD cohort without genetic diagnosis (<italic toggle="yes">n</italic> = 422, 5 pLOF variants) relative to a cohort comprising both male patients without mycobacterial infections and healthy male individuals (<italic toggle="yes">n</italic> = 1,932, 0 pLOF variants) was highly significant (<italic toggle="yes">p</italic> = 0.00013). The five patients come from unrelated, non-consanguineous families (<xref rid="F1" ref-type="fig">Figure 1A</xref>, Case reports, <xref rid="SD12" ref-type="supplementary-material">Table S1</xref>). The patients are Chinese (P1), Finnish (P2), Saudi Arabian (P3), and Iranian (P4, P5) and are of East Asian, Finnish, Semitic, and Indo-European ancestries, respectively (<xref rid="SD1" ref-type="supplementary-material">Figure S1F</xref>). All patients were vaccinated with BCG within a day of birth (<xref rid="SD12" ref-type="supplementary-material">Table S1</xref>). The patients developed life-threatening BCG disease three months to one year after vaccination. Disease was multifocal or disseminated in several cases (P1-P3, P5), and involved osteomyelitis in P1 and P3. P1 died from BCG disease at the age of two years. The maternal uncle of P5 (P6) died at the age of two years from a condition consistent with MSMD (no genetic material available). P2, P3, P4, and P5 survived BCG infection and are now healthy at the ages of 18, 12, 6 and 3 years, respectively. There was no history of any other unusually severe infectious or non-infectious disease in these patients, suggesting a diagnosis of isolated MSMD. The brother of P5 (P7) was born in 2021, and was diagnosed as hemizygous for the familial <italic toggle="yes">MCTS1</italic> variant six days after birth; BCG vaccination was, thus, contraindicated, and he remains asymptomatic to date. Detailed clinical reports are provided in the methods section. These cases highlight the potential role of <italic toggle="yes">MCTS1</italic> variants in isolated MSMD.</p>
      </sec>
      <sec id="S4">
        <title>pLOF variants of MCTS1 and DENR are absent from the general population</title>
        <p id="P11">All five pLOF variants of the <italic toggle="yes">MCTS1</italic> gene identified in the five index patients are private, with combined annotation-dependent depletion (CADD) scores well above the mutation significance cutoff (MSC) for <italic toggle="yes">MCTS1</italic><sup><xref rid="R55" ref-type="bibr">55</xref>,<xref rid="R56" ref-type="bibr">56</xref></sup> (<xref rid="F1" ref-type="fig">Figure 1C</xref>), further suggesting that they are deleterious. No pLOF variant of <italic toggle="yes">MCTS1</italic> in the hemizygous, homozygous, or heterozygous state was reported in the gnomAD dataset (v2, 125,748 whole-exome and 15,708 whole-genome sequences). Ten missense variants of <italic toggle="yes">MCTS1 (ENST00000371317</italic>) in the hemizygous state are reported in gnomAD (<xref rid="F1" ref-type="fig">Figure 1C</xref>). A search of our in-house WES and WGS (whole-genome sequencing) datasets from more than 15,000 individuals with various infectious diseases revealed no additional hemizygous pLOF variants of <italic toggle="yes">MCTS1</italic>. The probability of <italic toggle="yes">MCTS1</italic> being loss-of-function-intolerant (pLI) was found to be 0.87, indicating that truncating variants are not tolerated in the general population. Density-regulated re-initiation and release factor (DENR) is the constitutive binding partner of MCTS1, and these two proteins are interdependent for ribosome recycling and re-initiation activity (<xref rid="F1" ref-type="fig">Figure 1D</xref>)<sup><xref rid="R58" ref-type="bibr">58</xref>,<xref rid="R59" ref-type="bibr">59</xref></sup>. DENR knockout (KO) and MCTS1 knockdown (KD) are lethal during the development of <italic toggle="yes">Drosophila melanogaster</italic> because they impair histoblast proliferation<sup><xref rid="R58" ref-type="bibr">58</xref></sup>. No studies of DENR<sup>KO</sup> mice or MCTS1<sup>KO</sup> animal models have yet been published, but International Mouse Phenotyping Consortium (IMPC) data suggest that DENR<sup>KO</sup> is embryonically lethal in mice, whereas MCTS1<sup>KO</sup> mice are viable and have no obvious phenotype<sup><xref rid="R60" ref-type="bibr">60</xref></sup> (the DENR and MCTS1 KO phenotypes are summarized in <xref rid="SD12" ref-type="supplementary-material">Table S2</xref>). DENR pLOF variants are very rare in gnomAD, with a cumulative allele frequency of 5.5*10<sup>&#x2212;5</sup> and no homozygous carriers detected. We found no individuals heterozygous or homozygous for pLOF variants of <italic toggle="yes">DENR</italic> in our own cohort of patients with various infectious diseases, including MSMD. Collectively, these data suggest that the hemizygous pLOF variants of <italic toggle="yes">MCTS1</italic> identified in these patients from five unrelated kindreds probably underlie their MSMD.</p>
      </sec>
      <sec id="S5">
        <title>The patients&#x2019; variants are loss-of-expression (LOE)</title>
        <p id="P12"><italic toggle="yes">MCTS1</italic> (ENSG00000232119, ENST00000371317.10) encodes malignant T cell-amplified sequence 1, a 181-amino acid polypeptide composed of a domain of unknown function (DUF1947) and an RNA-binding domain (PUA) (<xref rid="F1" ref-type="fig">Figure 1B</xref>). P1&#x2019;s variant (c.225_226insG) causes a frameshift resulting in a premature stop codon (p.P77Afs*22, <xref rid="F1" ref-type="fig">Figure 1B</xref>). P2&#x2019;s variant (c.213dupT) creates a premature stop codon (p.R72*). The variant found in P3 (c.164+1_164+4delGTAA) is predicted to disrupt the consensus sequence for the splicing donor site of <italic toggle="yes">MCTS1</italic> intron 2. Indeed, exon trapping in COS-7 cells and the sequencing of whole-blood RNA from P3 and his parents confirmed a severe impairment of splicing at this site, with no production of the canonical transcript in COS-7 cells (<xref rid="SD2" ref-type="supplementary-material">Figure S2A</xref>) and less than 3% of reads supporting normal splicing in P3&#x2019;s blood (<xref rid="SD2" ref-type="supplementary-material">Figure S2B</xref>, <xref rid="SD2" ref-type="supplementary-material">C</xref>). In more than 90% of splicing events, exon 2 is skipped, resulting in a truncated MCTS1 protein lacking the 51 amino acids encoded by exon 2 (p.K4_C55delinsN). The residual splicing events skip both exon 2 and exon 3 or retain intron 2, leading, in both cases, to a frameshift and the gain of a premature stop codon. Finally, the <italic toggle="yes">MCTS1</italic> alleles of P4, P5 and P7 present two different large deletions (4,128 and 5,619 nucleotides) affecting the two exons at the 3&#x2019;-end of <italic toggle="yes">MCTS1</italic> (P4: g.120610122_120614250del; P5 and P7:g.120610241_120615860delinsCAT) (<xref rid="SD2" ref-type="supplementary-material">Figure S2D</xref>). Both lead to predicted truncation of the MCTS1 protein (p.A133_K181del). We assessed protein production for the patients&#x2019; <italic toggle="yes">MCTS1</italic> variants. We transiently transfected MCTS1<sup>KO</sup> HeLa cells<sup><xref rid="R59" ref-type="bibr">59</xref></sup> with wildtype (WT) or variant <italic toggle="yes">MCTS1</italic> cDNA constructs and assessed MCTS1 protein levels by western blotting (<xref rid="F2" ref-type="fig">Figure 2A</xref>). None of the five <italic toggle="yes">MCTS1</italic> alleles found in MSMD patients drove the expression of a full-length or truncated MCTS1 proteins, whereas all the missense <italic toggle="yes">MCTS1</italic> variants found in gnomAD drove MCTS1 expression. We also observed a lack of MCTS1 production and low levels of DENR protein in the primary fibroblasts of P2 (<xref rid="F2" ref-type="fig">Figure 2B</xref>), T-cell blasts (T-blasts) from P2, P4, P5, and P7 (<xref rid="F2" ref-type="fig">Figure 2C</xref>), and primary neutrophils from P2 (<xref rid="F2" ref-type="fig">Figure 2D</xref>). The heterozygous female carriers tested &#x2014; the sister and mother of P2 &#x2014; and the wild-type father of P2, had normal levels of MCTS1 protein in primary neutrophils (<xref rid="F2" ref-type="fig">Figure 2D</xref>). Thus, none of the <italic toggle="yes">MCTS1</italic> variants encodes a detectable MCTS1 protein when overexpressed in recipient cells or in primary hemizygous cells.</p>
      </sec>
      <sec id="S6">
        <title>The patients&#x2019; variants are loss-of-function for translation re-initiation</title>
        <p id="P13"><italic toggle="yes">MCTS1</italic> and <italic toggle="yes">DENR</italic> are ubiquitously expressed in all cell types and tissues in humans<sup><xref rid="R61" ref-type="bibr">61</xref></sup>. Following the translation of an open-reading frame (ORF) by a ribosome, the DENR-MCTS1 complex removes the tRNA from the 40S ribosome on the stop codon, as a part of ribosome recycling (<xref rid="F1" ref-type="fig">Figure 1D</xref>). In eukaryotic cells, there are at least two types of ORFs: classical, protein-coding ORFs (main ORFs, mORF) and upstream ORFs (uORF), which are small coding sequences in the 5&#x2019;UTR of mRNAs. These uORFs occur in about half of all mammalian mRNAs and downregulate the translation of mORFs<sup><xref rid="R60" ref-type="bibr">60</xref></sup>. We hypothesized that XR MCTS1 deficiency might disturb ribosome recycling at two types of stop codons: classical mORF and 5&#x2019;UTR uORF stop codons. We first assessed MCTS1 function on uORF stop codons, for which MCTS1 promotes the re-initiation of translation<sup><xref rid="R58" ref-type="bibr">58</xref>,<xref rid="R59" ref-type="bibr">59</xref></sup>. In the absence of MCTS1 or DENR, 40S ribosomes stall on the uORF stop codon, because the deacylated tRNA cannot be removed<sup><xref rid="R59" ref-type="bibr">59</xref></sup>. This has a roadblock-like effect, leading to poor expression of the corresponding mORF of the mRNA, due to impaired translation re-initiation. We assessed the five <italic toggle="yes">MCTS1</italic> LOE mutations in a luciferase-based translation re-initiation assay (<xref rid="F2" ref-type="fig">Figure 2E</xref>). This assay uses a reporter plasmid with a short uORF in its 5&#x2019;UTR, rendering expression of the reporter gene dependent on the MCTS1-DENR complex<sup><xref rid="R58" ref-type="bibr">58</xref>,<xref rid="R59" ref-type="bibr">59</xref></sup>. The <italic toggle="yes">MCTS1</italic> variants found in MSMD patients were loss-of-function (LOF) for MCTS1 activity (<xref rid="F2" ref-type="fig">Figure 2F</xref>), like the synthetic A109D LOF mutation used as a negative control<sup><xref rid="R62" ref-type="bibr">62</xref></sup>. All 16 non-synonymous variants found in the general population were tested and found to have activity levels similar to those of the (WT) MCTS1 (isomorphic variants). <italic toggle="yes">MCTS2P</italic> is an <italic toggle="yes">MCTS1</italic> paralog and pseudogene located on a different chromosome (Chr. 20). The predicted protein sequence of MCTS2P is ~95% identical to that of MCTS1 (<xref rid="SD2" ref-type="supplementary-material">Figure S2E</xref>). In our functional assay, MCTS2P had detectable but weak activity with the DENR-MCTS1-dependent reporter (<xref rid="SD2" ref-type="supplementary-material">Figure S2I</xref>). However, queries against all the RNA-sequencing datasets produced in this manuscript showed that none of the total of 4.7 billion reads mapped uniquely to <italic toggle="yes">MCTS2P</italic>, whereas 403,296 reads mapped to <italic toggle="yes">MCTS1</italic> (<xref rid="SD2" ref-type="supplementary-material">Figure S2F</xref>&#x2013;<xref rid="SD2" ref-type="supplementary-material">H</xref>). Consistently, CAGE data from the FANTOM5 project suggest that the <italic toggle="yes">MCTS1</italic> promoter is much stronger (score 33.8) than the putative <italic toggle="yes">MCTS2P</italic> promoter (score 0.69)<sup><xref rid="R63" ref-type="bibr">63</xref>,<xref rid="R64" ref-type="bibr">64</xref></sup>. These data suggest that <italic toggle="yes">MCTS2P</italic> is a non-functional paralog of <italic toggle="yes">MCTS1</italic>, due to its lack of transcription. Collectively, these results suggest that the <italic toggle="yes">MCTS1</italic> variants found in the MSMD patients from the five unrelated kindreds abolish MCTS1 reinitiation activity, resulting in complete MCTS1 deficiency.</p>
      </sec>
      <sec id="S7">
        <title>Ribosomal recycling is impaired in the patients&#x2019; cells</title>
        <p id="P14">We hypothesized that cells lacking MCTS1 might display ribosome recycling defects. We tested this hypothesis by performing 40S and 80S ribosome footprinting (<xref rid="SD3" ref-type="supplementary-material">Figure S3A</xref>) on MCTS1<sup>KO</sup> and WT HeLa cells (<xref rid="SD3" ref-type="supplementary-material">Figure S3B</xref>&#x2013;<xref rid="SD3" ref-type="supplementary-material">D</xref>)<sup><xref rid="R59" ref-type="bibr">59</xref>,<xref rid="R65" ref-type="bibr">65</xref>,<xref rid="R66" ref-type="bibr">66</xref></sup>. This method reveals the position and number of 40S and 80S ribosomes on endogenous mRNAs<sup><xref rid="R65" ref-type="bibr">65</xref>,<xref rid="R66" ref-type="bibr">66</xref></sup>. We found that the frequency of stalled, post-termination 40S ribosomes was higher on mORF stop codons in MCTS1<sup>KO</sup> cells (<xref rid="F3" ref-type="fig">Figure 3A</xref>, indicated by arrow), as in DENR<sup>KO</sup> HeLa cells, although the 40S peak for MCTS1<sup>KO</sup> was smaller<sup><xref rid="R59" ref-type="bibr">59</xref></sup>. This finding is consistent with MCTS1 deficiency, as post-termination 40S ribosomes are the substrate of DENR-MCTS1. We observed 80S ribosome queueing in front of mORF stop codons (<xref rid="F3" ref-type="fig">Figure 3B</xref>, indicated by an arrow), due to the translating 80S ribosomes running into the roadblock caused by the stalled 40S ribosome on the stop codon, as described in DENR<sup>KO</sup> HeLa cells and yeast strains lacking DENR or MCTS1<sup><xref rid="R59" ref-type="bibr">59</xref>,<xref rid="R67" ref-type="bibr">67</xref></sup> MCTS1<sup>KO</sup> HeLa cells, thus, have impaired ribosome recycling. We investigated whether cells from MCTS1-deficient patients had the same molecular phenotype. We used the same 40S and 80S footprinting method on SV40-fibroblasts from P2 stably transduced with lentiviral empty vector (EV) or a lentiviral vector encoding wildtype (WT) MCTS1 (<xref rid="SD3" ref-type="supplementary-material">Figure S3E</xref>&#x2013;<xref rid="SD3" ref-type="supplementary-material">G</xref>). P2&#x2019;s SV40-fibroblasts had a pronounced peak of stalled post-termination 40S ribosomes on mORF (<xref rid="F3" ref-type="fig">Figure 3C</xref>) and uORF stop codons (<xref rid="SD3" ref-type="supplementary-material">Figure S3H</xref>), which was rescued by transduction with WT <italic toggle="yes">MCTS1</italic>. The queueing 80S ribosomes in front of the stop codon were, therefore, also rescued by MCTS1 expression in P2&#x2019;s cells (<xref rid="F3" ref-type="fig">Figure 3D</xref>). Furthermore, cells from P2 transduced with EV presented an accumulation of 40S ribosomes on mORF (<xref rid="F3" ref-type="fig">Figure 3E</xref>) and uORF (<xref rid="SD3" ref-type="supplementary-material">Figure S3I</xref>) stop codons in the presence of certain penultimate (position &#x2212;1 relative to the stop) codons, such as ATG<sup>Met</sup> and GCG<sup>Leu</sup>, another phenocopy of DENR<sup>KO</sup> HeLa cells (<xref rid="SD3" ref-type="supplementary-material">Figure S3J</xref>&#x2013;<xref rid="SD3" ref-type="supplementary-material">K</xref>). We have previously shown that this ribosome recycling defect does not negatively affect the translation of the proteins concerned<sup><xref rid="R59" ref-type="bibr">59</xref></sup>. The patients&#x2019; cells, thus, display impaired ribosome recycling due to their lack of MCTS1, attesting to a deficiency of the two known functions of MCTS1.</p>
      </sec>
      <sec id="S8">
        <title>The patients&#x2019; cells are defective for translation re-initiation</title>
        <p id="P15">Translation may be re-initiated in almost half of all human genes<sup><xref rid="R60" ref-type="bibr">60</xref></sup>. The MCTS1-DENR complex is specifically required for translation re-initiation following uORFs that are either very short<sup><xref rid="R58" ref-type="bibr">58</xref>,<xref rid="R62" ref-type="bibr">62</xref></sup> or terminate in certain penultimate codons<sup><xref rid="R59" ref-type="bibr">59</xref></sup> (~200 of 8,900 detected genes<sup><xref rid="R59" ref-type="bibr">59</xref></sup>). We identified the genes poorly translated in MCTS1-deficient cells by comparing the translation efficiency of all detected genes (<italic toggle="yes">n</italic> = 10,505) between P2 SV40-fibroblasts transduced with EV and with WT MCTS1 (<xref rid="F3" ref-type="fig">Figure 3F</xref>). Xtail<sup><xref rid="R68" ref-type="bibr">68</xref></sup> analysis identified 26 genes as having significantly higher levels of translation after MCTS1 rescue in P2&#x2019;s cells (<xref rid="F3" ref-type="fig">Figure 3F</xref>), with translation levels decreasing for only two genes following such rescue (<xref rid="SD9" ref-type="supplementary-material">Table S3</xref>). <italic toggle="yes">JAK2</italic> is the only target gene directly related to IFN-&#x3B3; immunity, as JAK2 is required for the IL-12- and IL-23-dependent induction of IFN-&#x3B3; and the response to IFN-&#x3B3;<sup><xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R70" ref-type="bibr">70</xref></sup>. Another affected gene important for cytokine signaling is <italic toggle="yes">IFNAR1</italic>, encoding a chain of the IFN-&#x3B1;/&#x3B2; receptor (<xref rid="F3" ref-type="fig">Figure 3F</xref>). Patients with germline mutations of <italic toggle="yes">IFNAR1</italic> and related genes suffer from viral, but not mycobacterial disease<sup><xref rid="R2" ref-type="bibr">2</xref></sup>. We investigated the translational targets of MCTS1 in a more relevant cell type, by performing 80S ribosome footprinting in primary T-cell blasts from four healthy male individuals and four MCTS1-deficient patients (P2, P4, P5 and P7). We again found that many more genes had lower levels of translation (143 genes) in the patients&#x2019; cells than had higher levels of translation (46 genes) (<xref rid="F3" ref-type="fig">Figure 3G</xref>). We observed a substantial and significant overlap (<italic toggle="yes">n</italic> = 98, <italic toggle="yes">p</italic> &lt; 10<sup>&#x2212;20</sup>) between the DENR-dependent genes identified in DENR<sup>KO</sup> HeLa cells (<italic toggle="yes">n</italic> = 275, p &lt; 0.1) and the MCTS1-dependent genes in identified in MCTS1-deficient T-cell blasts (<italic toggle="yes">n</italic> = 297, <italic toggle="yes">p</italic> &lt; 0.1) (<xref rid="SD3" ref-type="supplementary-material">Figure S3L</xref>, <xref rid="SD12" ref-type="supplementary-material">Table S4</xref>). The cells of MCTS1-deficient patients, like DENR<sup>KO</sup> cells, therefore have a genome-wide translation re-initiation defect. <italic toggle="yes">IFNAR1</italic> was also affected, as in SV40-fibroblasts (<xref rid="SD10" ref-type="supplementary-material">Table S5</xref>). JAK2 translation levels were less than half those in wild-type cells (<xref rid="F3" ref-type="fig">Figure 3G</xref>&#x2013;<xref rid="F3" ref-type="fig">H</xref>). We also assessed the translation efficiency of 25 genes related to IFN-&#x3B3; immunity, including 16 of the 20 genes underlying MSMD endogenously expressed in these T-cell blasts; we found that only <italic toggle="yes">JAK2</italic> and <italic toggle="yes">IRF8</italic> were substantially affected in the patients&#x2019; cells (<xref rid="SD3" ref-type="supplementary-material">Figure S3M</xref>). <italic toggle="yes">IRF8</italic> mRNA levels are upregulated in MCTS1-deficient patients (<xref rid="SD3" ref-type="supplementary-material">Figure S3N</xref>), potentially compensating for the lower efficiency of translation at mRNA level, whereas <italic toggle="yes">JAK2</italic> mRNA levels were unaffected. Altogether, the patients&#x2019; cells presented defective translation re-initiation, resulting in the impaired translation of a subset of mRNAs, including that encoding JAK2.</p>
      </sec>
      <sec id="S9">
        <title>MCTS1-dependent translation re-initiation is required for JAK2 expression</title>
        <p id="P16">We hypothesized that MCTS1 deficiency underlies MSMD by disrupting the translation of JAK2. We assessed the MCTS1-dependence of 17 genes underlying MSMD and other genes involved in IFN-&#x3B3; immunity, including JAK2, by performing 5&#x2019;UTR reporter assays in MCTS1<sup>KO</sup> HeLa cells (<xref rid="F4" ref-type="fig">Figure 4A</xref>). For many of these genes, we tested multiple alternative 5&#x2019;UTRs. A significant decrease, of more than 65%, was observed only for the JAK2 reporter, which was rescued by the re-expression of WT MCTS1 but not the patients&#x2019; variants or the synthetic LOF allele A109D (<xref rid="F4" ref-type="fig">Figure 4B</xref>). JAK2 reporter translation was also dependent on the presence of DENR (<xref rid="SD4" ref-type="supplementary-material">Figure S4A</xref>). We then investigated the molecular mechanism of the dependence of JAK2 translation on MCTS1. We identified three uORFs within the JAK2 5&#x2019;UTR, two of which were ultra-short Start-Stop &#x201C;stuORFs&#x201D; (<xref rid="F4" ref-type="fig">Figure 4C</xref>, Scheme of WT JAK2 5&#x2019;UTR). Mutation of the uORFs within the JAK2 5&#x2019;UTR revealed that the two stuORFs (uORFl and 2, but not uORF3) contributed to the MCTS1-dependence of this 5&#x2019;UTR (<xref rid="F4" ref-type="fig">Figure 4C</xref>). We also observed an accumulation of 40S ribosome footprints on both stuORFs in the endogenous JAK2 5&#x2019;UTR (<xref rid="F4" ref-type="fig">Figure 4D</xref>). We, thus, showed that the translation of JAK2, unlike that of 28 other genes related to IFN-&#x3B3; immunity, was MCTS1-dependent. We then hypothesized that MCTS1 deficiency might impair JAK2 expression in MCTS1<sup>KO</sup> cell lines and patients&#x2019; cells. CRISPR/Cas9-mediated knockout of MCTS1 in monocytic leukemia THP-1 cells caused a reproducible drop in endogenous JAK2 levels in five independent MCTS1<sup>KO</sup> clones (<xref rid="F5" ref-type="fig">Figure 5A</xref>, Antibody validation: <xref rid="SD4" ref-type="supplementary-material">Figure S4B</xref>). JAK2 production was also decreased, but not abolished, in P2&#x2019;s SV40-fibroblasts, and this defect was rescued by transduction with WT MCTS1, but not with the patients&#x2019; variants or A109D (<xref rid="F5" ref-type="fig">Figure 5B</xref>). Patient-derived T-saimiri virus-transformed T cells (HVS-T) and T-cell blasts had four-fold lower levels of JAK2 (<xref rid="F5" ref-type="fig">Figure 5C</xref>&#x2013;<xref rid="F5" ref-type="fig">D</xref>). The re-expression of MCTS1 by stable transduction rescued JAK2 levels both in patients&#x2019; T-cell blasts (<xref rid="SD4" ref-type="supplementary-material">Figure S4C</xref>) and in MCTS1<sup>KO</sup> THP-1 cells (<xref rid="SD4" ref-type="supplementary-material">Figure S4D</xref>). Thus, MCTS1 deficiency caused a three- to five-fold decrease in JAK2 protein levels in the three cell types tested (<xref rid="F5" ref-type="fig">Figure 5E</xref>).</p>
      </sec>
      <sec id="S10">
        <title>Normal presence and frequency of leukocyte subsets in MCTS1 patients</title>
        <p id="P17">JAK2 is one of four members of the Janus kinase family involved in JAK-STAT signaling in response to more than 50 cytokines<sup><xref rid="R71" ref-type="bibr">71</xref></sup>. No complete or partial genetic deficiency of human JAK2 has ever been reported and JAK2 knockout is embryonically lethal in mice<sup><xref rid="R70" ref-type="bibr">70</xref></sup>. Given the major hematological alterations observed in humans with JAK3<sup><xref rid="R72" ref-type="bibr">72</xref></sup> deficiency (underlying SCID) and JAK2<sup>KO</sup> mice, we hypothesized that impaired JAK2 expression in MCTS1-deficient patients would lead to abnormal myeloid or lymphoid development. However, MCTS1-deficient patients had normal complete blood count (CBC) profiles (<xref rid="SD12" ref-type="supplementary-material">Table S1</xref>). We also performed deep, mass cytometry-based immunophenotyping on four MCTS1-deficient patients (P2, P4, P5 and P7). We found that all the subsets detected (<xref rid="SD4" ref-type="supplementary-material">Figure S5A</xref>&#x2013;<xref rid="SD4" ref-type="supplementary-material">D</xref>), including IFN-&#x3B3;-producing lymphocyte subsets (<xref rid="SD4" ref-type="supplementary-material">Figure S5B</xref>) and IL-12- and IL-23-producing monocytes and dendritic cells (DCs) (<xref rid="SD4" ref-type="supplementary-material">Figure S5C</xref>), were present at counts and frequencies (data not shown) in the range of age-matched controls. This suggests that MSMD in MCTS1-deficient patients is not mediated by an absence or low frequency of any particular leukocyte cell subset, consistent with the clinical phenotype of isolated, as opposed to syndromic MSMD.</p>
      </sec>
      <sec id="S11">
        <title><italic toggle="yes">MCTS1 deficiency impairs IFN</italic>-&#x3B3; <italic toggle="yes">production upon BCG infection</italic> in vitro</title>
        <p id="P18">As one of the four JAK kinases, JAK2 mediates responses to three cytokines related to IFN-&#x3B3;-mediated immunity &#x2014; IL-12, IL-23, and IFN-&#x3B3; &#x2014; through its association with the IL-12R&#xDF;2, IL-23R, and IFN-&#x3B3;R2 receptor chains and the mediation of signal transduction after cytokine binding<sup><xref rid="R73" ref-type="bibr">73</xref>&#x2013;<xref rid="R75" ref-type="bibr">75</xref></sup>. The 20 known JAK2-dependent cytokines and the phenotypes of humans with genetic variants resulting in a deficiency of one of these cytokines or the corresponding receptor are listed in <xref rid="SD12" ref-type="supplementary-material">Table S6</xref>. We hypothesized that MCTS1 deficiency might impair IFN-&#x3B3; circuit activation (i.e. the relevant leukocyte function) in response to mycobacterial infection by decreasing JAK2 levels. We tested this hypothesis by infecting fresh whole-blood cells from healthy travel controls and MCTS1-deficient patients with BCG and measuring IFN-&#x3B3; production after 48 hours. Whole blood from patients P2 and P5 contained IFN-&#x3B3; levels 13-fold lower than those of healthy travel controls (<xref rid="SD4" ref-type="supplementary-material">Figure S5F</xref>). IFN-&#x3B3; production was only partially rescued by co-stimulating the patients&#x2019; cells with IL-12, suggesting that IL-12 is not the major contributor to this defect. The defect of IFN-&#x3B3; production following stimulation with BCG alone was as profound as that in TYK2- and IL-12R&#xDF;1-deficient patients (<xref rid="SD4" ref-type="supplementary-material">Figure S5F</xref>). In summary, leukocytes from MCTS1-deficient patients have a severely impaired response to BCG infection <italic toggle="yes">in vitro</italic> in terms of IFN-&#x3B3; production, despite their normal counts of cells from the lymphoid and myeloid subsets.</p>
      </sec>
      <sec id="S12">
        <title>Intact type I and type II interferon response pathways in MCTS1-deficient cells and blood from the patients</title>
        <p id="P19">Based on the defective response of the patients&#x2019; blood cells to BCG and the role of JAK2 in the response to IFN-&#x3B3;<sup><xref rid="R70" ref-type="bibr">70</xref></sup>, we hypothesized that the low JAK2 levels in the cells of MCTS1-deficient patients would impair their response to IFN-&#x3B3;. However, we found that this was not the case. MCTS1<sup>KO</sup> THP-1 cells responded normally to IFN-&#x3B3; stimulation, as measured by the induction of pSTAT1 (<xref rid="SD6" ref-type="supplementary-material">Figure S6A</xref>) and <italic toggle="yes">IRF1</italic> mRNA (<xref rid="SD6" ref-type="supplementary-material">Figure S6B</xref>, <xref rid="SD6" ref-type="supplementary-material">C</xref>). MCTS1<sup>KO</sup> THP-1 cells also displayed normal levels of STAT1 phosphorylation in response to IFN-&#x3B1; (<xref rid="SD6" ref-type="supplementary-material">Figure S6A</xref>). Transcriptome-wide pathway induction, detected by RNA-seq upon treatment with IFN-&#x3B1; and two doses of IFN-&#x3B3;, was also intact in MCTS1<sup>KO</sup> THP-1 cells (<xref rid="SD6" ref-type="supplementary-material">Figure S6D</xref>). The response to IFN-&#x3B3; was normal in terms of STAT1 phosphorylation, as shown by the western blot of SV40-fibroblasts from P2 (<xref rid="SD6" ref-type="supplementary-material">Figure S6E</xref>) as was the response to IFN-&#x3B1;, as shown by the induction of <italic toggle="yes">MX1</italic> mRNA (<xref rid="SD6" ref-type="supplementary-material">Figure S6F</xref>). We then investigated the response to IFNs in primary cells from the patients. We studied the response to IFN-&#x3B3; and IFN-&#x3B1;2 in monocyte-derived macrophages (MDMs), monocyte-derived dendritic cells (MDDCs), and monocyte-derived osteoclasts (MOCs) for P2. These cells responded normally to both IFNs, as shown by assessments of STAT1 phosphorylation (<xref rid="SD6" ref-type="supplementary-material">Figure S6G</xref>&#x2013;<xref rid="SD6" ref-type="supplementary-material">I</xref>). Moreover, MDMs from P2 had normal transcriptional responses, as shown by RNA-seq (<xref rid="SD6" ref-type="supplementary-material">Figure S6J</xref>). We also stimulated fresh blood from patients P4, P5, and four healthy controls with IFN-&#x3B3; and IFN-&#x3B1;, and used mass cytometry to assess the induction of STAT phosphorylation. The induction of STAT1, STAT3, and STAT5 phosphorylation was generally similar in patients and controls following treatment with IFN-&#x3B1; or IFN-&#x3B3;, in all peripheral leukocyte subsets studied (<xref rid="SD6" ref-type="supplementary-material">Figure S6K</xref>). Two conclusions can be drawn from these findings. First, the low levels of JAK2 observed in MCTS1-deficient cells are not sufficiently low to impair responses to IFN-&#x3B3;, either in MCTS1-deficient cell lines or in primary cells from patients. Second, even though <italic toggle="yes">IFNAR1</italic> is a reproducible MCTS1 target in both patient-derived SV40-fibroblasts and T-cell blasts (<xref rid="F3" ref-type="fig">Figure 3F</xref>, <xref rid="F3" ref-type="fig">G</xref>), the response to IFN-&#x3B1; is intact in MCTS1-deficient cell lines and primary cells from the patients. This finding is consistent with the absence of severe viral infections in the five MCTS1-deficient patients (Case Reports in Methods Section), despite exposure to common viruses, as attested by positive viral serology results for P2 and P5 (<xref rid="SD6" ref-type="supplementary-material">Figure S6L</xref>, <xref rid="SD6" ref-type="supplementary-material">M</xref>, <xref rid="SD12" ref-type="supplementary-material">Table S7</xref>). The patients&#x2019; cellular responses to IFN-&#x3B3; and IFN-&#x3B1; were intact.</p>
      </sec>
      <sec id="S13">
        <title>Defective IL-23 and intact IL-12 response pathways in MCTS1-deficient cells</title>
        <p id="P20">Given the intact cellular response to IFN-&#x3B3; in the patients, we hypothesized that cellular responses to IL-12 and IL-23, which are also mediated by JAK2<sup><xref rid="R73" ref-type="bibr">73</xref>&#x2013;<xref rid="R75" ref-type="bibr">75</xref></sup>, might be impaired in MCTS1-deficient patients. We used primary T-cell blasts from the patients to assess cellular responses to IL-12. These cells responded normally to IL-12 stimulation, as assessed by measuring the induction of pSTAT4 (<xref rid="SD7" ref-type="supplementary-material">Figure S7A</xref>). Patient-derived HSV-T cells also responded normally to IL-12 through the induction of <italic toggle="yes">IFNG</italic> mRNA (<xref rid="SD7" ref-type="supplementary-material">Figure S7B</xref>). Patient-derived or isogenic IL-23-sensitive cells are not available, because T-cell blasts and HSV-T cells do not display robustly detectable STAT3 phosphorylation upon IL-23 treatment in long-term culture (<xref rid="SD7" ref-type="supplementary-material">Figure S7C</xref>). We assessed the response to IL-23 and IL-12 in T-cell blasts by transcriptome profiling. T-cell blasts from nine healthy individuals, four MCTS1-deficient patients, two patients homozygous for the hypomorphic P1104A TYK2 allele that selectively impairs responses to IL-23<sup>18</sup>, and one patient each with autosomal recessive, complete TYK2, IL-12R&#xDF;1, and IRAK4 deficiencies were stimulated with IL-12, IL-23, IL-1&#xDF;, or IL-1&#xDF; plus IL-23 for 6 hours. We then performed RNA sequencing. We used IL-1&#xDF; as an IL-23-sensitizing agent, as previously described<sup><xref rid="R35" ref-type="bibr">35</xref>,<xref rid="R42" ref-type="bibr">42</xref></sup>. We found that MCTS1-deficient T-cell blasts responded normally to IL-12 and IL-1&#xDF;, but that their responses to IL-23 and to IL-23 plus IL-1&#xDF; were impaired (<xref rid="F5" ref-type="fig">Figure 5G</xref>, <xref rid="SD7" ref-type="supplementary-material">Figure S7D</xref>). As MDMs apparently also respond weakly to IL-23 (Sun and Abraham, 2020) by inducing the expression of antimicrobial genes (e.g. p40phox and NOS2), we stimulated MDMs from three healthy controls and P2 with IL-23 for 6 hours. The response of MDMs from P2 to IL-23 was weak compared to healthy controls, as shown by pathway enrichment analysis on RNA-seq data, whereas these cells responded normally to IFNs (<xref rid="SD6" ref-type="supplementary-material">Figure S6J</xref>). Thus, the response to IL-12 was intact, whereas the response to IL-23 was impaired in the cells of MCTS1-deficient patients.</p>
      </sec>
      <sec id="S14">
        <title>Impaired JAK2 expression in MCTS1-deficient cells impairs cellular responses to IL-23</title>
        <p id="P21">We then investigated whether the impaired response to IL-23 in MCTS1-deficient cells was due to low levels of JAK2 expression. We used a HEK-Blue IL-23 reporter cell line, in which the cells were stably transduced with IL-23R and a STAT3-dependent reporter gene. We produced polyclonal knockout lines for MCTS1 (MCTS1<sup>KO</sup>) or JAK2 (JAK2<sup>KO</sup>) by CRISPR/Cas9 gene editing (<xref rid="SD7" ref-type="supplementary-material">Figure S7E</xref>). The MCTS1<sup>KO</sup> HEK cells had ~50% the normal level of JAK2 protein (<xref rid="SD7" ref-type="supplementary-material">Figure S7F</xref>), a deficit smaller than that observed in the patients&#x2019; cells (<xref rid="F5" ref-type="fig">Figure 5E</xref>). As expected, JAK2<sup>KO</sup> HEK-blue cells had a strongly impaired response to IL-23 (<xref rid="SD7" ref-type="supplementary-material">Figure S7G</xref>). We also found that MCTS1<sup>KO</sup> cells had an impaired response to IL-23 at concentrations of both 1 ng/ml and 0.1 ng/ml (<xref rid="SD7" ref-type="supplementary-material">Figure S7G</xref>). We stably transduced these HEK-blue cells with a construct harboring an empty expression vector (EV) or a construct containing the MCTS1 coding sequence (M). MCTS1 overexpression rescued JAK2 expression in MCTS1<sup>KO</sup> cells but not in JAK2<sup>KO</sup> HEK-Blue cells (<xref rid="F5" ref-type="fig">Figure 5G</xref>). Importantly, MCTS1 overexpression also rescued the impaired response to IL-23 of MCTS1<sup>KO</sup> HEK-Blue cells, whereas it increased the response to IL-23 only slightly in the other three lines (<xref rid="F5" ref-type="fig">Figure 5H</xref>). These findings confirm that the impaired response to IL-23 is due to the lack of MCTS1. Finally, we stably transduced these four HEK-Blue lines with an empty expression vector (EV) or a construct encoding the JAK2 ORF (J2) under the control of an endogenous promoter for the production of moderate amounts of JAK2. This partially rescued JAK2 levels in MCTS1<sup>KO</sup> and JAK2<sup>KO</sup> HEK-Blue cells (<xref rid="F5" ref-type="fig">Figure 5I</xref>). Importantly, JAK2 overexpression rescued the response to IL-23 in MCTS1<sup>KO</sup> and JAK2<sup>KO</sup> HEK-Blue cells (<xref rid="F5" ref-type="fig">Figure 5J</xref>). These findings demonstrate that a lack of MCTS1 impairs cellular responses to IL-23 through decreases in JAK2 expression.</p>
      </sec>
      <sec id="S15">
        <title>Particular dependence of the IL-23 response pathway on JAK2</title>
        <p id="P22">We investigated the possibility of the IL-23 response pathway being particularly sensitive to decreases in JAK2 levels or activity. We transfected JAK2-deficient &#x3B3;2A-fibrosarcoma cells expressing IL-23R and IL-12R&#x3B2;1 with various amounts of JAK2-encoding constructs and assessed their response to IL-23. In this system, the levels of IL-23-dependent STAT3 phosphorylation were dependent on JAK2 levels (<xref rid="SD7" ref-type="supplementary-material">Figure S7H</xref>). Thus, low levels of JAK2 protein can impair cellular responses to IL-23. We then investigated the dependence of several cytokine response pathways on JAK2. We expanded primary sorted NK cells by culture with feeder PBMCs and IL-2. These cells had a high purity (&gt;95%, <xref rid="SD7" ref-type="supplementary-material">Figure S7I</xref>) and responded robustly to IL-23 plus IL-1&#x3B2;, or to IL-12, by secreting IFN-&#x3B3; (<xref rid="SD7" ref-type="supplementary-material">Figure S7J</xref>). We also isolated primary monocytes, which responded to stimulation with IFN-&#x3B1; and/or IFN-&#x3B3; by producing IP-10, IL-12p70 and/or TNF (<xref rid="SD7" ref-type="supplementary-material">Figure S7K</xref>&#x2013;<xref rid="SD7" ref-type="supplementary-material">M</xref>). The response to IL-23 or IL-12 is mediated by JAK2 and TYK2, whereas the response to IFN-&#x3B3; depends on JAK1 and JAK2 and the response to IFN-&#x3B1; depends on JAK1 and TYK2<sup><xref rid="R77" ref-type="bibr">77</xref></sup>. By contrast, the response to IL-1&#x3B2; is JAK2-independent, and even entirely independent of JAK proteins. We investigated the dependence of these cytokine response pathways on JAK2, using increasing concentrations of gandotinib, a JAK2-specific inhibitor (IC<sub>50</sub> for JAK2=3nM, JAK1=19.8nM, TYK2=44nM, JAK3=48nM)<sup><xref rid="R78" ref-type="bibr">78</xref></sup>. We found that the response of NK cells to IL-23 + IL-1&#x3B2; was much more sensitive to gandotinib than the response to IL-12 (<xref rid="F5" ref-type="fig">Figure 5K</xref>, <xref rid="SD7" ref-type="supplementary-material">Figure S7N</xref>). In monocytes, the responses to IFN-&#x3B1; and IFN-&#x3B3; were as sensitive or less sensitive to gandotinib than the response to IL-12 (<xref rid="F5" ref-type="fig">Figure 5K</xref>, <xref rid="SD7" ref-type="supplementary-material">Figure S7O</xref>,<xref rid="SD7" ref-type="supplementary-material">P</xref>,<xref rid="SD7" ref-type="supplementary-material">Q</xref>). Impaired or abolished cytokine responses can lead to higher cytokine concentrations in plasma, as observed in patients with IFN-&#x3B3; or GM-CSF receptor deficiencies<sup><xref rid="R79" ref-type="bibr">79</xref>&#x2013;<xref rid="R81" ref-type="bibr">81</xref></sup>. We hypothesized that impaired cytokine responses due to low JAK2 levels might increase cytokine concentrations in the plasma of MCTS1-deficient patients. We assessed the levels of 13 JAK2-dependent cytokines (<xref rid="SD12" ref-type="supplementary-material">Table S6</xref>) by bead-based ELISA. We found no detectable increase in plasma cytokine levels in the patients tested (<xref rid="SD7" ref-type="supplementary-material">Figure S7R</xref>). Finally, as another control, we tested the response to another JAK2-mediated cytokine, IL-27, in the patients&#x2019; T-cell blasts. We found a normal response to several concentrations of IL-27, in terms of STAT1 and STAT3 phosphorylation in T-cell blasts from patients, relative to healthy controls (<xref rid="SD7" ref-type="supplementary-material">Figure S7S</xref>,<xref rid="SD7" ref-type="supplementary-material">T</xref>). Thus, the biological response to IL-23 is tightly dependent on JAK2 levels, to a greater extent than responses to other JAK2-dependent cytokines, including IL-12, IL-27, and IFN-&#x3B3;. These findings are consistent with the clinical phenotype of MCTS1-deficient patients being restricted to MSMD (<xref rid="SD12" ref-type="supplementary-material">Table S6</xref>).</p>
      </sec>
      <sec id="S16">
        <title>Defective IL-23 response pathway in the PBMCs of patients with MCTS1 deficiency</title>
        <p id="P23">Having shown that responses to IL-23 were impaired in the patients&#x2019; T-cell blasts, we investigated the responses of peripheral blood mononuclear cells (PBMCs) from the patients. We stimulated fresh PBMCs with IL-12, IL-23, or phorbol 12-myristate 13-acetate (PMA) plus ionomycin for 48 hours and measured IFN-&#x3B3; levels in the medium. We found that levels of IFN-&#x3B3; production by PBMCs from MCTS1-deficient patients were 10-fold lower after IL-12 treatment and 23-fold lower after IL-23 treatment than those of controls (<xref rid="F6" ref-type="fig">Figure 6A</xref>), whereas IFN-&#x3B3; production was normal after stimulation with PMA plus ionomycin. No <italic toggle="yes">IFNG</italic> mRNA induction upon IL-23 stimulation was observed in the PBMCs of MCTS1-deficient patients, whereas a 33-fold induction was observed in controls (<xref rid="F6" ref-type="fig">Figure 6B</xref>), suggesting that this defect was not due to an impairment of <italic toggle="yes">IFNG</italic> mRNA translation. We also observed that the amounts of TNF produced in response to IL-23 stimulation were 23-fold lower in cells from patients than in those of controls (<xref rid="SD7" ref-type="supplementary-material">Figure S7U</xref>). For these samples, RNA sequencing revealed a significant induction of 291 genes upon stimulation with IL-23 in healthy controls, but no significant induction of any gene in MCTS-deficient patients (<xref rid="SD11" ref-type="supplementary-material">Table S8</xref>). An analysis of the correlation of the changes in expression of these 291 genes revealed a broadly impaired response to IL-23 in the PBMCs of MCTS1-deficient patients (<xref rid="F6" ref-type="fig">Figure 6C</xref>). Modular repertoire analysis revealed that genes related to innate inflammation (inflammation, cytokines, monocytes, neutrophils), plasma cells, interferon and oxidative stress were poorly induced in the patients&#x2019; cells (<xref rid="F6" ref-type="fig">Figure 6D</xref>), probably due to the combined low levels of stimulation of the IL-23 and IFN-&#x3B3; response pathways, the latter being due to impaired IFN-&#x3B3; production. Control cryopreserved PBMCs produced no detectable IFN-&#x3B3; upon IL-23 stimulation (<xref rid="F6" ref-type="fig">Figure 6E</xref>, condition 2) and required co-stimulation with IL-1&#xDF; to produce detectable amounts of IFN-&#x3B3; upon IL-23 stimulation (<xref rid="F6" ref-type="fig">Figure 6E</xref>, condition 4)<sup><xref rid="R35" ref-type="bibr">35</xref></sup>. Assessments of the response to IL-23 in the presence of IL-1&#xDF; also revealed a defect in cryopreserved PBMCs from MCTS1-deficient patients (<xref rid="F6" ref-type="fig">Figure 6E</xref>, condition 3 versus condition 4). Cellular responses to IL-12 and IL-12 plus IL-1&#x3B2; were also partially impaired in the patients (<xref rid="F6" ref-type="fig">Figure 6E</xref>, conditions 5 and 6). MCTS1-deficient PBMCs, thus, phenocopied PBMCs with <italic toggle="yes">TYK2</italic> mutations (<italic toggle="yes">TYK2</italic><sup>&#x2212;/&#x2212;</sup> and <italic toggle="yes">TYK2</italic> P1104A/P1104A) (<xref rid="F6" ref-type="fig">Figure 6E</xref>). The patients&#x2019; PBMCs responded poorly to IL-23, with such stimulation failing, in particular, to induce IFN-&#x3B3;.</p>
      </sec>
      <sec id="S17">
        <title>Impaired IFNG mRNA induction by IL-23 in V&#x3B4;2<sup>+</sup> &#x3B3;&#x3B4; T, MAIT and T<sub>H</sub>1* cells</title>
        <p id="P24">IFN-&#x3B3; is mostly produced by T and NK lymphocytes<sup><xref rid="R84" ref-type="bibr">84</xref></sup>. Upon IL-23 stimulation, innate NK cells and innate-like adaptive V&#x3B4;2<sup>+</sup> &#x3B3;&#x3B4; T and MAIT cells are particularly potent producers of IFN-&#x3B3;<sup><xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R42" ref-type="bibr">42</xref></sup>. We hypothesized that some of these lymphocyte subsets might display impaired IFN-&#x3B3; production in response to IL-23 stimulation in MCTS1-deficient patients. We tested this hypothesis, by stimulating cryopreserved PBMCs from seven healthy controls, four MCTS1-deficient patients, two IL-23R-deficient patients and one IL-12R&#x3B2;1-deficient patient with IL-23 for six hours and then performing single-cell RNA sequencing (scRNA-seq). This dataset incorporates several samples previously studied by Ogishi et al.<sup><xref rid="R35" ref-type="bibr">35</xref></sup> and Philippot et al.<sup><xref rid="R42" ref-type="bibr">42</xref></sup>. After batch correction with Harmony and graph-based unsupervised clustering (<xref rid="SD8" ref-type="supplementary-material">Figure S8A</xref>&#x2013;<xref rid="SD8" ref-type="supplementary-material">C</xref>), we were able to identify most PBMC leukocyte subsets (<xref rid="F7" ref-type="fig">Figure 7A</xref>, <xref rid="SD8" ref-type="supplementary-material">Figure S8D</xref>&#x2013;<xref rid="SD8" ref-type="supplementary-material">E</xref>). As previously reported, NK, V&#x3B4;2<sup>+</sup> &#x3B3;&#x3B4; T, and MAIT cells were the major subsets displaying <italic toggle="yes">IFNG</italic> induction upon IL-23 stimulation (<xref rid="SD8" ref-type="supplementary-material">Figure S8F</xref>). As reported for patients with IL-23R or IL-12&#xDF;R1 deficiency, MCTS1-deficient V&#x3B4;2<sup>+</sup> &#x3B3;&#x3B4; T and MAIT cells displayed impaired <italic toggle="yes">IFNG</italic> induction following IL-23 stimulation relative to healthy controls (<xref rid="F7" ref-type="fig">Figure 7B</xref>, <xref rid="SD8" ref-type="supplementary-material">Figure S8G</xref>). The induction of <italic toggle="yes">IFNG</italic> expression was also impaired in purely adaptive Th1* cells, which normally produce less IFN-&#x3B3; in response to IL-23 than innate-like T cells<sup><xref rid="R42" ref-type="bibr">42</xref></sup>. By contrast to IL-23R and IL-12R&#x3B2;1 deficiencies, the induction of <italic toggle="yes">IFNG</italic> by NK cells was moderately impaired in MCTS1-deficient patients (<xref rid="F7" ref-type="fig">Figure 7B</xref>, <xref rid="SD8" ref-type="supplementary-material">Figure S8G</xref>). We also observed a broadly impaired transcriptional response to IL-23 stimulation in MCTS1-deficient PBMCs, resembling that seen in IL-12R&#x3B2;1- and IL-23R-deficient PBMCs (<xref rid="F7" ref-type="fig">Figure 7C</xref>). This global transcriptional response probably represents a combination of the cellular responses to IL-23 and to the IFN-&#x3B3; secreted in response to IL-23, as observed for example in monocytes following the stimulation of MCTS1-deficient PBMCs with IL-23 (<xref rid="F7" ref-type="fig">Figure 7D</xref>). Overall, the response to IL-23 is impaired in the V&#x3B4;2<sup>+</sup> &#x3B3;&#x3B4; T, MAIT, and T<sub>H</sub>1* cells of MCTS1-deficient patients, leading to an impairment of <italic toggle="yes">IFNG</italic> mRNA induction by these cells in response to stimulation with IL-23.</p>
      </sec>
      <sec id="S18">
        <title>Impaired induction of IFN-&#x3B3; secretion by IL-23 in V&#x3B4;2<sup>+</sup> &#x3B3;&#x3B4; T and MAIT cells</title>
        <p id="P25">We then investigated the possibility that the impaired response to IL-23 in V&#x3B4;2<sup>+</sup> &#x3B3;&#x3B4; T and MAIT cells might impair the response of these cells to mycobacterial infection. We treated cryopreserved PBMCs with various stimuli, including the two cytokines (IL-12, IL-23), BCG, alone or with either or both cytokines, for 48 hours and assessed the amount of IFN-&#x3B3; generated by these lymphocyte subsets by intracellular staining and flow cytometry. Consistent with our previous results, we found that IFN-&#x3B3; production by V&#x3B4;2<sup>+</sup> &#x3B3;&#x3B4; T and MAIT cells upon stimulation with IL-23, BCG, or IL-23 plus BCG, was defective relative to that in healthy controls (<xref rid="F7" ref-type="fig">Figure 7E</xref>&#x2013;<xref rid="F7" ref-type="fig">F</xref>). Interestingly, IFN-&#x3B3; production was impaired only very mildly, if at all, in NK cells (<xref rid="F7" ref-type="fig">Figure 7G</xref>). We investigated whether V&#x3B4;2<sup>+</sup> &#x3B3;&#x3B4; T and MAIT cells had a stronger defect of JAK2 expression than other T cells. We generated T-cell blasts from sorted CD4<sup>+</sup>, V&#x3B4;2<sup>+</sup> &#x3B3;&#x3B4; T, or MAIT cells (<xref rid="SD8" ref-type="supplementary-material">Figure S8H</xref>) and measured their JAK2 levels by western blotting. All T-cell blasts had low levels of JAK2 (<xref rid="SD8" ref-type="supplementary-material">Figure S8I</xref>), but the defect was not stronger in V&#x3B4;2<sup>+</sup> &#x3B3;&#x3B4; T-cell and MAIT blasts. Nevertheless, P2&#x2019;s primary T-cell blasts displayed a stronger mean decrease in JAK2 expression than the primary myeloid cells of P2 (particularly MDMs and MOCs) (<xref rid="SD8" ref-type="supplementary-material">Figure S8J</xref>). This suggests that the specific impairment of the IL-23 response pathway and the partial impairment of the IL-12 response pathway in MCTS1-deficient patients could be explained in part by stronger JAK2 depletion in T lymphocytes than in myeloid cells. In summary, JAK2 expression and IL-23-dependent IFN-&#x3B3; production are impaired in the V&#x3B4;2<sup>+</sup> &#x3B3;&#x3B4; T and MAIT cells of MCTS1-deficient patients.</p>
      </sec>
    </sec>
    <sec id="S19">
      <title>Discussion</title>
      <p id="P26">We describe a surprising, new genetic etiology of MSMD: XR MCTS1 deficiency in six male individuals from five unrelated kindreds and four distant ancestries. Complete MCTS1 deficiency impairs ribosome recycling and translation reinitiation in the patients&#x2019; cells. JAK2 is one of about 150 human genes subject to MCTS1-mediated translation re-initiation. JAK2 protein levels in MCTS1-deficient myeloid and lymphoid cells are about three- to four-fold lower than those in control cells, with a greater decrease in levels observed in lymphoid than in myeloid cells. Responses to IFN-&#x3B3; and IL-12, both of which normally require JAK2, were normal in these cells. By contrast, the response to IL-23 was impaired in the patients&#x2019; T-cell blasts and MCTS1 KO HEK Blue cells, which was rescued by exogenous expression of MCTS1 or JAK2. The patients MAIT and V&#x3B4;2<sup>+</sup> &#x3B3;&#x3B4; T-lymphocyte subsets produce only small amounts of IFN-&#x3B3; in response to IL-23 and BCG. We show here that decreases in JAK2 levels or activity impair IL-23-dependent IFN-&#x3B3; production by lymphocytes, providing a molecular and cellular basis for disease, and mechanistically and causally connecting the <italic toggle="yes">MCTS1</italic> genotype and the MSMD phenotype. Remarkably, an unbiased genome-wide forward genetics approach revealed an unexpected MSMD phenotype in patients with human MCTS1 deficiency.</p>
      <p id="P27">Our finding is unexpected because MCTS1 is ubiquitously expressed and has a fundamental molecular function in the dissociation of deacylated tRNAs from post-termination 40S ribosomal complexes during ribosome recycling (on mORF stop codons) and re-initiation (on uORF stop codons). The translation re-initiation functions of DENR and MCTS1 are essentially identical in amplitude <sup><xref rid="R58" ref-type="bibr">58</xref>,<xref rid="R59" ref-type="bibr">59</xref>,<xref rid="R62" ref-type="bibr">62</xref></sup>. However, DENR<sup>KO</sup> is embryonically lethal in mice, whereas MCTS1<sup>KO</sup> mice are viable <sup><xref rid="R60" ref-type="bibr">60</xref></sup>. This is consistent with the more severe ribosome recycling defect of DENR<sup>KO</sup> HeLa cells than of MCTS1<sup>KO</sup> HeLa cells. Furthermore, we found no MSMD patient homozygous for rare candidate DENR variants. The apparent lack or extreme rarity of DENR-deficient patients suggests that this deficiency may be embryonically lethal in humans, as it is in mice. This contrasts with our findings that all five patients with MCTS1 deficiency have isolated MSMD and are otherwise healthy at ages of six months to 18 years. However, only one MCTS1-deficient patient has yet reached adulthood, and other clinical phenotypes may appear as the patients age.</p>
      <p id="P28">We define the set of human MCTS1-dependent genes in cells from MCTS1-deficient patients. We identify JAK2 as a translational target of DENR-MCTS1 and probably the key contributor to MSMD. Decreases in the levels of other MCTS1-dependent proteins do not appear to have clinical consequences. Surprisingly, partial JAK2 deficiency impairs cellular responses to IL-23 and the subsequent induction of IFN-&#x3B3; in lymphocytes, but not other cytokine response pathways involving JAK2. DENR<sup>KO</sup> has been reported to impair JAK2 translation and subsequent responses to IFN-&#x3B3; in mouse tumor cells<sup><xref rid="R85" ref-type="bibr">85</xref></sup>. Responses to IL-12 and IL-23 were not tested in this previous study. We found the same connection between MCTS1 and JAK2 in human cells, but the response to IFN-&#x3B3; was intact. Low levels of JAK2 may have a much greater effect in IL-23- and IL-12-responsive cells than in IFN-&#x3B3;-responsive cells. It is probably no coincidence that the four types of MSMD-causing <italic toggle="yes">TYK2</italic> variants, including the common P1104A variant, have an impact on the IL-23 response pathway, whereas only two of these types of variants also impair responses to IL-12<sup>35</sup>. This finding suggests that the IL-23R is more dependent on qualitative and quantitative variations of JAK2 or TYK2 than the IL-12R. Biochemical differences may be responsible for the weaker IL-23R signaling observed.</p>
      <p id="P29">Our findings support our previous reports that human IL-23 is a key IFN-&#x3B3;-inducing cytokine<sup><xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R42" ref-type="bibr">42</xref>,<xref rid="R73" ref-type="bibr">73</xref></sup>. Despite having the p40 chain in common, IL-23 has historically been seen as an IL-17-inducing cytokine<sup><xref rid="R73" ref-type="bibr">73</xref>,<xref rid="R88" ref-type="bibr">88</xref>&#x2013;<xref rid="R91" ref-type="bibr">91</xref></sup>, whereas IL-12 is seen as the key IFN-&#x3B3;-inducing cytokine<sup><xref rid="R73" ref-type="bibr">73</xref>,<xref rid="R91" ref-type="bibr">91</xref></sup>. Recent discoveries have suggested that human IL-23 plays a key role in IFN-&#x3B3;-mediated immunity to mycobacteria, and a more minor role in IL-17-mediated immunity to fungi. First, AR complete IL-23R deficiency underlies MSMD with almost complete clinical penetrance but only a mild form of CMC with incomplete penetrance<sup><xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R42" ref-type="bibr">42</xref></sup>. Second, homozygosity for the common TYK2 P1104A allele selectively impairs responses to IL-23 and underlies MSMD with low penetrance and tuberculosis with high penetrance, but has no effect on susceptibility to CMC<sup><xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R54" ref-type="bibr">54</xref></sup>. Third, impairment of the cellular response to IL-23 is the only mechanism underlying mycobacterial disease common to patients with the five forms of AR TYK2 deficiency<sup><xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R60" ref-type="bibr">60</xref></sup>. Fourth, MCTS1-deficient patients have impaired cellular responses to IL-23 and isolated MSMD, with no detectable IL-17 deficiency or CMC. Collectively, these observations suggest that human IL-23 acts more as an IFN&#x3B3;-inducing antimycobacterial cytokine than as an IL-17-inducing antifungal cytokine.</p>
      <p id="P30">We found that IFN-&#x3B3; induction in response to IL-23 stimulation was impaired in the V&#x3B4;2<sup>+</sup> &#x3B3;&#x3B4; T and MAIT cells of MCTS1-deficient patients. This finding is consistent with previous reports, as V&#x3B4;2<sup>+</sup> &#x3B3;&#x3B4; T and MAIT cells are among the subsets producing the largest amounts of IFN-&#x3B3; in response to IL-23<sup><xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R42" ref-type="bibr">42</xref></sup>. Furthermore, the IFN-&#x3B3; production of these cells in response to IL-23 is impaired in IL-12R&#x3B2;1<sup>&#x2212;/&#x2212;</sup>, IL-23R<sup>&#x2212;/&#x2212;</sup> and TYK2<sup>&#x2212;/&#x2212;</sup> individuals<sup><xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R42" ref-type="bibr">42</xref>,<xref rid="R60" ref-type="bibr">60</xref></sup>. NK cells are also potent inducers of IFN-&#x3B3; upon stimulation with IL-23, but their transcriptional response to IL-23 is only moderately impaired in MCTS1-deficient patients. Interestingly, the induction of IFN-&#x3B3; was also impaired in the patients&#x2019; T<sc>h</sc>1* cells. T<sc>h</sc>1* cells have a lower level of IFN-&#x3B3; induction than MAIT, V&#x3B4;2<sup>+</sup> &#x3B3;&#x3B4; T and NK cells. Nonetheless, T<sc>h</sc>1* cells display more than an eight-fold induction of IFN-&#x3B3; in response to IL-23 (<xref rid="SD8" ref-type="supplementary-material">Figure S8F</xref>), this induction being totally abolished in MCTS1-, IL-12R&#x3B2;1-, and IL-23R-deficient patients. T<sc>h</sc>1* cells are the major lymphocyte subset producing IFN-&#x3B3; after exposure to BCG <italic toggle="yes">in vitro</italic><sup><xref rid="R92" ref-type="bibr">92</xref>,<xref rid="R93" ref-type="bibr">93</xref></sup>. The counts of these cells in the blood increase in individuals with latent tuberculosis infection<sup><xref rid="R94" ref-type="bibr">94</xref></sup>. IL-23 may, thus, also contribute to T<sc>h</sc>1*-mediated immunity to mycobacteria.</p>
      <p id="P31">Finally, we can speculate about the clinical phenotype of MCTS1-deficient patients in the absence of BCG vaccination. Surprisingly, none of the six MCTS1-deficient individuals had EM disease. This may be due to the protection afforded by BCG disease, as seen in IL-12R&#xDF;1-deficient patients<sup><xref rid="R38" ref-type="bibr">38</xref>,<xref rid="R39" ref-type="bibr">39</xref></sup>. It may also reflect an incomplete IFN-&#x3B3; deficit, as only one of the seven reported IL-23R-deficient patients suffered from EM disease<sup><xref rid="R41" ref-type="bibr">41</xref>,<xref rid="R42" ref-type="bibr">42</xref></sup> and cellular responses to IL-23 are impaired, but not abolished in MCTS1-deficient patients. In regions of endemic tuberculosis, in which BCG vaccination is not widely or efficiently performed, or if penetrance for BCG disease is incomplete, MCTS1 deficiency may be revealed by severe tuberculosis. Overall, this study reveals a surprising mechanistic connection between deficiency of a basic, ubiquitous, biochemical mechanism and a selective predisposition to mycobacterial disease.</p>
      <sec id="S20">
        <title>Limitations of the study</title>
        <p id="P32">The five unrelated patients studied are all relatively young, between 1 and 18 years of age. We cannot therefore rule out the possibility of hitherto undetected clinical phenotypes other than MSMD arising as the patients age. We demonstrated that there is an impaired response to IL-23 in MCTS1<sup>KO</sup> HEK-Blue cells and that this can be rescued by JAK2 overexpression. This suggests that the impaired IL-23 response in MCTS1 deficient patients is solely due to reduced levels of JAK2 expression. Yet, we have not, for technical limitations, carried out this rescue experiment in PBMCs of the patients and can therefore not completely rule out the possibility that other MCTS1 targets contribute to the phenotype <italic toggle="yes">in vivo</italic>.</p>
      </sec>
    </sec>
    <sec id="S21">
      <title>STAR METHODS</title>
      <sec id="S22">
        <title>RESOURCE AVAILABILITY</title>
        <sec id="S23">
          <title>Lead contact</title>
          <p id="P42">Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Jonathan Bohlen (<email>jonathan.bohlen@institutimagine.org</email>).</p>
        </sec>
        <sec id="S24">
          <title>Materials availability</title>
          <p id="P43">All raw and processed data and biological materials, including immortalized cell lines from patients, are available upon request from the <underline>lead contact</underline> under a Material/Data Transfer Agreement with Inserm or the Rockefeller University.</p>
        </sec>
        <sec sec-type="data-availability" id="S25">
          <title>Data and Code Availability</title>
          <p id="P44">The RNA-seq, single-cell RNA-seq, and CITE-seq data have been deposited at SRA and are available at project ID PRJNA1004232. Custom software is available from GitHub: <ext-link xlink:href="https://github.com/aurelioteleman/Teleman-Lab" ext-link-type="uri">https://github.com/aurelioteleman/Teleman-Lab</ext-link>. The original western-blot images, flow cytometry data, mass spectrometry data, and microscopy data reported in this paper will be shared by the lead contact upon request.</p>
          <p id="P45">Any additional information required to reanalyze the data reported in this paper can be obtained from the lead contact upon request.</p>
          <p id="P46">This paper does not report original code.</p>
        </sec>
      </sec>
      <sec id="S26">
        <title>EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS</title>
        <p id="P47">The age, sex, ancestry and race of the studied patients is reported in the main text of the paper and in the method details below. Information on gender and socioeconomic status of the patients was not collected. All patients are male because we study an X-linked recessive genetic disease. Informed consent was obtained in the countries of residence of the patients, in accordance with local regulations (kindred A in China, kindred B in Finland, kindred C in Saudi Arabia and kindreds D and E in Iran) and with institutional review board (IRB) approval. Experiments were conducted in France, Germany, Qatar, and the United States of America, in accordance with local regulations and with the approval of the IRB of the Rockefeller University (protocol no. JCA-0699) and INSERM (protocol no. C10-07 and C10-16) and by the Institutional Research Ethics Boards of Sidra Medicine and Qatar Biobank, for the United States of America, France and Qatar, respectively. Healthy controls were recruited in Finland, France, Iran, Saudi Arabia, and the United States of America.</p>
      </sec>
      <sec id="S27">
        <title>METHODS DETAILS</title>
        <sec id="S28">
          <title>Human patients</title>
          <p id="P48">Informed consent was obtained in the countries of residence of the patients, in accordance with local regulations (kindred A in China, kindred B in Finland, kindred C in Saudi Arabia and kindreds D and E in Iran) and with institutional review board (IRB) approval. A detailed questionnaire was completed by the physicians caring for the patients, including demographic data, clinical features, and biological and microbiological results, and the data were sent to J.Bo., Q.Zha. and J.Bu. A detailed clinical case report is provided below.</p>
        </sec>
        <sec id="S29">
          <title>Case reports</title>
          <sec id="S30">
            <title>Kindred A, P1.</title>
            <p id="P49">P1 was the third child of nonconsanguineous parents of Chinese origin, with two healthy older sisters (<xref rid="SD12" ref-type="supplementary-material">Table S1</xref>, <xref rid="F1" ref-type="fig">Figure 1A</xref>). He was born at full term in 2017, with no perinatal complications. He received the BCG vaccine (Danish strain) on the day after delivery. He was well until seven months of age, when an enlarged left axillary lymph node that was erythematous and tender was detected. Surgical incision and drainage were performed, but the local lesions relapsed. The lymph node under the mandibular region was also found to be enlarged. At the age of 14 months, P1 had recurrent fever associated with hepatosplenomegaly, chest wall abscess and osteomyelitis with multiple bone lesions. A computerized tomography (CT) scan showed an enlarged lymph node under the left armpit, with necrosis, multiple sublobe atelectasis in the left lung, multiple abscesses in the spleen, lesions in the ribs on both sides of the body, multiple vertebrae, and the right ilium. Hepatosplenomegaly was confirmed by CT-scan. Acid-fast bacilli (AFB) were detected in the abscess and disseminated mycobacterial infection (BCG-osis) was diagnosed. The whole metagenome of the abscess was shotgun-sequenced, and <italic toggle="yes">Mycobacterium bovis</italic> BCG was detected. Antimycobacterial treatment was implemented, based on isoniazid (INH), rifampin (RIF), ethambutol (EMB), amikacin, and linezolid; subcutaneous treatment with recombinant IFN-&#x3B3; was also initiated. However, the patient&#x2019;s medical condition deteriorated, and the patient died in 2019.</p>
          </sec>
          <sec id="S31">
            <title>Kindred B, P2.</title>
            <p id="P50">P2 is a boy originating from and living in Finland (<xref rid="SD12" ref-type="supplementary-material">Table S1</xref>, <xref rid="F1" ref-type="fig">Figure 1A</xref>). He was born in 2003 and received the BCG vaccine (Danish strain) at birth. Three months later, he developed BCG-itis consisting of an enlarged lymph node in the left groin. On ultrasound examination, intra-abdominal lymph nodes were detected, with para-iliac and para-aortic extension. One lymph node was excised and cultured, yielding <italic toggle="yes">M. bovis</italic> BCG. P2 progressively developed a high fever, tiredness and poor appetite, and a diagnosis of disseminated BCG-osis was established. Treatment with INH, RIF, EMB, ciprofloxacin, amikacin and IFN-&#x3B3; was initiated and the patient recovered well. Treatment with four antimycobacterial drugs (excluding amikacin) and IFN-&#x3B3; was continued for one year, and drug treatment was then gradually stopped. When P2 was two years and nine months old and on RIF/INH, the symptoms recurred, a severe relapse was diagnosed and treatment with five drugs plus IFN-&#x3B3; was reinstated. At the age of five years, P2 was well, with no symptoms, a normal chest X ray and abdominal ultrasound results, and was treated with RIF/INH/IFN-&#x3B3; twice weekly. At his most recent consultations (in 2019 and 2021), he was well, without treatment. No other severe infections have occurred. P2 has a healthy sister who is growing normally. P2 received all other routinely indicated vaccines without complication. At five years of age, he was assessed by a neurologist for learning difficulties, but no neurological issues were identified and magnetic resonance imaging (MRI) was not indicated. At the age of seven years, a CT scan of the head, thorax and upper abdomen showed no abnormalities. Abdominal ultrasound was performed yearly until the age of nine years, and all the organs detected were of normal size and development. At the age of 16 years, the patient consulted an endocrinologist as he was slightly overweight. Thyrotropin-releasing hormone (TRH) stimulation test results and the levels of sex hormones, T3 and TSH were all normal. T4V levels were slightly below the lower limit of the normal range. The patient was therefore considered healthy. He swims, skis, and rides horses and motorbikes.</p>
          </sec>
          <sec id="S32">
            <title>Kindred C, P3.</title>
            <p id="P51">P3 is a boy originating from and living in Saudi Arabia (<xref rid="SD12" ref-type="supplementary-material">Table S1</xref>, <xref rid="F1" ref-type="fig">Figure 1A</xref>). He was born in 2010 and received the BCG vaccine (Danish strain) at birth. At the age of one year, he underwent excision of the left axillary lymph node due to BCG-itis. At the age of three years, he was referred to the hospital for painful swelling of the distal third of the left leg of six months&#x2019; duration. An X ray of the left leg showed an intramedullary lytic lesion with surrounding cortical thickening at the diaphysis of the distal tibia, and magnetic resonance imaging (MRI) results were suggestive of chronic osteomyelitis, with a lesion in the distal tibia diaphysis measuring 5.2 cm x 1.1 cm associated with an extensive periosteal reaction. A biopsy was performed on the left tibia; histological examination revealed inflammatory granulation, and <italic toggle="yes">M. bovis</italic> BCG susceptible to INH, RIF, and EMB and resistant to pyrazinamide (PZA) grew in culture. P3 was treated with INH, RIF, and clarithromycin for 12 months, with an excellent clinical response resulting in total resolution. Immunophenotyping results for T, B and NK cells, immunoglobulin levels (IgG, IgM and IgA) and oxidative burst assay (in neutrophils) results were normal. The patient is currently 12 years old, alive and well, and performing well at school. He presented no unusual infections during follow-up and was fully immunized according to the usual schedule, with no adverse effects. P3 has four sisters and one brother, who is 18 years old and healthy, and, like the sisters, presented no complications after BCG vaccination or severe/atypical infections.</p>
          </sec>
          <sec id="S33">
            <title>Kindred D, P4.</title>
            <p id="P52">P4 is a boy, born in 2016 to nonconsanguineous parents from Iran (<xref rid="SD12" ref-type="supplementary-material">Table S1</xref>, <xref rid="F1" ref-type="fig">Figure 1A</xref>). He received the BCG vaccine (Pasteur 1173p2 strain) at birth. He was hospitalized at the age of five months for right axillary lymphadenopathy. He developed an abscess with pus discharge in this area. An ultrasound scan of the axillary area revealed an internal echogenic mass (4.2 x 3.4 x 2.7 cm) and another hypoechoic node (3.7 x 3.3 x 1.5 cm). PCR results were positive for <italic toggle="yes">M. tuberculosis</italic> complex and culture confirmed <italic toggle="yes">M. bovis</italic> BCG infection. P4 received INH, EMB, RIF and levofloxacin supplemented with folic acid and vitamins, but the parents stopped the treatment after four months. Nine months later, P4 suffered another right axillary lymphadenopathy with pus discharge and fever. PCR was positive for <italic toggle="yes">M. tuberculosis</italic> complex. The patient received treatment with INH, EMB and clarithromycin for nine months. Abdominal ultrasound results and a bone scan were normal. P4 presented no infection with any other organism and was in good health, except for his low Ig levels. He is currently in good health, on monthly IVIG treatment for his low Ig levels. He has no siblings, and there is no history of IEI in his relatives and cousins. His mother had a history of abortion due to the absence of a fetal heartbeat and a neural tube defect at 16 weeks of pregnancy. At the age of five months, P4 underwent abdominal ultrasound and abdominopelvic CT scans. All the organs detected were of normal size and development. P4 is now seven years old. He is physically active, plays football and socializes with his peers. His growth is normal, and abdominal and pelvic ultrasound scans show the detected organs (including the liver, spleen, bile ducts, gallbladder, pancreas, kidneys and urinary bladder) to be normal in size and development.</p>
          </sec>
          <sec id="S34">
            <title>Kindred E, P5, P6 and P7.</title>
            <p id="P53">P5 was born to consanguineous Iranian parents in 2019 (<xref rid="SD12" ref-type="supplementary-material">Table S1</xref>, <xref rid="F1" ref-type="fig">Figure 1A</xref>). He was vaccinated with BCG (Pasteur 1173P2 strain) at birth. At the age of three months, he presented a left axillary draining adenopathy, which was resected surgically at seven months. Histological analysis of the lymph node showed an epithelioid granuloma containing AFB. The presence of BCG was documented by PCR. P5 was treated with RIF and INH for six months. At 13 months of age, he developed ascites, multiple abdominal adenopathies, and hepatic calcified nodules. Ascitic fluid analysis revealed a lymphocytic exudate. Liver biopsy showed cirrhosis, but no mycobacterial elements were documented. Bone marrow biopsy results were normal. P5 received antimycobacterial treatment with RIF, INH, EMB, ofloxacin and clarithromycin for nine months. He is currently well without treatment, with mild hepatosplenomegaly but no other symptoms. P5 has a sister who is well and has never been hospitalized, and a brother (<bold>P7</bold>) who was identified as a mutation carrier a few days after birth and was therefore not vaccinated with BCG; P7 has no history of mycobacterial infection. The height and weight of P5 and P7 have been routinely monitored and no abnormalities have been found. P5 and P7 also had an uncle (<bold>P6</bold>), the brother of their mother, who died at the age of two years from fever and hepatosplenomegaly. P6 was vaccinated with BCG (Pasteur 1173P2 strain) at birth.</p>
          </sec>
        </sec>
        <sec id="S35">
          <title>WES and Sanger sequencing</title>
          <p id="P54">For P1, genomic DNA (gDNA) was extracted with the Qiagen blood mini kit, and DNA fragments were generated and enriched for whole-exome sequencing with the Agilent SureSelect XT Human All Exon V5 kit. Sequencing was performed on an Illumina HiSeq X10 apparatus (Illumina). Reads were mapped on the human reference genome <sup><xref rid="R95" ref-type="bibr">95</xref></sup> with Burrows-Wheeler aligner-0.7.12 <sup><xref rid="R96" ref-type="bibr">96</xref></sup>. Variant calling was then performed on the aligned reads, with GATK-3.4-46 best practices <sup><xref rid="R97" ref-type="bibr">97</xref></sup>. For annotation of the variants, we used SnpEff-4.1a <sup><xref rid="R98" ref-type="bibr">98</xref></sup> tools. For P2, P3 and P4, gDNA was isolated from whole blood with the iPrep PureLink gDNA Blood Kit and iPrep Instruments (Life Technologies, Thermo Fisher Scientific). Exome capture was performed with the SureSelect Human All Exon 50 Mb kit (Agilent Technologies), with 3 &#x3BC;g gDNA. Single-end sequencing was performed on an Illumina Genome Analyzer IIx (Illumina). For P5, gDNA was isolated from whole blood. WES was performed at Macrogen Korea (Macrogen, Inc., Seoul, South Korea). For WES, exon enrichment was performed with the SureSelect XT Library Prep Kit (Agilent Technologies, CA, USA). Sequencing was performed on a NovaSeq 6000 (Illumina, CA, USA) sequencer generating 150 bp reads, with 100&#xD7; coverage. The NGS platform generally covered &gt;95% of the targeted regions with up to 99% sensitivity.</p>
          <p id="P55">All variants from the patients and their familial segregation (when appropriate materials were available for analysis) were confirmed by amplifying the flanking regions of the variants obtained with specific primers (<xref rid="SD1" ref-type="supplementary-material">Figure S1A</xref>&#x2013;<xref rid="SD1" ref-type="supplementary-material">E</xref>). PCR products were analyzed by electrophoresis in 1% agarose gels, sequenced with the Big Dye Terminator v3.1 cycle sequencing kit (Applied Biosystems), and analyzed on an ABI Prism 3700 sequencer (Applied Biosystems).</p>
        </sec>
        <sec id="S36">
          <title>Enrichment analysis</title>
          <p id="P56">We performed an enrichment analysis for pLOF variants of the <italic toggle="yes">MCTS1</italic> gene on our cohort of 422 male patients with MSMD of unidentified genetic etiology. As controls, we used 1,932 male individuals of diverse ethnic origins from our in-house database. These controls were patients with various genetically unexplained non-mycobacterial infections other than chronic mucocutaneous candidiasis (CMC). We used the Firth penalized logistic regression method <sup><xref rid="R99" ref-type="bibr">99</xref></sup>, as implemented in the R (v4.1) <sup><xref rid="R100" ref-type="bibr">100</xref></sup> package logistf, to compare the proportion of individuals with pLOF variants between the MSMD and control groups. The analysis was adjusted for the first five principal components (PCs) to account for the ethnic heterogeneity of the samples. Principal component analysis (PCA) was performed with Plink v1.9 software on WES data, with the 1000 Genomes (1kG) Project phase 3 public database as a reference, for 2,942 exonic variants with minor allele frequency (MAF) &gt; 1% and a call rate &gt; 99%.</p>
        </sec>
        <sec id="S37">
          <title>Exon trapping assay</title>
          <p id="P57">A DNA segment encompassing the <italic toggle="yes">MCTS1</italic> exon 2 and 3 region (ChrX: 120604950 to ChrX: 120606870 region, GRCh38 reference, release 13) was amplified from genomic DNA extracted from whole-blood samples from a healthy control. It was inserted between the <italic toggle="yes">Xho</italic>I and <italic toggle="yes">Bam</italic>HI sites of the pSPL3 vector. The sequence was then mutated to encode the variant of P3. Plasmids containing wild-type (WT) and mutant <italic toggle="yes">MCTS1</italic> exon 2-3 regions were then used to transfect COS-7 cells. After 24 hours, total RNA was extracted and reverse-transcribed. The cDNA products were amplified with primers binding to the flanking HIV-TAT sequences of the pSPL3 vector and ligated into the pCR<sup>&#x2122;</sup>4-TOPO<sup>&#xAE;</sup> vector (Invitrogen). Stellar<sup>&#x2122;</sup> cells (Takara) were transformed with the resulting plasmids. Colony PCR and sequencing with primers binding to the flanking HIV-TAT sequences of pSPL3 were performed to assess the splicing products transcribed from the WT and mutant alleles.</p>
        </sec>
        <sec id="S38">
          <title>Patient-derived cell lines</title>
          <p id="P58"><italic toggle="yes">Herpesvirus saimiri</italic>-transformed T (HVS-T) cells were generated with the TERT transformation system. HVS-T cells were cultured in 40% RPMI, 40% Panserin 401, 20% fetal-calf serum (FCS) supplemented with 10 ng/ml IL-2, 50 &#x3BC;g/ml gentamycin (Gibco, 15750060) and GlutaMAX<sup>&#x2122;</sup> (Gibco, 35050061). T-cell blasts (T-blasts) were induced from 2 million PBMCs (fresh or cryopreserved) in 2 ml ImmunoCult<sup>&#x2122;</sup>-XF T Cell Expansion Medium (Stem Cell Technologies, 10981) supplemented with 10 ng/ml IL-2 (Gibco, PHC0023) and 1:40 diluted ImmunoCult<sup>&#x2122;</sup> Human CD3/CD28/CD2 T Cell Activator. T-blasts were then cultured in ImmunoCult medium with IL-2 for 2-3 weeks, before restimulation in the same manner. Dermal primary fibroblasts were obtained from skin biopsy specimens, transformed with SV40 antigen and cultured in DMEM (Gibco) supplemented with 10% FCS. All cell lines used tested negative for mycoplasma.</p>
        </sec>
        <sec id="S39">
          <title>Cell-line culture</title>
          <p id="P59">We cultured HeLa cells, HEK293T cells, &#x3B3;2A- fibrosarcoma cells and HT1080 cells in DMEM +10% FCS +100 U/ml penicillin/streptomycin (Gibco 15140122). We subcultured the cells with trypsin-EDTA. HeLa cells tested negative for mycoplasma and were authenticated by SNP typing. THP-1 cells were cultured in RPMI supplemented with 10% FCS.</p>
        </sec>
        <sec id="S40">
          <title>Translation reporter assays</title>
          <p id="P60">HeLa cells were used to seed 96-well plates at a density of 8,000 cells per well. Cells were transfected for 16-20 hours in the presence of Lipofectamine 2000, with 100 ng <italic toggle="yes">Renilla</italic> luciferase plasmid and 100 ng firefly luciferase plasmid per well. For translation reporter assays including MCTS1 reconstitution conditions, we used 60 ng of EV, <italic toggle="yes">MCTS1</italic> WT or variant expression plasmid, 70 ng of <italic toggle="yes">Renilla</italic> luciferase reporter plasmid and 70 ng of firefly reporter plasmid per well. Four hours after transfection, the medium was replaced. All the <italic toggle="yes">Renilla</italic> luciferase plasmids contained the 5&#x2019;UTR of interest, whereas all the firefly luciferase plasmids contained the MCTS1-independent <italic toggle="yes">Lamin B1</italic> 5&#x2019;UTR and were used as a transfection normalization control. We added 0.4 &#x3BC;l Lipofectamine reagent to each well. Cell transfection was always performed with technical triplicates. Luciferase activity was assessed 16-20 hours after transfection, with the Promega Dual-Luciferase<sup>&#xAE;</sup> Reporter Assay System, in accordance with the manufacturer&#x2019;s instructions.</p>
        </sec>
        <sec id="S41">
          <title>40S and 80S ribosome footprinting</title>
          <p id="P61">We performed 40S and 80S ribosome footprinting, as previously described <sup><xref rid="R65" ref-type="bibr">65</xref>,<xref rid="R101" ref-type="bibr">101</xref></sup>. Briefly, HeLa cells and SV40-fibroblasts were grown to ~80% confluence in multiple 15 cm dishes (2-3 dishes per treatment). The cells were briefly washed with 1x PBS, 10 mM MgCl<sub>2</sub>, and 400 &#x3BC;M cycloheximide, and freshly prepared crosslinking solution (1x PBS, 10 mM MgCl<sub>2</sub>, 400 &#x3BC;M cycloheximide, 0.025% PFA, 0.5 mM DSP) was added. Cells were incubated with crosslinking solution for 15 minutes at room temperature with slow rocking. The crosslinking solution was then poured off and the remaining crosslinker was inactivated by incubation for 5 minutes with ice-cold quenching solution (1x PBS, 10 mM MgCl<sub>2</sub>, 200 &#x3BC;M cycloheximide, 300 mM glycine). The quenching solution was poured off and 150 &#x3BC;l lysis buffer (0.25 M HEPES pH 7.5, 50 mM MgCl<sub>2</sub>, 1 M KCl, 5% NP40, 1000 &#x3BC;M cycloheximide) was added to each 15 cm dish. The cells were incubated at 4&#xB0;C for two minutes for lysis. The cell debris was scraped off the dish and the lysate was collected. The lysates were briefly vortexed and clarified by centrifugation at 20,000 x <italic toggle="yes">g</italic> for 10 minutes at 4&#xB0;C. The supernatant was collected and its RNA concentration was determined with a Nanodrop spectrophotometer. We then added 100 U RNAse 1 (Ambion, AM2294) per 120 &#x3BC;g of RNA. Lysates were incubated for 5 minutes at 4&#xB0;C and then loaded onto 17.5%-50% sucrose gradients and centrifuged for 5 hours at 35,000 rpm in a Beckman Ultracentrifuge equipped with an SW40 rotor. Gradients were fractionated with a Biocomp Gradient Profiler system. We collected the 40S and 80S fractions for immunoprecipitation and footprint isolation. The 40S and 80S fractions corresponding to one or two 15 cm dishes were used for the direct extraction of RNA for total footprint samples. The crosslinker was then removed and RNA was extracted from the footprint fractions: 55 &#x3BC;l (1/9 volume) of crosslink-removal solution (10% SDS, 100 mM EDTA, 50 mM DTT) and 600 &#x3BC;l acid-phenol chloroform (Ambion) were added and the mixture was incubated at 65&#xB0;C, with shaking at 1,300 rpm for 45 minutes. The tubes were then placed on ice for 5 minutes and centrifuged for 5 minutes at 20,000 x <italic toggle="yes">g</italic>. The supernatant was washed once with acid-phenol chloroform and twice with chloroform, and the RNA was then precipitated with isopropanol and used for library preparation (see below). The precipitated or total proteins were isolated from the organic phase. We added 300 &#x3BC;l ethanol and 1.5 ml isopropanol and the solutions were incubated at &#x2212;20&#xB0;C for 1 hour. Proteins were sedimented by centrifugation at 20,000 x <italic toggle="yes">g</italic> for 20 minutes, washed twice with 95% ethanol and 0.3 M guanidine-HCl, dried and resuspended in 1x Laemmli buffer.</p>
        </sec>
        <sec id="S42">
          <title>Deep-sequencing library preparation</title>
          <p id="P62">The quality and integrity of the 40S and 80S RNA extracted were determined on an Agilent Bioanalyzer with the total RNA Nano 6000 Chip. For size selection, RNA was subjected to electrophoresis in 15% urea-polyacrylamide gels (Invitrogen) and fragments of 20-80 nt (40S) or 25-35 nt (80S) in size were excised, with the Agilent small RNA ladder used as a reference. RNA was extracted from the gel pieces by smashing the gels into small pieces with gel smasher tubes and extracting the RNA in 0.5 ml 10 mM Tris pH 7 at 70&#xB0;C for 10 minutes. The gel pieces were removed and RNA was precipitated in isopropanol. The RNA was then dephosphorylated by incubation with T4 PNK (NEB, M0201S) for 2 hours at 37&#xB0;C in PNK buffer without ATP. It was precipitated again and purified in isopropanol. Footprints were then analyzed with an Agilent Bioanalyzer small-RNA chip and the Qubit smRNA kit. We used up to 25 ng of footprint RNA as input for library preparation with the SMARTer smRNA-SeqKit for Illumina from Takara/Clontech Laboratories, according to the manufacturer&#x2019;s instructions. For RNA-seq libraries, total cell RNA was extracted with TRIzol and libraries were prepared with the Illumina TruSeq stranded library preparation kit. Deep-sequencing libraries were sequenced on the Illumina Next-Seq 550 system.</p>
        </sec>
        <sec id="S43">
          <title>Data analysis and statistics</title>
          <p id="P63">Analysis of ribosome footprinting NGS data: Adapter poly-A sequence nucleotides were trimmed from raw reads with cutadapt (<ext-link xlink:href="https://doi.org/10.14806/ej.17.1.200" ext-link-type="uri">https://doi.org/10.14806/ej.17.1.200</ext-link>). Ribosomal RNA and tRNA reads were removed by bowtie2 alignment with human tRNA and rRNA sequences <sup><xref rid="R102" ref-type="bibr">102</xref></sup>. The remaining reads were then separately aligned with the human transcriptome (Ensembl transcript assembly 94) and the human genome (hg38) with BBmap (<ext-link xlink:href="http://sourceforge.net/projects/bbmap/" ext-link-type="uri">sourceforge.net/projects/bbmap/</ext-link>). Counted reads were generally normalized by sequencing depth (number of alignments per library). Reads were counted, and metagene plots and single-transcript traces were obtained with custom software written in C and available from GitHub (<ext-link xlink:href="https://github.com/aurelioteleman/Teleman-Lab" ext-link-type="uri">https://github.com/aurelioteleman/Teleman-Lab</ext-link>). Translation efficiency (TE) was calculated from the number of 80S ribosome footprints in a coding sequence divided by the number of RNA sequencing reads on the coding sequence. uORFs were annotated on the basis of the presence of an ATG and an inframe stop codon within the 5&#x2019;UTR of any mRNA. Only uORFs beginning with an ATG were considered.</p>
        </sec>
        <sec id="S44">
          <title>Stable lentiviral transduction</title>
          <p id="P64">Lentiviral particles were produced in HEK293T cells by transfection with pPAX2, pHBX2, pVSV-G and pTRIP EV or plasmids containing the <italic toggle="yes">MCTS1</italic> variants, with X-tremeGENE 9 (Roche, 6365779001). The medium was replaced after five hours. The supernatant was harvested 20 hours post-transfection, filtered, supplemented with 8 &#x3BC;g/ml protamine sulfate and added, in a 1:1 volumetric ratio, to 150,000 cells in 100 &#x3BC;l medium. Cells were spinoculated for 2 hours at 1200 x <italic toggle="yes">g</italic>. The cells were cultured for three to four days, assayed for transgene expression by FACS staining for &#x394;NGFR, and subjected to enrichment for MACS sorting.</p>
        </sec>
        <sec id="S45">
          <title>Generation of MCTS1 and JAK2 knockouts in THP-1 cells and HEK-Blue IL-23 cells</title>
          <p id="P65">THP-1 cells or HEK-Blue IL-23 cells were transduced with pLENTI-V2 constructs encoding Cas9 and an sgRNA (GCCTGGGAAGGATACAACAA) targeting the <italic toggle="yes">MCTS1</italic> gene and an sgRNA targeting <italic toggle="yes">JAK2</italic> (GGTAAGAATGTCTTGTAGCT). Cells were then selected by culture with 5 &#x3BC;g/ml (THP-1) or 1 &#x3BC;g/ml (HEK-Blue) puromycin for two weeks. The KO pool was then tested for efficient knockout by western blotting, and seeding was performed by limiting dilution for clonal expansion. Clones were screened by western blotting and <italic toggle="yes">MCTS1</italic> knockout was confirmed by gDNA sequencing.</p>
        </sec>
        <sec id="S46">
          <title>Immunoblotting</title>
          <p id="P66">Cells were lysed in standard RIPA lysis buffer containing protease inhibitors (Roche mini EDTA-free, 1 tablet in 10 ml) and phosphatase inhibitors (2 mM sodium Ortho-vanadate, Roche Phosstop 1 tablet in 10 ml, 0.1 M sodium fluoride, 0.1 M beta-glycerophosphate) and Benzonase (50 U/ml), after brief washing in FCS-free DMEM or PBS. Lysates were clarified and protein concentration was determined in a BCA or Bradford assay. Equal amounts of protein were subjected to SDS-PAGE and the resulting bands were transferred to a nitrocellulose membrane with 0.2 &#x3BC;m pores. Membranes were subjected to Ponceau staining, incubated in 5% skim milk in PBST for 1 hour, briefly rinsed with PBST and then incubated in primary antibody solution (5% BSA in PBST or 5% skim milk in PBST) overnight at 4&#xB0;C. Membranes were then washed three times, for 15 minutes each, in PBST, incubated in secondary antibody solution (1:5,000 in 5% skim milk in PBST) for 1 hour at room temperature, then washed again three times, for 15 minutes each, in PBST. Finally, chemiluminescence was detected with ECL reagents and a Biorad Chemidoc. The membranes were not stripped. The antibodies used in this study are listed in the <xref rid="T1" ref-type="table">key resources table</xref>.</p>
        </sec>
        <sec id="S47">
          <title>RT-qPCR</title>
          <p id="P67">Total RNA was isolated from cells with the Quick-RNA MicroPrep spin column kit (Zymogen, R1050), according to the manufacturer&#x2019;s protocol. For cDNA synthesis, we used 10 ng of total RNA for random oligomer-primed reverse transcription with Superscript II Reverse Transcriptase (Invitrogen, 18064022). Quantitative RT-PCR was carried out with the <italic toggle="yes">Taq</italic>Man Universal Master Mix (Applied Biosystems, 4305719) and <italic toggle="yes">Taq</italic>man probes for <italic toggle="yes">GUSB</italic> (4326320E), <italic toggle="yes">IRF1</italic> (Hs00971965_m1), <italic toggle="yes">IFNG</italic> (Hs00989291_m1) and <italic toggle="yes">MX1</italic> (Hs00895608_m1; Thermo Fisher Scientific).</p>
        </sec>
        <sec id="S48">
          <title>Deep immunophenotyping of primary leukocytes by mass cytometry (CyTOF)</title>
          <p id="P68">CyTOF was performed on whole blood treated with heparin (1.0 &#xD7; 10<sup>6</sup> cells per panel), with the Maxpar Direct Immune Profiling Assay (Fluidigm), according to the manufacturer&#x2019;s instructions. Cells were frozen at &#x2212;80&#xB0;C after overnight dead-cell staining. Acquisition was performed on a Helios machine (Fluidigm). All the samples were processed within 24 hours of sampling. Data were analyzed with OMIQ software.</p>
        </sec>
        <sec id="S49">
          <title>Monocyte isolation and differentiation into MDMs, MDDCs and osteoclasts</title>
          <p id="P69">CD14<sup>+</sup> monocytes were isolated from fresh PBMCs with CD14 MicroBeads (Miltenyi Biotec, 130-050-201) according to the manufacturer&#x2019;s instructions. For the induction of monocyte-derived macrophages (MDMs), CD14<sup>+</sup> monocytes were cultured in RPMI 1640 supplemented with 10% FCS, 1% penicillin/streptomycin and 50 ng/ml recombinant human (rh)M-CSF (R&amp;D Systems, 216-MC) for 7 days, and were then allowed to differentiate for seven days in the presence of 50 ng/ml rhM-CSF and 50 ng/ml rhIL-4 (R&amp;D Systems, 204-IL). Monocyte-derived dendritic cells (MDDCs) were induced by culturing CD14<sup>+</sup> monocytes for 7 days in RPMI 1640 supplemented with 10% FCS, 1% penicillin/streptomycin, 50 ng/ml rhGM-CSF (R&amp;D Systems, 215-GM) and 20 ng/ml rhIL-13 (R&amp;D Systems, 213-ILB). For osteoclast differentiation, CD14<sup>+</sup> cells were cultured in <italic toggle="yes">&#x3B1;</italic>-MEM (Thermo Fisher Scientific, 12571063) containing 10% FCS, 1% penicillin/streptomycin, 30 ng/ml rhM-CSF and 10 ng/ml rhRANKL (Peprotech, 310-01) for 7 days. The medium was replaced every three days.</p>
        </sec>
        <sec id="S50">
          <title>Cell-line cytokine stimulation and flow cytometry</title>
          <p id="P70">Cell lines were cultured as described above. For stimulation, cells were starved of IL-2 and 2% FCS overnight, as appropriate. They were then stimulated with the indicated cytokine concentrations for the indicated times at 37&#xB0;C. Subsequently, for qPCR, total RNA was extracted and subjected to reverse transcription, as described above. Alternatively, dead cells were removed by Live/Dead Aqua (Thermo Fisher Scientific, L34966) staining for 5 minutes at 4&#xB0;C, and the cells were then fixed and permeabilized for FACS analysis with BD Fix Buffer I and Perm Buffer III. The cells were then stained with antibodies against pSTAT1 (BD, 612564), pSTAT4 (BD, 562073) or pSTAT3 (BD, 612569) and fluorescence was assessed on a Beckman Gallios Cytometer.</p>
        </sec>
        <sec id="S51">
          <title>T-cell blast cytokine stimulation and RNA sequencing</title>
          <p id="P71">T-cell blasts were starved of IL-2 overnight. They were then stimulated with 50 ng/ml IL-12 (R&amp;D Systems, CAT: 219-IL-005) or 100 ng/ml IL-23 (R&amp;D Systems, Cat: 1290-IL) for 6 hours or with 2.5 ng/ml IL-1&#xDF; (R&amp;D Systems, CAT: 201-LB-005) for 24 hours. Double-stimulated cells were stimulated with IL-1&#xDF; for 18 hours and then with IL-23 and IL-1&#xDF; for 6 hours. Total RNA was isolated from cells with the Quick-RNA MicroPrep spin-column kit (Zymogen, R1050), according to the manufacturer&#x2019;s protocol. RNA was then subjected to RNA-seq library preparation and deep-sequencing at the Rockefeller University Genomics Core Facility.</p>
        </sec>
        <sec id="S52">
          <title>The HEK-Blue IL-23 sensitive cytokine stimulation and colorimetric assay</title>
          <p id="P72">HEK-Blue assays were performed in accordance with the manufacturer&#x2019;s instructions. Briefly, HEK-Blue cells were maintained under selection with the supplier&#x2019;s selection compound mixture at a dilution of 1:250. For cytokine stimulations, cells were used to seed 96-well plates at a density of 25,200 cells per well, in 200 &#x3BC;l stimulation medium containing either without cytokines or containing 5 ng/ml IL-12, 1 ng/ml IL-23, 0.1 ng/ml IL-23 or 10.000 IU/ml IFN-&#x3B1;2a. After incubation for 20 hours, 20 &#x3BC;l culture supernatant was mixed with 180 &#x3BC;l QUANTI-Blue solution, incubated for 30 minutes at 37&#xB0;C and then its optical density at 620-655 nm was then measured on a photometric plate reader.</p>
        </sec>
        <sec id="S53">
          <title>Monocyte and NK cell sorting, culture and stimulation</title>
          <p id="P73">NK cells were sorted from fresh PBMCs with a BD Aria II, SORP cytometer and CD56<sup>+</sup> CD3<sup>&#x2212;</sup> negative live cells were selected. This cell population was then expanded by culture in the presence of a 10-fold excess of PBMCs from the same donor irradiated with 35 grays in ImmunoCult<sup>&#x2122;</sup>-XF T Cell Expansion Medium (Stem Cell Technologies, 10981) supplemented with 10 ng/ml IL-2 (Gibco, PHC0023) and 8% FCS. Before stimulation, the cells were starved of FCS and IL-2 for 20 hours. They were incubated with the indicated concentration of gandotinib for 1 hour and then treated with 100 ng/ml IL-23, 2.5 ng/ml IL-1&#x3B2; and/or 50 ng/ml IL-12. The purity of the NK cell preparation was assessed by flow cytometry, as illustrated in <xref rid="SD7" ref-type="supplementary-material">Figure S7F</xref>. Monocytes were sorted from fresh PBMCs with Miltenyi Biotec anti-CD14 magnetic microbeads in accordance with the manufacturer&#x2019;s instructions. They were transferred to RPMI supplemented with 10% FCS, and 1% penicillin/streptomycin and stimulated, on the same day, with gandotinib and cytokines, as described above for NK cells. IFN-&#x3B1;2a and IFN-&#x3B3; were both used at a concentration of 10,000 IU/ml. After 24 hours, supernatants were collected and assayed by LEGENDplex bead-based ELISA.</p>
        </sec>
        <sec id="S54">
          <title>PBMC stimulation</title>
          <p id="P74">PBMCs were isolated with Lymphoprep (StemCell, 07801), from blood drawn no more than 48 hours previously into lithium heparin tubes, in accordance with the manufacturers&#x2019; instructions. PBMCs were then either cryopreserved in 90% FCS, 10% DMSO or used fresh. For PBMC stimulation (fresh or cryopreserved), 100,000 PBMCs were used to seed each well of a round-bottomed 96-well plate, in RPMI supplemented with 10% human serum. They were stimulated for 48 hours with 2.5 ng/ml IL-1&#xDF;, 50 ng/ml IL-12, 100 ng/ml IL-23, 0.1 v/v% BCG or a combination of these stimuli. We added PMA (Sigma CAT: P1585-1MG, 8 ng/mL) + ionomycin (Sigma CAT: 56092-81-0, 10<sup>&#x2212;5</sup> M) for the last 24 hours only. The supernatants and cell pellets were collected. Supernatants were subjected to LEGENDplex multiplex ELISA with Human Inflammation Panel 1 (BioLegend, 740809), according to the manufacturer&#x2019;s instructions. Total RNA was extracted from the cell pellets for qPCR and RNA-seq analysis, as described below.</p>
        </sec>
        <sec id="S55">
          <title>RNA sequencing analysis</title>
          <p id="P75">Total RNA sequencing was performed with an Illumina NovaSeq S2 flowcell (read length 100 bp) with a read depth of 30 M. All FASTQ sequences passed quality control tests and were aligned with the GRCh38 reference genome with STAR (2.6.1d). BAM files were converted to a raw count expression matrix with featurecount. Raw count data were normalized with DEseq2. The ensemble ID targeting multiple genes was collapsed (average) and a final gene data matrix was used for a modular repertoire analysis as previously described <sup><xref rid="R82" ref-type="bibr">82</xref>,<xref rid="R83" ref-type="bibr">83</xref></sup> or for gene set enrichment analysis (GSEA: fgsea) with hallmark gene sets (<ext-link xlink:href="http://www.gsea-msigdb.org/" ext-link-type="uri">http://www.gsea-msigdb.org/</ext-link>).</p>
        </sec>
        <sec id="S56">
          <title>Protein isolation from human polymorphonuclear neutrophils</title>
          <p id="P76">Polymorphonuclear neutrophils were isolated by density gradient centrifugation (Lymphoprep, Stem Cell Technologies) and red blood cells were lysed by incubation in red cell lysis buffer (8.02 g NH<sub>4</sub>Cl, 0.84 g NaHCO<sub>3</sub>, 0.37 g EDTA in 1 L H<sub>2</sub>O, pH 7.4) at 37&#xB0;C for 15 min. Proteins were isolated with modified RIPA buffer (25 mM Tris&#x2013;HCl pH 7.4, 150 mM NaCl, 1% NP-40 and 1 mM EDTA) supplemented with DTT (0.1 mM, Thermo Fisher Scientific), protease inhibitor cocktail (Merck), phosphatase inhibitor cocktail (Merck), PMSF (1 mM, Merck) and DFP (0.1 mM, Merck).</p>
        </sec>
        <sec id="S57">
          <title>Whole-blood activation and ELISA for cytokines</title>
          <p id="P77">Venous blood samples from healthy (local and travel) controls and patients were collected into heparin-containing collection tubes. These samples were diluted 1:2 in RPMI 1640 (GibcoBRL) supplemented with 100 IU/ml penicillin and 100 &#x3BC;g/ml streptomycin (GibcoBRL). We then dispensed 1 ml of each diluted blood sample into each of five wells (1 ml/well) of a 48-well plate (Nunc), which was incubated for 48 hours at 37&#xB0;C, under an atmosphere containing 5% CO<sub>2</sub>/ 95% air. The activation conditions were: medium alone, live BCG (<italic toggle="yes">M. bovis</italic>-BCG, Pasteur substrain) at a MOI of 20 BCG cells/leukocyte, BCG plus recombinant (rh) IL-12 (20 ng/ml; R&amp;D Systems), or BCG plus IFN-&#x3B3; (Imukin). The supernatants were collected after 48 hours and subjected to ELISA with the human IFN-&#x3B3;, IL-12p40 (R&amp;D) and IL-12p70 (R&amp;D) ELISA kits, according to the manufacturer&#x2019;s instructions.</p>
        </sec>
        <sec id="S58">
          <title>VirScan - phage immunoprecipitation sequencing (PhIP-Seq)</title>
          <p id="P78">Antibody profiling by phage immunoprecipitation sequencing (PhIP-Seq) was performed on plasma samples from patients and controls with an expanded version of the original VirScan library, and the data were analyzed as previously described <sup><xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R103" ref-type="bibr">103</xref>&#x2013;<xref rid="R105" ref-type="bibr">105</xref></sup>, but with the following modifications. We calculated species-specific significance cutoff values to estimate the minimum number of enriched, non-homologous peptides required to consider a sample seropositive, as previously described with an in-house dataset and a generalized linear model <sup><xref rid="R106" ref-type="bibr">106</xref>,<xref rid="R107" ref-type="bibr">107</xref></sup>. For each sample, we calculated virus-specific scores, by dividing the counts of enriched, non-homologous peptides by the estimated cutoff score. These adjusted virus scores are depicted on heatmap plots. We randomly selected an age-matched subset of 19 individuals from a larger cohort of 800 individuals of Arab ancestry (representing the general adult population) from our in-house database, for comparison with the patients and initial controls. Pooled human plasma used for IVIg (Privigen<sup>&#xAE;</sup> CSL Behring AG), and human IgG-depleted serum (Molecular Innovations, Inc.) were used as additional controls.</p>
        </sec>
        <sec id="S59">
          <title>Single-cell RNA sequencing</title>
          <p id="P79">For scRNASeq analysis following stimulation, we analyzed cryopreserved PBMCs from six healthy controls, two MCTS1-deficient patients, two IL-23R-deficient patients and one IL-12R&#x3B2;1-deficient patient, as previously described <sup><xref rid="R35" ref-type="bibr">35</xref>,<xref rid="R42" ref-type="bibr">42</xref></sup>. Briefly, we filtered cells through a MACS SmartStrainer with 70 &#x3BC;m pores (Miltenyi Biotec, Cat: 130-098-462) to remove large debris, washed them three times with PBS plus 0.5% FCS, and finally filtered them through a Falcon Cell Strainer with 40 &#x3BC;m pores (Corning, Cat: 352340), before subjecting them to single-cell capture with the 10X Genomics Chromium chip. We prepared libraries with the Chromium Single Cell 3&#x2019; Reagent Kit (v3 Chemistry) and sequenced them with an Illumina NovaSeq 6000 sequencer. We preprocessed sequences with CellRanger. We sequenced about 10,000 cells per sample. We filtered data manually on the basis of common quality-control metrics. For cell-type identification, after integration with Harmony <sup><xref rid="R108" ref-type="bibr">108</xref></sup> to eliminate batch-, genotype-, and stimulation-dependent variation, we performed two sequential graph-based clustering analyses. The first round of clustering identified general leukocyte subsets, whereas the second round identified memory and effector T-lymphocyte subsets and NK lymphocytes at sufficiently high resolution. We identified clusters with the SingleR pipeline <sup><xref rid="R109" ref-type="bibr">109</xref></sup> guided by the reference RNA-Seq dataset generated by Monaco et al. <sup><xref rid="R110" ref-type="bibr">110</xref></sup>, and cell type-specific marker gene expression was then assessed manually. We visualized clusters by uniform manifold approximation and projection (UMAP). We quantified gene expression at the single-cell level with Seurat <sup><xref rid="R111" ref-type="bibr">111</xref></sup>. Pseudobulk analysis was performed by aggregating all reads from cells assigned to a given cluster, as previously described <sup><xref rid="R112" ref-type="bibr">112</xref></sup>. We performed differential expression analysis with DESeq2 <sup><xref rid="R113" ref-type="bibr">113</xref></sup>. We conducted geneset enrichment analysis (GSEA) with the fgsea package, by projecting the fold-change ranking onto various MSigDB genesets (<ext-link xlink:href="http://www.gsea-msigdb.org/gsea/msigdb/genesets.jsp" ext-link-type="uri">http://www.gsea-msigdb.org/gsea/msigdb/genesets.jsp</ext-link>). All analyses were performed in R v.4 (<ext-link xlink:href="http://www.R-project.org/" ext-link-type="uri">http://www.R-project.org/</ext-link>). Raw data will be made available from SRA BioProject upon publication of the manuscript.</p>
        </sec>
        <sec id="S60">
          <title>Stimulation of PBMCs with IL-12, IL-23, BCG and PMA/ionomycin for intracellular staining and flow cytometry analysis</title>
          <p id="P80">This experiment was performed as previously described <sup><xref rid="R34" ref-type="bibr">34</xref></sup>. Healthy adult donors were recruited at the Rockefeller University (New York, USA) and Necker Hospital (Paris, France). We plated 300,000 cells per well in 96-well U-bottomed plates, at a density of 1.5 to 3 x 10<sup>6</sup> cells/ml. Cells were stimulated with IL-12 (50 ng/ml), IL-23 (100 ng/ml) and/or BCG (MOI of 1) for 41 hours. For PMA plus ionomycin treatment, cells were cultured for 40 h in RPMI. They were then stimulated with 50 ng/mL PMA and 1 mM ionomycin. After 1 hour, Golgiplug was added to all cultures, in accordance with the manufacturer&#x2019;s protocol. Seven hours later, the cells were harvested for staining and flow cytometry. Cells were first stained with the Zombie NIR Viability kit (BioLegend) for 15 minutes. They were then stained with FcBlock (Miltenyi Biotec), anti-gdTCR-Alexa 647 (BioLegend), anti-CD3-V450 (BD Biosciences), anti-CD56-BV605 (BioLegend), anti-CD4-BUV563 (BD Biosciences), anti-Vd1TCR-FITC (Miltenyi Biotec), anti-CD8-BUV737 (BD Biosciences), anti-Vd2TCR-APC/Fire750 (BioLegend), anti-CD20-BV785 (BioLegend), anti-Va7.2-Alexa 700 (BioLegend), MR1-5-OP-RU-tetramer (NIH tetramer core facility), anti-Vb11-APC (Miltenyi Biotec), and anti-iNKT-BV480 (BD Biosciences) antibodies for 30 minutes. The stained cells were fixed with the FOXP3/Transcription Factor kit (Thermo Fisher Scientific) and subjected to intracellular staining with anti-T-bet-PE/Cy7 (BioLegend), anti-IFN-g-BV711 (BioLegend), anti-TNF-a-BV510 (BioLegend), anti-IL-17A-PERCP/Cy5.5, anti-RORgT-PE (BD Biosciences), anti-CD3-V450 (BD Biosciences), anti-CD4-BUV563 (BD Biosciences) and anti-CD8-BUV737 (BD Biosciences) antibodies in Perm/Wash buffer. Cells were then analyzed in a CyTek Aurora spectral flow cytometer.</p>
        </sec>
      </sec>
      <sec id="S61">
        <title>QUANTIFICATION AND STATISTICAL ANALYSIS</title>
        <p id="P81">Appropriate statistical analyses were chosen depending on the experimental setting, number of replicates and type of data. The type of statistical test is always indicated in the figure legends of figure panels where statistical tests were performed. Generally, R suite was used to calculate statistical significance. All error bards in this paper display standard deviations (SD). No standard error of mean (SEM) is shown. Typically p &lt; 0.05 was used as a threshold to determine statistical significance, this is always indicated in the figure legends.</p>
      </sec>
    </sec>
    <sec sec-type="supplementary-material" id="SM1">
      <title>Supplementary Material</title>
      <supplementary-material id="SD1" position="float" content-type="local-data">
        <label>1</label>
        <caption>
          <p id="P34"><bold>Figure S1. Confirmation of patient variants and ethnicity, related to</bold>
<xref rid="F1" ref-type="fig">Figure 1</xref>. <bold>(A-E)</bold> Sanger sequencing traces for probands (P1-P5) and their relatives. <bold>(F)</bold> PCA plot for patients P1-P5 and control data from the 1000 Genomes project generated from the WES data for the patients.</p>
        </caption>
        <media xlink:href="NIHMS1935775-supplement-1.pdf" id="d64e2755" position="anchor"/>
      </supplementary-material>
      <supplementary-material id="SD2" position="float" content-type="local-data">
        <label>2</label>
        <caption>
          <p id="P35"><bold>Figure S2. Exon trapping for the P3 variant demonstrating aberrant splicing and an IGV snapshot of P4 and P5 WES data, related to</bold>
<xref rid="F2" ref-type="fig">Figure 2</xref>. <bold>(A)</bold> Exon-trapping results for <italic toggle="yes">MCTS1</italic> exons 2 and 3, for the wild-type and P3 sequences. The region from the <italic toggle="yes">MCTS1</italic> gene is indicated by a blue line, whereas the region from the plasmid backbone is shown in black. <bold>(B-C)</bold> Aberrant <italic toggle="yes">MCTS1</italic> splicing in whole blood from patient 3. <bold>(B)</bold> Counts of reads mapping to junctions between exons 1-4 and intron 2 of the <italic toggle="yes">MCTS1</italic> mRNA in patient 3 and his parents. <bold>(C)</bold> Sashimi plot illustrating the splicing events observed in patient 3 and his parents. <bold>(D)</bold> Large deletion affecting exons 5 and 6 of <italic toggle="yes">MCTS1</italic> in P4 and P5. IGV snapshot of WES reads aligned with the <italic toggle="yes">MCTS1</italic> gene for data from P4, P5 and a control. <bold>(E)</bold> Amino-acid sequence alignment for MCTS2P and MCTS1. <bold>(F-H)</bold> Counts of RNA-seq reads aligned with <italic toggle="yes">MCTS1</italic> and <italic toggle="yes">MCTS2P</italic> for <bold>(F)</bold> whole-blood samples from P3 and his family, <bold>(G)</bold> MCTS1<sup>KO</sup> and WT THP-1 cells, and <bold>(H)</bold> T-cell blasts of the indicated genotypes. <bold>(I)</bold> MCTS2P is hypomorphic for MCTS1-dependent reinitiation. Translation reporter assay on HeLa WT and MCTS1 KO cells. Cells were transfected with the indicated construct and reporter activity was measured. Columns and error bars indicate the mean and SD.</p>
        </caption>
        <media xlink:href="NIHMS1935775-supplement-2.pdf" id="d64e2816" position="anchor"/>
      </supplementary-material>
      <supplementary-material id="SD3" position="float" content-type="local-data">
        <label>3</label>
        <caption>
          <p id="P36"><bold>Figure S3. Defective ribosome recycling and translation reinitiation in the patients&#x2019; cells, related to</bold>
<xref rid="F3" ref-type="fig">Figure 3</xref>. <bold>(A)</bold> Summary of the experimental setup for 40S and 80S ribosome footprinting in SV40-fibroblasts. SV40-fibroblasts from P2, stably transfected with empty vector (EV) or wild-type (WT) MCTS1 were subjected to standard RNA-seq. In parallel, the cells were crosslinked and lysed. Lysates were treated with RNase 1 to obtain ribosome-protected mRNA fragments (footprints). The ribosomes were then separated on a sucrose gradient by density centrifugation, RNA was extracted from ribosome-containing fractions and deep-sequencing libraries of the ribosome footprints were prepared. <bold>(B)</bold> Western blot of the MCTS1 and tubulin proteins in the samples used for ribosome footprinting on WT and MCTS1<sup>KO</sup> HeLa cells. Data from two independent experiments are shown. <bold>(C-D)</bold> Metagene profile of 40S <bold>(C)</bold> and 80S <bold>(D)</bold> ribosome footprints from control and MCTS1-knockout HeLa cells showing the position of the 5&#x2019; end of the ribosome footprints relative to the start codons. Read counts were normalized by sequencing depth. &#x201C;Smooth&#x201D; indicates that the curve was smoothed with a 3 nt sliding window. <bold>(E)</bold> Western blot of the MCTS1, DENR and tubulin proteins in the samples used for ribosome footprinting of P2&#x2019;s SV40 fibroblasts +/&#x2212; MCTS1 transduction. <bold>(F-G)</bold> Metagene profile of 40S <bold>(F)</bold> and 80S <bold>(G)</bold> ribosome footprints from SV40-fibroblasts from P2 transduced with empty vector (EV) or <italic toggle="yes">MCTS1</italic>, showing the positions of the 5&#x2019; ends of the ribosome footprints relative to the start codons. Read counts were normalized against sequencing depth. &#x201C;Smooth&#x201D; indicates the curve was smoothed with a 3 nt sliding window. <bold>(H)</bold> Metagene profiles for 40S ribosome footprints showing the positions of the 5&#x2019; ends of the ribosome footprints relative to uORF stop codons in SV40-fibroblasts. Read counts were normalized against sequencing depth. <bold>(I)</bold> The ribosome recycling defect is dependent on the penultimate codon of the uORFs. Penultimate codon enrichments for uORFs in the top quartile for 40S accumulation (<italic toggle="yes">n</italic> = 1048) relative to all detected uORF stop codons (<italic toggle="yes">n</italic> = 4230). Blue indicates significant enrichment, whereas red indicates significant depletion in the top quartile. Significance was assessed in binomial tests adjusted for multiple testing. <bold>(J-K)</bold> Penultimate stop codon enrichments for mORF <bold>(J)</bold> and uORF <bold>(K)</bold> stop codons in P2&#x2019;s SV40-fibroblasts versus DENR<sup>KO</sup> HeLa cells. <bold>(L)</bold> Correlation of differences in translation efficiency between MCTS1-deficient T-cell blasts and DENR<sup>KO</sup> HeLa cells. Genes that are significantly (<italic toggle="yes">p</italic>&lt;0.1) down-regulated in both datasets are shown in red. <bold>(M-N)</bold> Differences in translational efficiency <bold>(M)</bold> and RNA levels <bold>(N)</bold> of genes related to the IFN-&#x3B3; circuit between T-cell blasts from patients (in red) and controls (in black). Data are normalized against healthy controls for each gene.</p>
        </caption>
        <media xlink:href="NIHMS1935775-supplement-3.pdf" id="d64e2884" position="anchor"/>
      </supplementary-material>
      <supplementary-material id="SD4" position="float" content-type="local-data">
        <label>4</label>
        <caption>
          <p id="P37"><bold>Figure S4. Antibody-based confirmation of the presence of JAK2 protein and JAK2 expression in patient-derived cells upon rescue transduction, related to</bold>
<xref rid="F4" ref-type="fig">Figures 4</xref> and <xref rid="F5" ref-type="fig">5</xref>. <bold>(A)</bold> JAK2 translation is dependent on DENR. Efficiency of JAK2 reporter translation in HeLa cells transfected with siRNA targeting GFP or DENR, as assessed in dual-luciferase assays. Results are shown for three technical replicates representative of three biological replicates. <bold>(B)</bold> Western blot on total protein extracts from control (WT) and JAK<sup>&#x2212;/&#x2212;</sup> HT1080 fibrosarcoma cells for the JAK2, MCTS1 and GAPDH proteins. <bold>(C)</bold> Western blot of T-cell blasts stably transduced with empty vector (EV) or <italic toggle="yes">MCTS1</italic>. Whole-cell lysates of T-cell blast lines from 1-2 healthy controls (HC), P2, P5, an IRAK4-deficient and an IL-12R&#x3B2;1-deficient patient were probed for JAK2, MCTS1, DENR and GAPDH. <bold>(D)</bold> Western blot of WT and MCTS1<sup>KO</sup> THP-1 cells stably transduced with empty vector (EV), <italic toggle="yes">MCTS1</italic> or <italic toggle="yes">JAK2</italic>. Western blots were performed for JAK2, MCTS1 and DENR and the membrane was stained with Ponceau solution for the detection of all proteins present.</p>
        </caption>
        <media xlink:href="NIHMS1935775-supplement-4.pdf" id="d64e2919" position="anchor"/>
      </supplementary-material>
      <supplementary-material id="SD5" position="float" content-type="local-data">
        <label>5</label>
        <caption>
          <p id="P38"><bold>Figure S5. Immunophenotyping of MCTS1-deficient patients, related to</bold>
<xref rid="F5" ref-type="fig">Figure 5</xref>. <bold>(A)</bold> Deep immunophenotyping by mass cytometry of NK-cell subsets in healthy adults, healthy children and patients (P2, P4, P5, P7). <bold>(B)</bold> Deep immunophenotyping by mass cytometry of T-cell subsets. <bold>(C)</bold> Deep immunophenotyping by mass cytometry of dendritic-cell and monocyte subsets. <bold>(D)</bold> Deep immunophenotyping by mass cytometry of B-cell subsets. <bold>(A-D)</bold> No significant differences could be found between controls and the MCTS1-deficient patients in multiple <italic toggle="yes">t</italic>-tests incorporating correction for multiple tests. <bold>(E)</bold> Normal frequency of MAIT cells in MCTS1-deficient patients. The frequency of CD161<sup>+</sup> TCRV&#x3B1;7.2<sup>+</sup> MAIT cells as a percentage of CD3<sup>+</sup> T cells was determined by flow cytometry in healthy controls, P2, P4 and P5 and two IL23R-deficient patients. <bold>(F)</bold> The patients&#x2019; leukocytes fail to produce sufficient IFN-&#x3B3; upon infection with mycobacteria. ELISA analysis of IFN-&#x3B3; levels in whole blood after stimulation with BCG, or BCG plus IL-12, in travel controls (historical and daily shown separately), MCTS1-deficient (P2 and P5), TYK2-deficient and IL-12R&#x3B2;1-deficient patients. UT, unstimulated. Statistical significance was assessed in Mann-Whitney tests, *<italic toggle="yes">p</italic>&lt;0.05.</p>
        </caption>
        <media xlink:href="NIHMS1935775-supplement-5.pdf" id="d64e2957" position="anchor"/>
      </supplementary-material>
      <supplementary-material id="SD6" position="float" content-type="local-data">
        <label>6</label>
        <caption>
          <p id="P39"><bold>Figure S6. Normal responses to IFN-&#x3B3; and IFN-&#x3B1; in MCTS1-deficient cells and blood from the patients, related to</bold>
<xref rid="F5" ref-type="fig">Figure 5</xref>. <bold>(A)</bold> Response of WT and MCTS1<sup>KO</sup> THP-1 cells to IFN-&#x3B3;. Cells were stimulated with IFN-&#x3B3; or IFN-&#x3B1;2b at the indicated dose for 15 minutes and then fixed, stained for pSTAT1 and analyzed by flow cytometry. <bold>(B)</bold> Response of WT and MCTS1<sup>KO</sup> THP-1 cells to IFN-&#x3B3;. Cells were stimulated with IFN-&#x3B3; or IFN-&#x3B1; at the indicated dose for 16 hours, and total RNA was then extracted and gene expression was assessed by RT-qPCR. <bold>(C)</bold> Western blot of the THP-1 MCTS1 polyclonal KO pool. Western blots were performed for MCTS1 and vinculin. <bold>(D-E)</bold> Intact IFN-&#x3B3; and IFN-&#x3B1;2b responses in MCTS1KO THP-1 cells. Analysis of differentially expressed genes (DEGs) in THP-1 cells treated with IFN-&#x3B1; or IFN&#x3B3; for 6 hours. The IFN-&#x3B1;2b and IFN-&#x3B3; treatment conditions were compared to non-stimulated conditions. Gene set enrichment analysis (GSEA) was based on the fold-change in ranking against the Hallmark (HM) gene sets (<ext-link xlink:href="http://www.gsea-msigdb.org/gsea/msigdb/genesets.jsp?collection=H" ext-link-type="uri">http://www.gsea-msigdb.org/gsea/msigdb/genesets.jsp?collection=H</ext-link>). <bold>(D)</bold> The top 10 HM pathways are shown on a dot heatmap. Red colors indicate that the normalized enrichment score (NES) of transcripts for a given gene set mostly increased, whereas blue colors indicate a predominant decrease in enrichment scores relative to non-stimulation conditions. Dot size indicates &#x2212;log<sub>10</sub>FDR (false discovery rate). <bold>(E)</bold> Response of the SV40 fibroblasts of patient P2 and a control (HC) to IFN-&#x3B3;. Cells were left unstimulated (US) or were stimulated with IFN-&#x3B3; at the indicated dose for the indicated time. Whole-cell lysate was then obtained and subjected to western blotting. <bold>(F)</bold> Response of SV40-fibroblasts from P2 and a control, and of fibroblasts from IFNAR1-, IFNAR2-, STAT2- and IRF9-deficient patients to IFN-&#x3B1;. Cells were stimulated with IFN-&#x3B1; at the indicated dose or were left unstimulated (US) for eight hours, and levels of mRNA for <italic toggle="yes">MX1</italic> relative to <italic toggle="yes">GUSB</italic> were then determined by RT-qPCR. The data shown were obtained in four independent experiments. <bold>(G-I)</bold> Intact response to interferons in the patients&#x2019; primary myeloid cells. MDMs (G), MDDCs (H) and osteoclasts (I) from three healthy controls and P2 were derived from primary monocytes by differentiation protocols outlined in the methods section. These cells were stimulated with the indicated concentrations of IFN for 30 minutes and were then lysed and analyzed by western blotting. <bold>(J)</bold> MDMs were stimulated with the indicated cytokines for 6 hours and total RNA was analyzed by RNA-sequencing. Analysis of differentially expressed genes (DEGs) in the indicated conditions relative to non-stimulated cells. Gene set enrichment analysis (GSEA) was based on the fold-change in ranking against the Hallmark (HM) gene sets. <bold>(K)</bold> The patients&#x2019; primary leukocytes respond normally to IFN-&#x3B1;2b and IFN-&#x3B3;. Fresh blood from P4 and P5 and three healthy controls was treated with IFN-&#x3B1;2b or IFN-&#x3B3; for 20 minutes and then subjected to mass cytometry as described in the methods section. STAT phosphorylation was assessed by determining the log<sub>2</sub> fold-change in mean fluorescence intensity (MFI) between non-stimulated and stimulated conditions for each individual. Mean values are shown on a color-coded scale. <bold>(K)</bold> Viral serological results for P2, P4 (under IgG IV), P5 and P7. <bold>(L)</bold> The pathogen-specific antibodies in P4 and his mother are similar to those found in healthy children. Normalized detection of pathogen-specific antibodies by VirScan. P4 was under IgG IV at the time of this sampling.</p>
        </caption>
        <media xlink:href="NIHMS1935775-supplement-6.pdf" id="d64e3011" position="anchor"/>
      </supplementary-material>
      <supplementary-material id="SD7" position="float" content-type="local-data">
        <label>7</label>
        <caption>
          <p id="P40"><bold>Figure S7. Responses to IL-12 and IL-23 in MCTS1-deficient cells and PBMCs, related to</bold>
<xref rid="F5" ref-type="fig">Figures 5</xref> and <xref rid="F6" ref-type="fig">6</xref>. <bold>(A)</bold> Responses of T-cell blasts from patients (P2 and P5) and healthy controls to IL-12. Cells were stimulated with IL-12 or IFN-&#x3B1;2b at the indicated dose for 15 minutes and were then fixed, stained for pSTAT4 and analyzed by flow cytometry. <bold>(B)</bold> Response of patient (P2) and control HSV-T cells (healthy controls and IL-12R&#x3B2;1<sup>&#x2212;/&#x2212;</sup>) to IL-12. Cells were stimulated with IL-12 or IFN-&#x3B1; at the indicated dose for 4 hours; total RNA was then extracted and gene expression was assessed by RT-qPCR. <bold>(C)</bold> Response of healthy control T-cell blasts to IL-23. Cells were stimulated with IL-23 or IFN-&#x3B1; at the indicated dose for 15 minutes and were then fixed, stained for pSTAT3 and analyzed by flow cytometry. <bold>(D)</bold> Impaired response to IL-23 in MCTS1-deficient T-cell blasts. Heatmap representation of the log<sub>2</sub> fold-change (stimulation vs. non-stimulation) in expression for the MYC Target V2 Hallmark gene sets. Rows represent individual genes and columns represent samples grouped by stimulus, with the expression profiles of individual subjects shown for each set of conditions. <bold>(E-F)</bold> Western blot <bold>(E)</bold> of MCTS1KO and JAK2KO HEK-Blue Il-23 sensitive cells and quantification <bold>(F)</bold> of JAK2 levels from three biological replicates of the western blot. <bold>(G)</bold> Cytokine stimulation of HEK-Blue Il-23 sensitive cells. Cells were stimulated for 20 hours with the indicated cytokines and enzymatic reporter activity was assessed according to the manufacturer&#x2019;s instructions. The plot shows four biological replicates with statistical significance assessed in paired, two-tailed <italic toggle="yes">t</italic>-tests, *<italic toggle="yes">p</italic>&lt;0.05. <bold>(H)</bold> JAK2 is rate-limiting for the IL-23 response. JAK2-deficient &#x3B3;2A<sup>&#x2212;</sup> fibrosarcoma cells stably expressing IL-23R and IL-12R&#x3B2;1 were transiently transfected with various amounts of plasmid encoding JAK2, diluted against a plasmid encoding GFP. The cells were then stimulated with 10 ng/ml IL-23 for 30 minutes and harvested for western blotting. HT1080 fibrosarcoma cells were used to determine endogenous JAK2 protein levels. <bold>(I)</bold> The expanded NK cell population is pure. Cultured NK cells were analyzed by flow cytometry after two weeks of culture. <bold>(J-M)</bold> Responses of primary NK cells and monocytes to cytokine stimulation as determined by assessing cytokine secretion. <bold>(J)</bold> Cultured NK cells were starved of IL-2 for 24 hours and were then stimulated for 24 hours with the indicate cytokines. <bold>(K,L,M)</bold> Monocytes were isolated from fresh PBMCs by magnetic sorting for CD14<sup>+</sup> and were directly stimulated with the indicated cytokines for 24 hours. Culture supernatants were analyzed by bead-based ELISA. <bold>(N)</bold> Cultured NK cells were stimulated with the indicated concentration of gandotinib, with the addition of IL-12 or IL-1&#x3B2; + IL-23 after 1 hour and further incubation for 24 hours. Supernatants were analyzed by bead-based ELISA. (<bold>O,P,Q</bold>) Sorted monocytes were stimulated with the indicated concentration of gandotinib, with the addition of IFN-&#x3B1; or IFN-&#x3B3; after one hour and further incubation for 24 hours. Supernatants were analyzed by bead-based ELISA. <bold>(R)</bold> Cytokine levels in the plasma of MCTS1-deficient patients P2, P4 and P5 and healthy, ethnically matched controls. Cytokine levels were assessed by LEGENDplex bead-based ELISA. <bold>(S, T)</bold> Quantification of the response to IFN-&#x3B1; and IL-27 in T-cell blasts from controls and patients by staining for <bold>(S)</bold> pSTATl and <bold>(T)</bold> pSTAT3 and flow cytometry. Statistical significance was assessed in unpaired, two-tailed non-parametric <italic toggle="yes">t</italic>-tests; no significant differences were observed, ns = not significant. <bold>(U)</bold> The patients&#x2019; PBMCs do not secrete TNF in response to IL-23 stimulation. Fresh PBMCs from patients (in red) and heathy controls (WT/WT, in black) were stimulated with 100 ng/ml IL-23 for 48 hours or with PMA plus ionomycin for 24 hours. TNF production was assessed by subjecting the supernatant to LEGENDplex multiplex ELISA. Statistical significance was assessed in unpaired, two-tailed non-parametric <italic toggle="yes">t</italic>-tests, *<italic toggle="yes">p</italic>&lt;0.05, ns = not significant.</p>
        </caption>
        <media xlink:href="NIHMS1935775-supplement-7.pdf" id="d64e3092" position="anchor"/>
      </supplementary-material>
      <supplementary-material id="SD8" position="float" content-type="local-data">
        <label>8</label>
        <caption>
          <p id="P41"><bold>Figure S8. Single-cell transcriptomic analysis of MCTS1-deficient leukocytes, related to</bold>
<xref rid="F7" ref-type="fig">Figure 7</xref>. <bold>(A-C)</bold> Harmonized UMAPs for scRNA-seq data color-coded for batch <bold>(A)</bold>, genotype <bold>(B)</bold> and stimulation <bold>(C)</bold>, showing appropriate integration with respect to the corresponding variables. <bold>(D)</bold> Expression levels of characteristic marker genes in the indicated leukocyte subsets, confirming appropriate subset attribution. <bold>(E)</bold> Leukocyte subset frequency in cryopreserved PBMCs from healthy controls (ctrls), IL-23R-, IL-12R&#x3B2;1- and MCTS-deficient patients. <bold>(F)</bold> Normalized IFN-&#x3B3; expression in healthy control leukocyte subsets in non-stimulated and IL-23-stimulated conditions. <bold>(G)</bold>
<italic toggle="yes">IFNG</italic> expression is poorly induced by IL-23 stimulation in MCTS1-deficient patients&#x2019; V&#x3B4;2<sup>+</sup> &#x3B3;&#x3B4; T, MAIT and T<sc>h</sc>1* cells. The fold-change in <italic toggle="yes">IFNG</italic> mRNA levels following stimulation in MCTS1 patients relative to that in controls is shown on the <italic toggle="yes">x</italic>-axis. The <italic toggle="yes">y</italic>-axis shows the same parameter for IL-12R&#x3B2;1-deficient patients for comparison. The size of the circles indicates the median change (IL-23 versus NS) in normalized <italic toggle="yes">IFNG</italic> mRNA levels in controls for the corresponding subset. <bold>(H)</bold> Flow-cytometry analysis of cell type-specific T-cell blasts from healthy controls, P2 and an IL-12R&#xDF;1-deficient patient. <bold>(I)</bold> JAK2 levels in patients&#x2019; innate-like T-cell blasts. T-cell blasts induced from the sorted T-cell populations indicated, analyzed by western blotting. <bold>(J)</bold> Summary of JAK2 levels in patients&#x2019; lymphoid and myeloid cells. JAK2 levels were determined by western blotting and normalized against loading controls. Columns and error bars represent the mean and SD, respectively.</p>
        </caption>
        <media xlink:href="NIHMS1935775-supplement-8.pdf" id="d64e3146" position="anchor"/>
      </supplementary-material>
      <supplementary-material id="SD9" position="float" content-type="local-data">
        <label>9</label>
        <caption>
          <p id="P83"><bold>Table S3, related to</bold>
<xref rid="F3" ref-type="fig">figure 3</xref><bold>:</bold> Genes differentially expressed in P2 SV40-fibroblasts upon MCTS1 transduction</p>
        </caption>
        <media xlink:href="NIHMS1935775-supplement-9.xlsx" id="d64e3157" position="anchor"/>
      </supplementary-material>
      <supplementary-material id="SD10" position="float" content-type="local-data">
        <label>10</label>
        <caption>
          <p id="P84"><bold>Table S5, related to</bold>
<xref rid="F3" ref-type="fig">figure 3</xref><bold>:</bold> Genes differentially expressed in the T-cell blasts of patients (<italic toggle="yes">n</italic> = 4) relative to controls (<italic toggle="yes">n</italic> = 4)</p>
        </caption>
        <media xlink:href="NIHMS1935775-supplement-10.xlsx" id="d64e3174" position="anchor"/>
      </supplementary-material>
      <supplementary-material id="SD11" position="float" content-type="local-data">
        <label>11</label>
        <caption>
          <p id="P85"><bold>Table S8, related to</bold>
<xref rid="F6" ref-type="fig">figure 6</xref><bold>:</bold> RNA-seq of PBMC stimulated with IL-23.</p>
        </caption>
        <media xlink:href="NIHMS1935775-supplement-11.xlsx" id="d64e3186" position="anchor"/>
      </supplementary-material>
      <supplementary-material id="SD12" position="float" content-type="local-data">
        <label>12</label>
        <media xlink:href="NIHMS1935775-supplement-12.pdf" id="d64e3189" position="anchor"/>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="S62">
      <title>Acknowledgements</title>
      <p id="P86">The authors thank all the patients, their relatives and the treatment teams for their cooperation in this study. We also thank: all the members of the HGID laboratory for helpful discussions, Christine Rivalain, Lazaro Lorenzo-Diaz, Maya Chrabieh, Mark Woollet, Erin Williams, Dana Liu and Yelena Nemirovskaya for administrative assistance. the INEM flow-cytometry facility, in particular Jerome Megret, for their support and services.</p>
      <sec id="S63">
        <title>Funding</title>
        <p id="P87">The Laboratory of Human Genetics of Infectious Diseases was funded by the Howard Hughes Medical Institute, The Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R37AI095983), the National Center for Research Resources and the National Center for Advancing Sciences, NIH (UL1TR001866), the Shapiro-Silverberg Fund for the Advancement of Translational Research, the French Foundation for Medical Research (FRM) (EQU201903007798), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French National Research Agency (ANR) under the &#x201C;Investments for the future&#x201D; program (ANR-10-IAHU-01), ANR-GENMSMD (ANR-16-CE17-0005-01 for J.Bu.), ANR-MAFMACRO, the European Union&#x2019;s Horizon 2020 research and innovation program under grant agreement no. 824110 (EASI-genomics), the Square Foundation, <italic toggle="yes">Grandir</italic> - <italic toggle="yes">Fonds de solidarit&#xE9; pour l</italic>&#x2019;<italic toggle="yes">enfance</italic>, the SCOR Corporate Foundation for Science, <italic toggle="yes">Institut National de la Sant&#xE9; et de la Recherche M&#xE9;dicale</italic> (INSERM), and Paris Cit&#xE9; University. N.M. was supported by Sidra Medicine and the Qatar National Research Fund (grant no.: NPRP9-251-3-045). The Yale Center for Mendelian Genomics (UM1HG006504) was funded by the National Human Genome Research Institute, the Yale GSP Coordinating Center (U24 HG008956), and the Yale High-Performance Computing Center (S10OD018521). J.Bo. was supported by a fellowship from EMBO and a Marie Curie Research grant. M.O. was supported by the David Rockefeller Graduate Program, the Funai Foundation for Information Technology (FFIT), the Honjo International Scholarship Foundation (HISF), the New York Hideyo Noguchi Memorial Society (HNMS), and the National Cancer Institute (NCI) F99 Award (F99CA274708). Q.P. was supported by the <italic toggle="yes">Assistance Publique Hopitaux de Paris</italic> (research year) and the MD-PhD program of INSERM (<italic toggle="yes">Ecole de l&#x2019;INSERM Liliane Bettencourt</italic>). J.R. was supported by the INSERM PhD program for doctors of pharmacy (<italic toggle="yes">poste d&#x2019;accueil</italic> INSERM). J.R. and T.L.-V. were supported by the Bettencourt-Schueller Foundation and the MD-PhD program of the Imagine Institute. A-L.N. was supported by the Bettencourt Schueller Foundation and the International PhD program of the Imagine Institute. Q. Zhou was supported by the &#x2018;Outstanding Youth Talent Training Program&#x2019; of the Children&#x2019;s Hospital of Fudan University.</p>
      </sec>
    </ack>
    <fn-group>
      <fn id="FN3">
        <p id="P88" content-type="publisher-disclaimer">This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.</p>
      </fn>
      <fn fn-type="COI-statement" id="FN4">
        <p id="P89">Declaration of interests</p>
        <p id="P90">J.-L.C. serves on the scientific advisory boards of ADMA Biologics Inc., Kymera Therapeutics, and Elixiron Immunotherapeutics.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1.</label>
        <mixed-citation publication-type="journal"><name><surname>Casanova</surname><given-names>JL</given-names></name>, and <name><surname>Abel</surname><given-names>L</given-names></name> (<year>2021</year>). <article-title>Lethal Infectious Diseases as Inborn Errors of Immunity: Toward a Synthesis of the Germ and Genetic Theories</article-title>. <source>Annu Rev Pathol</source>
<volume>16</volume>, <fpage>23</fpage>&#x2013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-pathol-031920-101429</pub-id>.<pub-id pub-id-type="pmid">32289233</pub-id>
</mixed-citation>
      </ref>
      <ref id="R2">
        <label>2.</label>
        <mixed-citation publication-type="journal"><name><surname>Casanova</surname><given-names>JL</given-names></name>, and <name><surname>Abel</surname><given-names>L</given-names></name> (<year>2022</year>). <article-title>From rare disorders of immunity to common determinants of infection: Following the mechanistic thread</article-title>. <source>Cell</source>
<volume>185</volume>, <fpage>3086</fpage>&#x2013;<lpage>3103</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2022.07.004</pub-id>.<pub-id pub-id-type="pmid">35985287</pub-id>
</mixed-citation>
      </ref>
      <ref id="R3">
        <label>3.</label>
        <mixed-citation publication-type="journal"><name><surname>Furin</surname><given-names>J</given-names></name>, <name><surname>Cox</surname><given-names>H</given-names></name>, and <name><surname>Pai</surname><given-names>M</given-names></name> (<year>2019</year>). <source>Tuberculosis. Lancet</source>
<volume>393</volume>, <fpage>1642</fpage>&#x2013;<lpage>1656</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(19)30308-3</pub-id>.<pub-id pub-id-type="pmid">30904262</pub-id>
</mixed-citation>
      </ref>
      <ref id="R4">
        <label>4.</label>
        <mixed-citation publication-type="journal"><name><surname>Jouanguy</surname><given-names>E</given-names></name>, <name><surname>Altare</surname><given-names>F</given-names></name>, <name><surname>Lamhamedi</surname><given-names>S</given-names></name>, <name><surname>Revy</surname><given-names>P</given-names></name>, <name><surname>Emile</surname><given-names>JF</given-names></name>, <name><surname>Newport</surname><given-names>M</given-names></name>, <name><surname>Levin</surname><given-names>M</given-names></name>, <name><surname>Blanche</surname><given-names>S</given-names></name>, <name><surname>Seboun</surname><given-names>E</given-names></name>, <name><surname>Fischer</surname><given-names>A</given-names></name>, and <name><surname>Casanova</surname><given-names>JL</given-names></name> (<year>1996</year>). <article-title>Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection</article-title>. <source>N Engl J Med</source>
<volume>335</volume>, <fpage>1956</fpage>&#x2013;<lpage>1961</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM199612263352604</pub-id>.<pub-id pub-id-type="pmid">8960475</pub-id>
</mixed-citation>
      </ref>
      <ref id="R5">
        <label>5.</label>
        <mixed-citation publication-type="journal"><name><surname>Newport</surname><given-names>MJ</given-names></name>, <name><surname>Huxley</surname><given-names>CM</given-names></name>, <name><surname>Huston</surname><given-names>S</given-names></name>, <name><surname>Hawrylowicz</surname><given-names>CM</given-names></name>, <name><surname>Oostra</surname><given-names>BA</given-names></name>, <name><surname>Williamson</surname><given-names>R</given-names></name>, and <name><surname>Levin</surname><given-names>M</given-names></name> (<year>1996</year>). <article-title>A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection</article-title>. <source>N Engl J Med</source>
<volume>335</volume>, <fpage>1941</fpage>&#x2013;<lpage>1949</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM199612263352602</pub-id>.<pub-id pub-id-type="pmid">8960473</pub-id>
</mixed-citation>
      </ref>
      <ref id="R6">
        <label>6.</label>
        <mixed-citation publication-type="journal"><name><surname>Altare</surname><given-names>F</given-names></name>, <name><surname>Durandy</surname><given-names>A</given-names></name>, <name><surname>Lammas</surname><given-names>D</given-names></name>, <name><surname>Emile</surname><given-names>JF</given-names></name>, <name><surname>Lamhamedi</surname><given-names>S</given-names></name>, <name><surname>Le Deist</surname><given-names>F</given-names></name>, <name><surname>Drysdale</surname><given-names>P</given-names></name>, <name><surname>Jouanguy</surname><given-names>E</given-names></name>, <name><surname>Doffinger</surname><given-names>R</given-names></name>, <name><surname>Bernaudin</surname><given-names>F</given-names></name>, <etal/> (<year>1998</year>). <article-title>Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency</article-title>. <source>Science</source>
<volume>280</volume>, <fpage>1432</fpage>&#x2013;<lpage>1435</lpage>. <pub-id pub-id-type="doi">10.1126/science.280.5368.1432</pub-id>.<pub-id pub-id-type="pmid">9603732</pub-id>
</mixed-citation>
      </ref>
      <ref id="R7">
        <label>7.</label>
        <mixed-citation publication-type="journal"><name><surname>Altare</surname><given-names>F</given-names></name>, <name><surname>Lammas</surname><given-names>D</given-names></name>, <name><surname>Revy</surname><given-names>P</given-names></name>, <name><surname>Jouanguy</surname><given-names>E</given-names></name>, <name><surname>Doffinger</surname><given-names>R</given-names></name>, <name><surname>Lamhamedi</surname><given-names>S</given-names></name>, <name><surname>Drysdale</surname><given-names>P</given-names></name>, <name><surname>Scheel-Toellner</surname><given-names>D</given-names></name>, <name><surname>Girdlestone</surname><given-names>J</given-names></name>, <name><surname>Darbyshire</surname><given-names>P</given-names></name>, <etal/> (<year>1998</year>). <article-title>Inherited interleukin 12 deficiency in a child with bacille Calmette-Guerin and Salmonella enteritidis disseminated infection</article-title>. <source>J Clin Invest</source>
<volume>102</volume>, <fpage>2035</fpage>&#x2013;<lpage>2040</lpage>. <pub-id pub-id-type="doi">10.1172/JCI4950</pub-id>.<pub-id pub-id-type="pmid">9854038</pub-id>
</mixed-citation>
      </ref>
      <ref id="R8">
        <label>8.</label>
        <mixed-citation publication-type="journal"><name><surname>Dorman</surname><given-names>SE</given-names></name>, and <name><surname>Holland</surname><given-names>SM</given-names></name> (<year>1998</year>). <article-title>Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection</article-title>. <source>J Clin Invest</source>
<volume>101</volume>, <fpage>2364</fpage>&#x2013;<lpage>2369</lpage>. <pub-id pub-id-type="doi">10.1172/JCI2901</pub-id>.<pub-id pub-id-type="pmid">9616207</pub-id>
</mixed-citation>
      </ref>
      <ref id="R9">
        <label>9.</label>
        <mixed-citation publication-type="journal"><name><surname>Casanova</surname><given-names>JL</given-names></name>, and <name><surname>Abel</surname><given-names>L</given-names></name> (<year>2002</year>). <article-title>Genetic dissection of immunity to mycobacteria: the human model</article-title>. <source>Annu Rev Immunol</source>
<volume>20</volume>, <fpage>581</fpage>&#x2013;<lpage>620</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.immunol.20.081501.125851</pub-id>.<pub-id pub-id-type="pmid">11861613</pub-id>
</mixed-citation>
      </ref>
      <ref id="R10">
        <label>10.</label>
        <mixed-citation publication-type="journal"><name><surname>Casanova</surname><given-names>JL</given-names></name>, <name><surname>Blanche</surname><given-names>S</given-names></name>, <name><surname>Emile</surname><given-names>JF</given-names></name>, <name><surname>Jouanguy</surname><given-names>E</given-names></name>, <name><surname>Lamhamedi</surname><given-names>S</given-names></name>, <name><surname>Altare</surname><given-names>F</given-names></name>, <name><surname>Stephan</surname><given-names>JL</given-names></name>, <name><surname>Bernaudin</surname><given-names>F</given-names></name>, <name><surname>Bordigoni</surname><given-names>P</given-names></name>, <name><surname>Turck</surname><given-names>D</given-names></name>, <etal/> (<year>1996</year>). <article-title>Idiopathic disseminated bacillus Calmette-Guerin infection: a French national retrospective study</article-title>. <source>Pediatrics</source>
<volume>98</volume>, <fpage>774</fpage>&#x2013;<lpage>778</lpage>.<pub-id pub-id-type="pmid">8885960</pub-id>
</mixed-citation>
      </ref>
      <ref id="R11">
        <label>11.</label>
        <mixed-citation publication-type="journal"><name><surname>Bustamante</surname><given-names>J</given-names></name>. (<year>2020</year>). <article-title>Mendelian susceptibility to mycobacterial disease: recent discoveries</article-title>. <source>Hum Genet</source>
<volume>139</volume>, <fpage>993</fpage>&#x2013;<lpage>1000</lpage>. <pub-id pub-id-type="doi">10.1007/s00439-020-02120-y</pub-id>.<pub-id pub-id-type="pmid">32025907</pub-id>
</mixed-citation>
      </ref>
      <ref id="R12">
        <label>12.</label>
        <mixed-citation publication-type="journal"><name><surname>Bustamante</surname><given-names>J</given-names></name>, <name><surname>Boisson-Dupuis</surname><given-names>S</given-names></name>, <name><surname>Abel</surname><given-names>L</given-names></name>, and <name><surname>Casanova</surname><given-names>JL</given-names></name> (<year>2014</year>). <article-title>Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-gamma immunity</article-title>. <source>Semin Immunol</source>
<volume>26</volume>, <fpage>454</fpage>&#x2013;<lpage>470</lpage>. <pub-id pub-id-type="doi">10.1016/j.smim.2014.09.008</pub-id>.<pub-id pub-id-type="pmid">25453225</pub-id>
</mixed-citation>
      </ref>
      <ref id="R13">
        <label>13.</label>
        <mixed-citation publication-type="journal"><name><surname>Boisson-Dupuis</surname><given-names>S</given-names></name>, and <name><surname>Bustamante</surname><given-names>J</given-names></name> (<year>2021</year>). <article-title>Mycobacterial diseases in patients with inborn errors of immunity</article-title>. <source>Curr Opin Immunol</source>
<volume>72</volume>, <fpage>262</fpage>&#x2013;<lpage>271</lpage>. <pub-id pub-id-type="doi">10.1016/j.coi.2021.07.001</pub-id>.<pub-id pub-id-type="pmid">34315005</pub-id>
</mixed-citation>
      </ref>
      <ref id="R14">
        <label>14.</label>
        <mixed-citation publication-type="journal"><name><surname>Rosain</surname><given-names>J</given-names></name>, <name><surname>Kong</surname><given-names>XF</given-names></name>, <name><surname>Martinez-Barricarte</surname><given-names>R</given-names></name>, <name><surname>Oleaga-Quintas</surname><given-names>C</given-names></name>, <name><surname>Ramirez-Alejo</surname><given-names>N</given-names></name>, <name><surname>Markle</surname><given-names>J</given-names></name>, <name><surname>Okada</surname><given-names>S</given-names></name>, <name><surname>Boisson-Dupuis</surname><given-names>S</given-names></name>, <name><surname>Casanova</surname><given-names>JL</given-names></name>, and <name><surname>Bustamante</surname><given-names>J</given-names></name> (<year>2019</year>). <article-title>Mendelian susceptibility to mycobacterial disease: 2014-2018 update</article-title>. <source>Immunol Cell Biol</source>
<volume>97</volume>, <fpage>360</fpage>&#x2013;<lpage>367</lpage>. <pub-id pub-id-type="doi">10.1111/imcb.12210</pub-id>.<pub-id pub-id-type="pmid">30264912</pub-id>
</mixed-citation>
      </ref>
      <ref id="R15">
        <label>15.</label>
        <mixed-citation publication-type="journal"><name><surname>Martin-Fernandez</surname><given-names>M</given-names></name>, <name><surname>Buta</surname><given-names>S</given-names></name>, <name><surname>Le Voyer</surname><given-names>T</given-names></name>, <name><surname>Li</surname><given-names>Z</given-names></name>, <name><surname>Dynesen</surname><given-names>LT</given-names></name>, <name><surname>Vuillier</surname><given-names>F</given-names></name>, <name><surname>Franklin</surname><given-names>L</given-names></name>, <name><surname>Ailal</surname><given-names>F</given-names></name>, <name><surname>Muglia Amancio</surname><given-names>A</given-names></name>, <name><surname>Malle</surname><given-names>L</given-names></name>, <etal/> (<year>2022</year>). <article-title>A partial form of inherited human USP18 deficiency underlies infection and inflammation</article-title>. <source>J Exp Med</source>
<volume>219</volume>. <pub-id pub-id-type="doi">10.1084/jem.20211273</pub-id>.</mixed-citation>
      </ref>
      <ref id="R16">
        <label>16.</label>
        <mixed-citation publication-type="journal"><name><surname>Boisson-Dupuis</surname><given-names>S</given-names></name>. (<year>2020</year>). <article-title>The monogenic basis of human tuberculosis</article-title>. <source>Hum Genet</source>
<volume>139</volume>, <fpage>1001</fpage>&#x2013;<lpage>1009</lpage>. <pub-id pub-id-type="doi">10.1007/s00439-020-02126-6</pub-id>.<pub-id pub-id-type="pmid">32055999</pub-id>
</mixed-citation>
      </ref>
      <ref id="R17">
        <label>17.</label>
        <mixed-citation publication-type="journal"><name><surname>Bogunovic</surname><given-names>D</given-names></name>, <name><surname>Byun</surname><given-names>M</given-names></name>, <name><surname>Durfee</surname><given-names>LA</given-names></name>, <name><surname>Abhyankar</surname><given-names>A</given-names></name>, <name><surname>Sanal</surname><given-names>O</given-names></name>, <name><surname>Mansouri</surname><given-names>D</given-names></name>, <name><surname>Salem</surname><given-names>S</given-names></name>, <name><surname>Radovanovic</surname><given-names>I</given-names></name>, <name><surname>Grant</surname><given-names>AV</given-names></name>, <name><surname>Adimi</surname><given-names>P</given-names></name>, <etal/> (<year>2012</year>). <article-title>Mycobacterial disease and impaired IFN-gamma immunity in humans with inherited ISG15 deficiency</article-title>. <source>Science</source>
<volume>337</volume>, <fpage>1684</fpage>&#x2013;<lpage>1688</lpage>. <pub-id pub-id-type="doi">10.1126/science.1224026</pub-id>.<pub-id pub-id-type="pmid">22859821</pub-id>
</mixed-citation>
      </ref>
      <ref id="R18">
        <label>18.</label>
        <mixed-citation publication-type="journal"><name><surname>Boisson-Dupuis</surname><given-names>S</given-names></name>, <name><surname>Ramirez-Alejo</surname><given-names>N</given-names></name>, <name><surname>Li</surname><given-names>Z</given-names></name>, <name><surname>Patin</surname><given-names>E</given-names></name>, <name><surname>Rao</surname><given-names>G</given-names></name>, <name><surname>Kerner</surname><given-names>G</given-names></name>, <name><surname>Lim</surname><given-names>CK</given-names></name>, <name><surname>Krementsov</surname><given-names>DN</given-names></name>, <name><surname>Hernandez</surname><given-names>N</given-names></name>, <name><surname>Ma</surname><given-names>CS</given-names></name>, <etal/> (<year>2018</year>). <article-title>Tuberculosis and impaired IL-23-dependent IFN-gamma immunity in humans homozygous for a common TYK2 missense variant</article-title>. <source>Sci Immunol</source>
<volume>3</volume>. <pub-id pub-id-type="doi">10.1126/sciimmunol.aau8714</pub-id>.</mixed-citation>
      </ref>
      <ref id="R19">
        <label>19.</label>
        <mixed-citation publication-type="journal"><name><surname>Bustamante</surname><given-names>J</given-names></name>, <name><surname>Arias</surname><given-names>AA</given-names></name>, <name><surname>Vogt</surname><given-names>G</given-names></name>, <name><surname>Picard</surname><given-names>C</given-names></name>, <name><surname>Galicia</surname><given-names>LB</given-names></name>, <name><surname>Prando</surname><given-names>C</given-names></name> , <name><surname>Grant</surname><given-names>AV</given-names></name>, <name><surname>Marchal</surname><given-names>CC</given-names></name>, <name><surname>Hubeau</surname><given-names>M</given-names></name>, <name><surname>Chapgier</surname><given-names>A</given-names></name>, <etal/> (<year>2011</year>). <article-title>Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease</article-title>. <source>Nat Immunol</source>
<volume>12</volume>, <fpage>213</fpage>&#x2013;<lpage>221</lpage>. <pub-id pub-id-type="doi">10.1038/ni.1992</pub-id>.<pub-id pub-id-type="pmid">21278736</pub-id>
</mixed-citation>
      </ref>
      <ref id="R20">
        <label>20.</label>
        <mixed-citation publication-type="journal"><name><surname>Dupuis</surname><given-names>S</given-names></name>, <name><surname>Dargemont</surname><given-names>C</given-names></name>, <name><surname>Fieschi</surname><given-names>C</given-names></name>, <name><surname>Thomassin</surname><given-names>N</given-names></name>, <name><surname>Rosenzweig</surname><given-names>S</given-names></name>, <name><surname>Harris</surname><given-names>J</given-names></name>, <name><surname>Holland</surname><given-names>SM</given-names></name>, <name><surname>Schreiber</surname><given-names>RD</given-names></name>, and <name><surname>Casanova</surname><given-names>JL</given-names></name> (<year>2001</year>). <article-title>Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation</article-title>. <source>Science</source>
<volume>293</volume>, <fpage>300</fpage>&#x2013;<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1126/science.1061154</pub-id>.<pub-id pub-id-type="pmid">11452125</pub-id>
</mixed-citation>
      </ref>
      <ref id="R21">
        <label>21.</label>
        <mixed-citation publication-type="journal"><name><surname>Dupuis</surname><given-names>S</given-names></name>, <name><surname>Jouanguy</surname><given-names>E</given-names></name>, <name><surname>Al-Hajjar</surname><given-names>S</given-names></name>, <name><surname>Fieschi</surname><given-names>C</given-names></name>, <name><surname>Al-Mohsen</surname><given-names>IZ</given-names></name>, <name><surname>Al-Jumaah</surname><given-names>S</given-names></name>, <name><surname>Yang</surname><given-names>K</given-names></name>, <name><surname>Chapgier</surname><given-names>A</given-names></name>, <name><surname>Eidenschenk</surname><given-names>C</given-names></name>, <name><surname>Eid</surname><given-names>P</given-names></name>, <etal/> (<year>2003</year>). <article-title>Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency</article-title>. <source>Nat Genet</source>
<volume>33</volume>, <fpage>388</fpage>&#x2013;<lpage>391</lpage>. <pub-id pub-id-type="doi">10.1038/ng1097</pub-id>.<pub-id pub-id-type="pmid">12590259</pub-id>
</mixed-citation>
      </ref>
      <ref id="R22">
        <label>22.</label>
        <mixed-citation publication-type="journal"><name><surname>Eletto</surname><given-names>D</given-names></name>, <name><surname>Burns</surname><given-names>SO</given-names></name>, <name><surname>Angulo</surname><given-names>I</given-names></name>, <name><surname>Plagnol</surname><given-names>V</given-names></name>, <name><surname>Gilmour</surname><given-names>KC</given-names></name>, <name><surname>Henriquez</surname><given-names>F</given-names></name>, <name><surname>Curtis</surname><given-names>J</given-names></name>, <name><surname>Gaspar</surname><given-names>M</given-names></name>, <name><surname>Nowak</surname><given-names>K</given-names></name>, <name><surname>Daza-Cajigal</surname><given-names>V</given-names></name>, <etal/> (<year>2016</year>). <article-title>Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection</article-title>. <source>Nat Commun</source>
<volume>7</volume>, <fpage>13992</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms13992</pub-id>.<pub-id pub-id-type="pmid">28008925</pub-id>
</mixed-citation>
      </ref>
      <ref id="R23">
        <label>23.</label>
        <mixed-citation publication-type="journal"><name><surname>Filipe-Santos</surname><given-names>O</given-names></name>, <name><surname>Bustamante</surname><given-names>J</given-names></name>, <name><surname>Haverkamp</surname><given-names>MH</given-names></name>, <name><surname>Vinolo</surname><given-names>E</given-names></name>, <name><surname>Ku</surname><given-names>CL</given-names></name>, <name><surname>Puel</surname><given-names>A</given-names></name>, <name><surname>Frucht</surname><given-names>DM</given-names></name>, <name><surname>Christel</surname><given-names>K</given-names></name>, <name><surname>von Bernuth</surname><given-names>H</given-names></name>, <name><surname>Jouanguy</surname><given-names>E</given-names></name>, <etal/> (<year>2006</year>). <article-title>X-linked susceptibility to mycobacteria is caused by mutations in NEMO impairing CD40-dependent IL-12 production</article-title>. <source>J Exp Med</source>
<volume>203</volume>, <fpage>1745</fpage>&#x2013;<lpage>1759</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20060085</pub-id>.<pub-id pub-id-type="pmid">16818673</pub-id>
</mixed-citation>
      </ref>
      <ref id="R24">
        <label>24.</label>
        <mixed-citation publication-type="journal"><name><surname>Hambleton</surname><given-names>S</given-names></name>, <name><surname>Salem</surname><given-names>S</given-names></name>, <name><surname>Bustamante</surname><given-names>J</given-names></name>, <name><surname>Bigley</surname><given-names>V</given-names></name>, <name><surname>Boisson-Dupuis</surname><given-names>S</given-names></name>, <name><surname>Azevedo</surname><given-names>J</given-names></name>, <name><surname>Fortin</surname><given-names>A</given-names></name>, <name><surname>Haniffa</surname><given-names>M</given-names></name>, <name><surname>Ceron-Gutierrez</surname><given-names>L</given-names></name>, <name><surname>Bacon</surname><given-names>CM</given-names></name>, <etal/> (<year>2011</year>). <article-title>IRF8 mutations and human dendritic-cell immunodeficiency</article-title>. <source>N Engl J Med</source>
<volume>365</volume>, <fpage>127</fpage>&#x2013;<lpage>138</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1100066</pub-id>.<pub-id pub-id-type="pmid">21524210</pub-id>
</mixed-citation>
      </ref>
      <ref id="R25">
        <label>25.</label>
        <mixed-citation publication-type="journal"><name><surname>Jouanguy</surname><given-names>E</given-names></name>, <name><surname>Lamhamedi-Cherradi</surname><given-names>S</given-names></name>, <name><surname>Lammas</surname><given-names>D</given-names></name>, <name><surname>Dorman</surname><given-names>SE</given-names></name>, <name><surname>Fondaneche</surname><given-names>MC</given-names></name>, <name><surname>Dupuis</surname><given-names>S</given-names></name>, <name><surname>Doffinger</surname><given-names>R</given-names></name>, <name><surname>Altare</surname><given-names>F</given-names></name>, <name><surname>Girdlestone</surname><given-names>J</given-names></name>, <name><surname>Emile</surname><given-names>JF</given-names></name>, <etal/> (<year>1999</year>). <article-title>A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection</article-title>. <source>Nat Genet</source>
<volume>21</volume>, <fpage>370</fpage>&#x2013;<lpage>378</lpage>. <pub-id pub-id-type="doi">10.1038/7701</pub-id>.<pub-id pub-id-type="pmid">10192386</pub-id>
</mixed-citation>
      </ref>
      <ref id="R26">
        <label>26.</label>
        <mixed-citation publication-type="journal"><name><surname>Kerner</surname><given-names>G</given-names></name>, <name><surname>Rosain</surname><given-names>J</given-names></name>, <name><surname>Guerin</surname><given-names>A</given-names></name>, <name><surname>Al-Khabaz</surname><given-names>A</given-names></name>, <name><surname>Oleaga-Quintas</surname><given-names>C</given-names></name>, <name><surname>Rapaport</surname><given-names>F</given-names></name>, <name><surname>Massaad</surname><given-names>MJ</given-names></name>, <name><surname>Ding</surname><given-names>JY</given-names></name>, <name><surname>Khan</surname><given-names>T</given-names></name>, <name><surname>Ali</surname><given-names>FA</given-names></name>, <etal/> (<year>2020</year>). <article-title>Inherited human IFN-gamma deficiency underlies mycobacterial disease</article-title>. <source>J Clin Invest</source>
<volume>130</volume>, <fpage>3158</fpage>&#x2013;<lpage>3171</lpage>. <pub-id pub-id-type="doi">10.1172/JCI135460</pub-id>.<pub-id pub-id-type="pmid">32163377</pub-id>
</mixed-citation>
      </ref>
      <ref id="R27">
        <label>27.</label>
        <mixed-citation publication-type="journal"><name><surname>Kong</surname><given-names>XF</given-names></name>, <name><surname>Martinez-Barricarte</surname><given-names>R</given-names></name>, <name><surname>Kennedy</surname><given-names>J</given-names></name>, <name><surname>Mele</surname><given-names>F</given-names></name>, <name><surname>Lazarov</surname><given-names>T</given-names></name>, <name><surname>Deenick</surname><given-names>EK</given-names></name>, <name><surname>Ma</surname><given-names>CS</given-names></name>, <name><surname>Breton</surname><given-names>G</given-names></name>, <name><surname>Lucero</surname><given-names>KB</given-names></name>, <name><surname>Langlais</surname><given-names>D</given-names></name>, <etal/> (<year>2018</year>). <article-title>Disruption of an antimycobacterial circuit between dendritic and helper T cells in human SPPL2a deficiency</article-title>. <source>Nat Immunol</source>
<volume>19</volume>, <fpage>973</fpage>&#x2013;<lpage>985</lpage>. <pub-id pub-id-type="doi">10.1038/s41590-018-0178-z</pub-id>.<pub-id pub-id-type="pmid">30127434</pub-id>
</mixed-citation>
      </ref>
      <ref id="R28">
        <label>28.</label>
        <mixed-citation publication-type="journal"><name><surname>Kreins</surname><given-names>AY</given-names></name>, <name><surname>Ciancanelli</surname><given-names>MJ</given-names></name>, <name><surname>Okada</surname><given-names>S</given-names></name>, <name><surname>Kong</surname><given-names>XF</given-names></name>, <name><surname>Ramirez-Alejo</surname><given-names>N</given-names></name>, <name><surname>Kilic</surname><given-names>SS</given-names></name>, <name><surname>El Baghdadi</surname><given-names>J</given-names></name>, <name><surname>Nonoyama</surname><given-names>S</given-names></name>, <name><surname>Mahdaviani</surname><given-names>SA</given-names></name>, <name><surname>Ailal</surname><given-names>F</given-names></name>, <etal/> (<year>2015</year>). <article-title>Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome</article-title>. <source>J Exp Med</source>
<volume>212</volume>, <fpage>1641</fpage>&#x2013;<lpage>1662</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20140280</pub-id>.<pub-id pub-id-type="pmid">26304966</pub-id>
</mixed-citation>
      </ref>
      <ref id="R29">
        <label>29.</label>
        <mixed-citation publication-type="journal"><name><surname>Le Voyer</surname><given-names>T</given-names></name>, <name><surname>Neehus</surname><given-names>AL</given-names></name>, <name><surname>Yang</surname><given-names>R</given-names></name>, <name><surname>Ogishi</surname><given-names>M</given-names></name>, <name><surname>Rosain</surname><given-names>J</given-names></name>, <name><surname>Alroqi</surname><given-names>F</given-names></name>, <name><surname>Alshalan</surname><given-names>M</given-names></name>, <name><surname>Blumental</surname><given-names>S</given-names></name>, <name><surname>Al Ali</surname><given-names>F</given-names></name>, <name><surname>Khan</surname><given-names>T</given-names></name>, <etal/> (<year>2021</year>). <article-title>Inherited deficiency of stress granule ZNFX1 in patients with monocytosis and mycobacterial disease</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>118</volume>. <pub-id pub-id-type="doi">10.1073/pnas.2102804118</pub-id>.</mixed-citation>
      </ref>
      <ref id="R30">
        <label>30.</label>
        <mixed-citation publication-type="journal"><name><surname>Martinez-Barricarte</surname><given-names>R</given-names></name>, <name><surname>Markle</surname><given-names>JG</given-names></name>, <name><surname>Ma</surname><given-names>CS</given-names></name>, <name><surname>Deenick</surname><given-names>EK</given-names></name>, <name><surname>Ramirez-Alejo</surname><given-names>N</given-names></name>, <name><surname>Mele</surname><given-names>F</given-names></name>, <name><surname>Latorre</surname><given-names>D</given-names></name>, <name><surname>Mahdaviani</surname><given-names>SA</given-names></name>, <name><surname>Aytekin</surname><given-names>C</given-names></name>, <name><surname>Mansouri</surname><given-names>D</given-names></name> , <etal/> (<year>2018</year>). <article-title>Human IFN-gamma immunity to mycobacteria is governed by both IL-12 and IL-23</article-title>. <source>Sci Immunol</source>
<volume>3</volume>. <pub-id pub-id-type="doi">10.1126/sciimmunol.aau6759</pub-id>.</mixed-citation>
      </ref>
      <ref id="R31">
        <label>31.</label>
        <mixed-citation publication-type="journal"><name><surname>Okada</surname><given-names>S</given-names></name>, <name><surname>Markle</surname><given-names>JG</given-names></name>, <name><surname>Deenick</surname><given-names>EK</given-names></name>, <name><surname>Mele</surname><given-names>F</given-names></name>, <name><surname>Averbuch</surname><given-names>D</given-names></name>, <name><surname>Lagos</surname><given-names>M</given-names></name>, <name><surname>Alzahrani</surname><given-names>M</given-names></name>, <name><surname>Al-Muhsen</surname><given-names>S</given-names></name>, <name><surname>Halwani</surname><given-names>R</given-names></name>, <name><surname>Ma</surname><given-names>CS</given-names></name>, <etal/> (<year>2015</year>). <article-title>IMMUNODEFICIENCIES. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations</article-title>. <source>Science</source>
<volume>349</volume>, <fpage>606</fpage>&#x2013;<lpage>613</lpage>. <pub-id pub-id-type="doi">10.1126/science.aaa4282</pub-id>.<pub-id pub-id-type="pmid">26160376</pub-id>
</mixed-citation>
      </ref>
      <ref id="R32">
        <label>32.</label>
        <mixed-citation publication-type="journal"><name><surname>Vogt</surname><given-names>G</given-names></name>, <name><surname>Bustamante</surname><given-names>J</given-names></name>, <name><surname>Chapgier</surname><given-names>A</given-names></name>, <name><surname>Feinberg</surname><given-names>J</given-names></name>, <name><surname>Boisson Dupuis</surname><given-names>S</given-names></name>, <name><surname>Picard</surname><given-names>C</given-names></name>, <name><surname>Mahlaoui</surname><given-names>N</given-names></name>, <name><surname>Gineau</surname><given-names>L</given-names></name>, <name><surname>Alcais</surname><given-names>A</given-names></name>, <name><surname>Lamaze</surname><given-names>C</given-names></name>, <etal/> (<year>2008</year>). <article-title>Complementation of a pathogenic IFNGR2 misfolding mutation with modifiers of N-glycosylation</article-title>. <source>J Exp Med</source>
<volume>205</volume>, <fpage>1729</fpage>&#x2013;<lpage>1737</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20071987</pub-id>.<pub-id pub-id-type="pmid">18625743</pub-id>
</mixed-citation>
      </ref>
      <ref id="R33">
        <label>33.</label>
        <mixed-citation publication-type="journal"><name><surname>Vogt</surname><given-names>G</given-names></name>, <name><surname>Chapgier</surname><given-names>A</given-names></name>, <name><surname>Yang</surname><given-names>K</given-names></name>, <name><surname>Chuzhanova</surname><given-names>N</given-names></name>, <name><surname>Feinberg</surname><given-names>J</given-names></name>, <name><surname>Fieschi</surname><given-names>C</given-names></name>, <name><surname>Boisson-Dupuis</surname><given-names>S</given-names></name>, <name><surname>Alcais</surname><given-names>A</given-names></name>, <name><surname>Filipe-Santos</surname><given-names>O</given-names></name>, <name><surname>Bustamante</surname><given-names>J</given-names></name>, <etal/> (<year>2005</year>). <article-title>Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations</article-title>. <source>Nat Genet</source>
<volume>37</volume>, <fpage>692</fpage>&#x2013;<lpage>700</lpage>. <pub-id pub-id-type="doi">10.1038/ng1581</pub-id>.<pub-id pub-id-type="pmid">15924140</pub-id>
</mixed-citation>
      </ref>
      <ref id="R34">
        <label>34.</label>
        <mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>R</given-names></name>, <name><surname>Mele</surname><given-names>F</given-names></name>, <name><surname>Worley</surname><given-names>L</given-names></name>, <name><surname>Langlais</surname><given-names>D</given-names></name>, <name><surname>Rosain</surname><given-names>J</given-names></name>, <name><surname>Benhsaien</surname><given-names>I</given-names></name>, <name><surname>Elarabi</surname><given-names>H</given-names></name>, <name><surname>Croft</surname><given-names>CA</given-names></name>, <name><surname>Doisne</surname><given-names>JM</given-names></name>, <name><surname>Zhang</surname><given-names>P</given-names></name>, <etal/> (<year>2020</year>). <article-title>Human T-bet Governs Innate and Innate-like Adaptive IFN-gamma Immunity against Mycobacteria</article-title>. <source>Cell</source>
<volume>183</volume>, <fpage>1826</fpage>&#x2013;<lpage>1847 e1831</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.10.046</pub-id>.<pub-id pub-id-type="pmid">33296702</pub-id>
</mixed-citation>
      </ref>
      <ref id="R35">
        <label>35.</label>
        <mixed-citation publication-type="journal"><name><surname>Ogishi</surname><given-names>M</given-names></name>, <name><surname>Arias</surname><given-names>AA</given-names></name>, <name><surname>Yang</surname><given-names>R</given-names></name>, <name><surname>Han</surname><given-names>JE</given-names></name>, <name><surname>Zhang</surname><given-names>P</given-names></name>, <name><surname>Rinchai</surname><given-names>D</given-names></name>, <name><surname>Halpern</surname><given-names>J</given-names></name>, <name><surname>Mulwa</surname><given-names>J</given-names></name>, <name><surname>Keating</surname><given-names>N</given-names></name>, <name><surname>Chrabieh</surname><given-names>M</given-names></name>, <etal/> (<year>2022</year>). <article-title>Impaired IL-23-dependent induction of IFN-gamma underlies mycobacterial disease in patients with inherited TYK2 deficiency</article-title>. <source>J Exp Med</source>
<volume>219</volume>. <pub-id pub-id-type="doi">10.1084/jem.20220094</pub-id>.</mixed-citation>
      </ref>
      <ref id="R36">
        <label>36.</label>
        <mixed-citation publication-type="journal"><name><surname>Rosain</surname><given-names>J</given-names></name>, <name><surname>Neehus</surname><given-names>AL</given-names></name>, <name><surname>Manry</surname><given-names>J</given-names></name>, <name><surname>Yang</surname><given-names>R</given-names></name>, <name><surname>Le Pen</surname><given-names>J</given-names></name>, <name><surname>Daher</surname><given-names>W</given-names></name>, <name><surname>Liu</surname><given-names>Z</given-names></name>, <name><surname>Chan</surname><given-names>YH</given-names></name>, <name><surname>Tahuil</surname><given-names>N</given-names></name>, <name><surname>Turel</surname><given-names>O</given-names></name>, <etal/> (<year>2023</year>). <article-title>Human IRF1 governs macrophagic IFN-gamma immunity to mycobacteria</article-title>. <source>Cell</source>
<volume>186</volume>, <fpage>621</fpage>&#x2013;<lpage>645 e633</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2022.12.038</pub-id>.<pub-id pub-id-type="pmid">36736301</pub-id>
</mixed-citation>
      </ref>
      <ref id="R37">
        <label>37.</label>
        <mixed-citation publication-type="journal"><name><surname>Doffinger</surname><given-names>R</given-names></name>, <name><surname>Jouanguy</surname><given-names>E</given-names></name>, <name><surname>Dupuis</surname><given-names>S</given-names></name>, <name><surname>Fondaneche</surname><given-names>MC</given-names></name>, <name><surname>Stephan</surname><given-names>JL</given-names></name>, <name><surname>Emile</surname><given-names>JF</given-names></name>, <name><surname>Lamhamedi-Cherradi</surname><given-names>S</given-names></name>, <name><surname>Altare</surname><given-names>F</given-names></name>, <name><surname>Pallier</surname><given-names>A</given-names></name>, <name><surname>Barcenas-Morales</surname><given-names>G</given-names></name>, <etal/> (<year>2000</year>). <article-title>Partial interferon-gamma receptor signaling chain deficiency in a patient with bacille Calmette-Guerin and Mycobacterium abscessus infection</article-title>. <source>J Infect Dis</source>
<volume>181</volume>, <fpage>379</fpage>&#x2013;<lpage>384</lpage>. <pub-id pub-id-type="doi">10.1086/315197</pub-id>.<pub-id pub-id-type="pmid">10608793</pub-id>
</mixed-citation>
      </ref>
      <ref id="R38">
        <label>38.</label>
        <mixed-citation publication-type="journal"><name><surname>de Beaucoudrey</surname><given-names>L</given-names></name>, <name><surname>Samarina</surname><given-names>A</given-names></name>, <name><surname>Bustamante</surname><given-names>J</given-names></name>, <name><surname>Cobat</surname><given-names>A</given-names></name>, <name><surname>Boisson-Dupuis</surname><given-names>S</given-names></name>, <name><surname>Feinberg</surname><given-names>J</given-names></name>, <name><surname>Al-Muhsen</surname><given-names>S</given-names></name>, <name><surname>Janniere</surname><given-names>L</given-names></name>, <name><surname>Rose</surname><given-names>Y</given-names></name>, <name><surname>de Suremain</surname><given-names>M</given-names></name>, <etal/> (<year>2010</year>). <article-title>Revisiting human IL-12Rbeta1 deficiency: a survey of 141 patients from 30 countries</article-title>. <source>Medicine (Baltimore)</source>
<volume>89</volume>, <fpage>381</fpage>&#x2013;<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1097/MD.0b013e3181fdd832</pub-id>.<pub-id pub-id-type="pmid">21057261</pub-id>
</mixed-citation>
      </ref>
      <ref id="R39">
        <label>39.</label>
        <mixed-citation publication-type="journal"><name><surname>Fieschi</surname><given-names>C</given-names></name>, <name><surname>Dupuis</surname><given-names>S</given-names></name>, <name><surname>Catherinot</surname><given-names>E</given-names></name>, <name><surname>Feinberg</surname><given-names>J</given-names></name>, <name><surname>Bustamante</surname><given-names>J</given-names></name>, <name><surname>Breiman</surname><given-names>A</given-names></name>, <name><surname>Altare</surname><given-names>F</given-names></name>, <name><surname>Baretto</surname><given-names>R</given-names></name>, <name><surname>Le Deist</surname><given-names>F</given-names></name>, <name><surname>Kayal</surname><given-names>S</given-names></name>, <etal/> (<year>2003</year>). <article-title>Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor beta1 deficiency: medical and immunological implications</article-title>. <source>J Exp Med</source>
<volume>197</volume>, <fpage>527</fpage>&#x2013;<lpage>535</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20021769</pub-id>.<pub-id pub-id-type="pmid">12591909</pub-id>
</mixed-citation>
      </ref>
      <ref id="R40">
        <label>40.</label>
        <mixed-citation publication-type="journal"><name><surname>Rosain</surname><given-names>J</given-names></name>, <name><surname>Oleaga-Quintas</surname><given-names>C</given-names></name>, <name><surname>Deswarte</surname><given-names>C</given-names></name>, <name><surname>Verdin</surname><given-names>H</given-names></name>, <name><surname>Marot</surname><given-names>S</given-names></name>, <name><surname>Syridou</surname><given-names>G</given-names></name>, <name><surname>Mansouri</surname><given-names>M</given-names></name>, <name><surname>Mahdaviani</surname><given-names>SA</given-names></name>, <name><surname>Venegas-Montoya</surname><given-names>E</given-names></name>, <name><surname>Tsolia</surname><given-names>M</given-names></name>, <etal/> (<year>2018</year>). <article-title>A Variety of Alu-Mediated Copy Number Variations Can Underlie IL-12Rbeta1 Deficiency</article-title>. <source>J Clin Immunol</source>
<volume>38</volume>, <fpage>617</fpage>&#x2013;<lpage>627</lpage>. <pub-id pub-id-type="doi">10.1007/s10875-018-0527-6</pub-id>.<pub-id pub-id-type="pmid">29995221</pub-id>
</mixed-citation>
      </ref>
      <ref id="R41">
        <label>41.</label>
        <mixed-citation publication-type="journal"><name><surname>Staels</surname><given-names>F</given-names></name>, <name><surname>Lorenzetti</surname><given-names>F</given-names></name>, <name><surname>De Keukeleere</surname><given-names>K</given-names></name>, <name><surname>Willemsen</surname><given-names>M</given-names></name>, <name><surname>Gerbaux</surname><given-names>M</given-names></name>, <name><surname>Neumann</surname><given-names>J</given-names></name>, <name><surname>Tousseyn</surname><given-names>T</given-names></name>, <name><surname>Pasciuto</surname><given-names>E</given-names></name>, <name><surname>De Munter</surname><given-names>P</given-names></name>, <name><surname>Bossuyt</surname><given-names>X</given-names></name>, <etal/> (<year>2022</year>). <article-title>A Novel Homozygous Stop Mutation in IL23R Causes Mendelian Susceptibility to Mycobacterial Disease</article-title>. <source>J Clin Immunol</source>. <pub-id pub-id-type="doi">10.1007/s10875-022-01320-7</pub-id>.</mixed-citation>
      </ref>
      <ref id="R42">
        <label>42.</label>
        <mixed-citation publication-type="journal"><name><surname>Philippot</surname><given-names>Q</given-names></name>, <name><surname>Ogishi</surname><given-names>M</given-names></name>, <name><surname>Bohlen</surname><given-names>J</given-names></name>, <name><surname>Puchan</surname><given-names>J</given-names></name>, <name><surname>Arias</surname><given-names>AA</given-names></name>, <name><surname>Nguyen</surname><given-names>T</given-names></name>, <name><surname>Martin-Fernandez</surname><given-names>M</given-names></name>, <name><surname>Conil</surname><given-names>C</given-names></name>, <name><surname>Rinchai</surname><given-names>D</given-names></name>, <name><surname>Momenilandi</surname><given-names>M</given-names></name>, <etal/> (<year>2023</year>). <article-title>Human IL-23 is essential for IFN-gamma-dependent immunity to mycobacteria</article-title>. <source>Sci Immunol</source>
<volume>8</volume>, <fpage>eabq5204</fpage>. <pub-id pub-id-type="doi">10.1126/sciimmunol.abq5204</pub-id>.<pub-id pub-id-type="pmid">36763636</pub-id>
</mixed-citation>
      </ref>
      <ref id="R43">
        <label>43.</label>
        <mixed-citation publication-type="journal"><name><surname>Nathan</surname><given-names>CF</given-names></name>, <name><surname>Murray</surname><given-names>HW</given-names></name>, <name><surname>Wiebe</surname><given-names>ME</given-names></name>, and <name><surname>Rubin</surname><given-names>BY</given-names></name> (<year>1983</year>). <article-title>Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity</article-title>. <source>J Exp Med</source>
<volume>158</volume>, <fpage>670</fpage>&#x2013;<lpage>689</lpage>. <pub-id pub-id-type="doi">10.1084/jem.158.3.670</pub-id>.<pub-id pub-id-type="pmid">6411853</pub-id>
</mixed-citation>
      </ref>
      <ref id="R44">
        <label>44.</label>
        <mixed-citation publication-type="journal"><name><surname>Vogt</surname><given-names>G</given-names></name>, and <name><surname>Nathan</surname><given-names>C</given-names></name> (<year>2011</year>). <article-title>In vitro differentiation of human macrophages with enhanced antimycobacterial activity</article-title>. <source>J Clin Invest</source>
<volume>121</volume>, <fpage>3889</fpage>&#x2013;<lpage>3901</lpage>. <pub-id pub-id-type="doi">10.1172/JCI57235</pub-id>.<pub-id pub-id-type="pmid">21911939</pub-id>
</mixed-citation>
      </ref>
      <ref id="R45">
        <label>45.</label>
        <mixed-citation publication-type="journal"><name><surname>Levy</surname><given-names>R</given-names></name>, <name><surname>Langlais</surname><given-names>D</given-names></name>, <name><surname>Beziat</surname><given-names>V</given-names></name>, <name><surname>Rapaport</surname><given-names>F</given-names></name>, <name><surname>Rao</surname><given-names>G</given-names></name>, <name><surname>Lazarov</surname><given-names>T</given-names></name>, <name><surname>Bourgey</surname><given-names>M</given-names></name>, <name><surname>Zhou</surname><given-names>YJ</given-names></name>, <name><surname>Briand</surname><given-names>C</given-names></name>, <name><surname>Moriya</surname><given-names>K</given-names></name>, <etal/> (<year>2021</year>). <article-title>Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents</article-title>. <source>J Clin Invest</source>
<volume>131</volume>. <pub-id pub-id-type="doi">10.1172/JCI150143</pub-id>.</mixed-citation>
      </ref>
      <ref id="R46">
        <label>46.</label>
        <mixed-citation publication-type="journal"><name><surname>Rosain</surname><given-names>J</given-names></name>, <name><surname>Bernasconi</surname><given-names>A</given-names></name>, <name><surname>Prieto</surname><given-names>E</given-names></name>, <name><surname>Caputi</surname><given-names>L</given-names></name>, <name><surname>Le Voyer</surname><given-names>T</given-names></name>, <name><surname>Buda</surname><given-names>G</given-names></name>, <name><surname>Marti</surname><given-names>M</given-names></name>, <name><surname>Bohlen</surname><given-names>J</given-names></name>, <name><surname>Neehus</surname><given-names>AL</given-names></name>, <name><surname>Castanos</surname><given-names>C</given-names></name>, <etal/> (<year>2022</year>). <article-title>Pulmonary Alveolar Proteinosis and Multiple Infectious Diseases in a Child with Autosomal Recessive Complete IRF8 Deficiency</article-title>. <source>J Clin Immunol</source>
<volume>42</volume>, <fpage>975</fpage>&#x2013;<lpage>985</lpage>. <pub-id pub-id-type="doi">10.1007/s10875-022-01250-4</pub-id>.<pub-id pub-id-type="pmid">35338423</pub-id>
</mixed-citation>
      </ref>
      <ref id="R47">
        <label>47.</label>
        <mixed-citation publication-type="journal"><name><surname>Cytlak</surname><given-names>U</given-names></name>, <name><surname>Resteu</surname><given-names>A</given-names></name>, <name><surname>Pagan</surname><given-names>S</given-names></name>, <name><surname>Green</surname><given-names>K</given-names></name>, <name><surname>Milne</surname><given-names>P</given-names></name>, <name><surname>Maisuria</surname><given-names>S</given-names></name>, <name><surname>McDonald</surname><given-names>D</given-names></name>, <name><surname>Hulme</surname><given-names>G</given-names></name>, <name><surname>Filby</surname><given-names>A</given-names></name>, <name><surname>Carpenter</surname><given-names>B</given-names></name>, <etal/> (<year>2020</year>). <article-title>Differential IRF8 Transcription Factor Requirement Defines Two Pathways of Dendritic Cell Development in Humans</article-title>. <source>Immunity</source>
<volume>53</volume>, <fpage>353</fpage>&#x2013;<lpage>370 e358</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2020.07.003</pub-id>.<pub-id pub-id-type="pmid">32735845</pub-id>
</mixed-citation>
      </ref>
      <ref id="R48">
        <label>48.</label>
        <mixed-citation publication-type="journal"><name><surname>Villani</surname><given-names>AC</given-names></name>, <name><surname>Satija</surname><given-names>R</given-names></name>, <name><surname>Reynolds</surname><given-names>G</given-names></name>, <name><surname>Sarkizova</surname><given-names>S</given-names></name>, <name><surname>Shekhar</surname><given-names>K</given-names></name>, <name><surname>Fletcher</surname><given-names>J</given-names></name>, <name><surname>Griesbeck</surname><given-names>M</given-names></name>, <name><surname>Butler</surname><given-names>A</given-names></name>, <name><surname>Zheng</surname><given-names>S</given-names></name>, <name><surname>Lazo</surname><given-names>S</given-names></name>, <etal/> (<year>2017</year>). <article-title>Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors</article-title>. <source>Science</source>
<volume>356</volume>. <pub-id pub-id-type="doi">10.1126/science.aah4573</pub-id>.</mixed-citation>
      </ref>
      <ref id="R49">
        <label>49.</label>
        <mixed-citation publication-type="journal"><name><surname>Casanova</surname><given-names>JL</given-names></name>, and <name><surname>Abel</surname><given-names>L</given-names></name> (<year>2004</year>). <article-title>The human model: a genetic dissection of immunity to infection in natural conditions</article-title>. <source>Nat Rev Immunol</source>
<volume>4</volume>, <fpage>55</fpage>&#x2013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1038/nri1264</pub-id>.<pub-id pub-id-type="pmid">14704768</pub-id>
</mixed-citation>
      </ref>
      <ref id="R50">
        <label>50.</label>
        <mixed-citation publication-type="journal"><name><surname>Medetgul-Ernar</surname><given-names>K</given-names></name>, and <name><surname>Davis</surname><given-names>MM</given-names></name> (<year>2022</year>). <article-title>Standing on the shoulders of mice</article-title>. <source>Immunity</source>
<volume>55</volume>, <fpage>1343</fpage>&#x2013;<lpage>1353</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2022.07.008</pub-id>.<pub-id pub-id-type="pmid">35947979</pub-id>
</mixed-citation>
      </ref>
      <ref id="R51">
        <label>51.</label>
        <mixed-citation publication-type="journal"><name><surname>Wheelock</surname><given-names>EF</given-names></name> (<year>1965</year>). <article-title>Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin</article-title>. <source>Science</source>
<volume>149</volume>, <fpage>310</fpage>&#x2013;<lpage>311</lpage>.</mixed-citation>
      </ref>
      <ref id="R52">
        <label>52.</label>
        <mixed-citation publication-type="journal"><name><surname>Daza-Cajigal</surname><given-names>V</given-names></name>, <name><surname>Albuquerque</surname><given-names>AS</given-names></name>, <name><surname>Young</surname><given-names>DF</given-names></name>, <name><surname>Ciancanelli</surname><given-names>MJ</given-names></name>, <name><surname>Moulding</surname><given-names>D</given-names></name>, <name><surname>Angulo</surname><given-names>I</given-names></name>, <name><surname>Jeanne-Julien</surname><given-names>V</given-names></name>, <name><surname>Rosain</surname><given-names>J</given-names></name>, <name><surname>Minskaia</surname><given-names>E</given-names></name>, <name><surname>Casanova</surname><given-names>JL</given-names></name>, <etal/> (<year>2022</year>). <article-title>Partial human Janus kinase 1 deficiency predominantly impairs responses to interferon gamma and intracellular control of mycobacteria</article-title>. <source>Front Immunol</source>
<volume>13</volume>, <fpage>888427</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2022.888427</pub-id>.<pub-id pub-id-type="pmid">36159783</pub-id>
</mixed-citation>
      </ref>
      <ref id="R53">
        <label>53.</label>
        <mixed-citation publication-type="journal"><name><surname>Khanolkar</surname><given-names>A</given-names></name>, <name><surname>Kirschmann</surname><given-names>DA</given-names></name>, <name><surname>Caparelli</surname><given-names>EA</given-names></name>, <name><surname>Wilks</surname><given-names>JD</given-names></name>, <name><surname>Cerullo</surname><given-names>JM</given-names></name>, <name><surname>Bergerson</surname><given-names>JRE</given-names></name>, <name><surname>Jennings</surname><given-names>LJ</given-names></name>, and <name><surname>Fuleihan</surname><given-names>RL</given-names></name> (<year>2018</year>). <article-title>CD4 T cell-restricted IL-2 signaling defect in a patient with a novel IFNGR1 deficiency</article-title>. <source>J Allergy Clin Immunol</source>
<volume>141</volume>, <fpage>435</fpage>&#x2013;<lpage>439 e437</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2017.08.018</pub-id>.<pub-id pub-id-type="pmid">28927822</pub-id>
</mixed-citation>
      </ref>
      <ref id="R54">
        <label>54.</label>
        <mixed-citation publication-type="journal"><name><surname>Kerner</surname><given-names>G</given-names></name>, <name><surname>Ramirez-Alejo</surname><given-names>N</given-names></name>, <name><surname>Seeleuthner</surname><given-names>Y</given-names></name>, <name><surname>Yang</surname><given-names>R</given-names></name>, <name><surname>Ogishi</surname><given-names>M</given-names></name>, <name><surname>Cobat</surname><given-names>A</given-names></name>, <name><surname>Patin</surname><given-names>E</given-names></name>, <name><surname>Quintana-Murci</surname><given-names>L</given-names></name>, <name><surname>Boisson-Dupuis</surname><given-names>S</given-names></name>, <name><surname>Casanova</surname><given-names>JL</given-names></name>, and <name><surname>Abel</surname><given-names>L</given-names></name> (<year>2019</year>). <article-title>Homozygosity for TYK2 P1104A underlies tuberculosis in about 1% of patients in a cohort of European ancestry</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>116</volume>, <fpage>10430</fpage>&#x2013;<lpage>10434</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1903561116</pub-id>.<pub-id pub-id-type="pmid">31068474</pub-id>
</mixed-citation>
      </ref>
      <ref id="R55">
        <label>55.</label>
        <mixed-citation publication-type="journal"><name><surname>Itan</surname><given-names>Y</given-names></name>, <name><surname>Shang</surname><given-names>L</given-names></name>, <name><surname>Boisson</surname><given-names>B</given-names></name>, <name><surname>Ciancanelli</surname><given-names>MJ</given-names></name>, <name><surname>Markle</surname><given-names>JG</given-names></name>, <name><surname>Martinez-Barricarte</surname><given-names>R</given-names></name>, <name><surname>Scott</surname><given-names>E</given-names></name>, <name><surname>Shah</surname><given-names>I</given-names></name>, <name><surname>Stenson</surname><given-names>PD</given-names></name>, <name><surname>Gleeson</surname><given-names>J</given-names></name>, <etal/> (<year>2016</year>). <article-title>The mutation significance cutoff: gene-level thresholds for variant predictions</article-title>. <source>Nat Methods</source>
<volume>13</volume>, <fpage>109</fpage>&#x2013;<lpage>110</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.3739</pub-id>.<pub-id pub-id-type="pmid">26820543</pub-id>
</mixed-citation>
      </ref>
      <ref id="R56">
        <label>56.</label>
        <mixed-citation publication-type="journal"><name><surname>Kircher</surname><given-names>M</given-names></name>, <name><surname>Witten</surname><given-names>DM</given-names></name>, <name><surname>Jain</surname><given-names>P</given-names></name>, <name><surname>O&#x2019;Roak</surname><given-names>BJ</given-names></name>, <name><surname>Cooper</surname><given-names>GM</given-names></name>, and <name><surname>Shendure</surname><given-names>J</given-names></name> (<year>2014</year>). <article-title>A general framework for estimating the relative pathogenicity of human genetic variants</article-title>. <source>Nat Genet</source>
<volume>46</volume>, <fpage>310</fpage>&#x2013;<lpage>315</lpage>. <pub-id pub-id-type="doi">10.1038/ng.2892</pub-id>.<pub-id pub-id-type="pmid">24487276</pub-id>
</mixed-citation>
      </ref>
      <ref id="R57">
        <label>57.</label>
        <mixed-citation publication-type="journal"><name><surname>Rapaport</surname><given-names>F</given-names></name>, <name><surname>Boisson</surname><given-names>B</given-names></name>, <name><surname>Gregor</surname><given-names>A</given-names></name>, <name><surname>Beziat</surname><given-names>V</given-names></name>, <name><surname>Boisson-Dupuis</surname><given-names>S</given-names></name>, <name><surname>Bustamante</surname><given-names>J</given-names></name>, <name><surname>Jouanguy</surname><given-names>E</given-names></name>, <name><surname>Puel</surname><given-names>A</given-names></name>, <name><surname>Rosain</surname><given-names>J</given-names></name>, <name><surname>Zhang</surname><given-names>Q</given-names></name>, <etal/> (<year>2021</year>). <article-title>Negative selection on human genes underlying inborn errors depends on disease outcome and both the mode and mechanism of inheritance</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>118</volume>. <pub-id pub-id-type="doi">10.1073/pnas.2001248118</pub-id>.</mixed-citation>
      </ref>
      <ref id="R58">
        <label>58.</label>
        <mixed-citation publication-type="journal"><name><surname>Schleich</surname><given-names>S</given-names></name>, <name><surname>Strassburger</surname><given-names>K</given-names></name>, <name><surname>Janiesch</surname><given-names>PC</given-names></name>, <name><surname>Koledachkina</surname><given-names>T</given-names></name>, <name><surname>Miller</surname><given-names>KK</given-names></name>, <name><surname>Haneke</surname><given-names>K</given-names></name>, <name><surname>Cheng</surname><given-names>YS</given-names></name>, <name><surname>Kuechler</surname><given-names>K</given-names></name>, <name><surname>Stoecklin</surname><given-names>G</given-names></name>, <name><surname>Duncan</surname><given-names>KE</given-names></name>, and <name><surname>Teleman</surname><given-names>AA</given-names></name> (<year>2014</year>). <article-title>DENR-MCT-1 promotes translation reinitiation downstream of uORFs to control tissue growth</article-title>. <source>Nature</source>
<volume>512</volume>, <fpage>208</fpage>&#x2013;<lpage>212</lpage>. <pub-id pub-id-type="doi">10.1038/nature13401</pub-id>.<pub-id pub-id-type="pmid">25043021</pub-id>
</mixed-citation>
      </ref>
      <ref id="R59">
        <label>59.</label>
        <mixed-citation publication-type="journal"><name><surname>Bohlen</surname><given-names>J</given-names></name>, <name><surname>Harbrecht</surname><given-names>L</given-names></name>, <name><surname>Blanco</surname><given-names>S</given-names></name>, <name><surname>Clemm von Hohenberg</surname><given-names>K</given-names></name>, <name><surname>Fenzl</surname><given-names>K</given-names></name>, <name><surname>Kramer</surname><given-names>G</given-names></name>, <name><surname>Bukau</surname><given-names>B</given-names></name>, and <name><surname>Teleman</surname><given-names>AA</given-names></name> (<year>2020</year>). <article-title>DENR promotes translation reinitiation via ribosome recycling to drive expression of oncogenes including ATF4</article-title>. <source>Nat Commun</source>
<volume>11</volume>, <fpage>4676</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-18452-2</pub-id>.<pub-id pub-id-type="pmid">32938922</pub-id>
</mixed-citation>
      </ref>
      <ref id="R60">
        <label>60.</label>
        <mixed-citation publication-type="journal"><name><surname>Dickinson</surname><given-names>ME</given-names></name>, <name><surname>Flenniken</surname><given-names>AM</given-names></name>, <name><surname>Ji</surname><given-names>X</given-names></name>, <name><surname>Teboul</surname><given-names>L</given-names></name>, <name><surname>Wong</surname><given-names>MD</given-names></name>, <name><surname>White</surname><given-names>JK</given-names></name>, <name><surname>Meehan</surname><given-names>TF</given-names></name>, <name><surname>Weninger</surname><given-names>WJ</given-names></name>, <name><surname>Westerberg</surname><given-names>H</given-names></name>, <name><surname>Adissu</surname><given-names>H</given-names></name>, <etal/> (<year>2016</year>). <article-title>High-throughput discovery of novel developmental phenotypes</article-title>. <source>Nature</source>
<volume>537</volume>, <fpage>508</fpage>&#x2013;<lpage>514</lpage>. <pub-id pub-id-type="doi">10.1038/nature19356</pub-id>.<pub-id pub-id-type="pmid">27626380</pub-id>
</mixed-citation>
      </ref>
      <ref id="R61">
        <label>61.</label>
        <mixed-citation publication-type="journal"><name><surname>Uhlen</surname><given-names>M</given-names></name>, <name><surname>Fagerberg</surname><given-names>L</given-names></name>, <name><surname>Hallstrom</surname><given-names>BM</given-names></name>, <name><surname>Lindskog</surname><given-names>C</given-names></name>, <name><surname>Oksvold</surname><given-names>P</given-names></name>, <name><surname>Mardinoglu</surname><given-names>A</given-names></name>, <name><surname>Sivertsson</surname><given-names>A</given-names></name>, <name><surname>Kampf</surname><given-names>C</given-names></name>, <name><surname>Sjostedt</surname><given-names>E</given-names></name>, <name><surname>Asplund</surname><given-names>A</given-names></name>, <etal/> (<year>2015</year>). <article-title>Proteomics. Tissue-based map of the human proteome</article-title>. <source>Science</source>
<volume>347</volume>, <fpage>1260419</fpage>. <pub-id pub-id-type="doi">10.1126/science.1260419</pub-id>.<pub-id pub-id-type="pmid">25613900</pub-id>
</mixed-citation>
      </ref>
      <ref id="R62">
        <label>62.</label>
        <mixed-citation publication-type="journal"><name><surname>Schleich</surname><given-names>S</given-names></name>, <name><surname>Acevedo</surname><given-names>JM</given-names></name>, <name><surname>Clemm von Hohenberg</surname><given-names>K</given-names></name>, and <name><surname>Teleman</surname><given-names>AA</given-names></name> (<year>2017</year>). <article-title>Identification of transcripts with short stuORFs as targets for DENR*MCTS1-dependent translation in human cells</article-title>. <source>Sci Rep</source>
<volume>7</volume>, <fpage>3722</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-03949-6</pub-id>.<pub-id pub-id-type="pmid">28623304</pub-id>
</mixed-citation>
      </ref>
      <ref id="R63">
        <label>63.</label>
        <mixed-citation publication-type="journal"><name><surname>Lizio</surname><given-names>M</given-names></name>, <name><surname>Abugessaisa</surname><given-names>I</given-names></name>, <name><surname>Noguchi</surname><given-names>S</given-names></name>, <name><surname>Kondo</surname><given-names>A</given-names></name>, <name><surname>Hasegawa</surname><given-names>A</given-names></name>, <name><surname>Hon</surname><given-names>CC</given-names></name>, <name><surname>de Hoon</surname><given-names>M</given-names></name>, <name><surname>Severin</surname><given-names>J</given-names></name>, <name><surname>Oki</surname><given-names>S</given-names></name>, <name><surname>Hayashizaki</surname><given-names>Y</given-names></name>, <etal/> (<year>2019</year>). <article-title>Update of the FANTOM web resource: expansion to provide additional transcriptome atlases</article-title>. <source>Nucleic Acids Res</source>
<volume>47</volume>, <fpage>D752</fpage>&#x2013;<lpage>D758</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky1099</pub-id>.<pub-id pub-id-type="pmid">30407557</pub-id>
</mixed-citation>
      </ref>
      <ref id="R64">
        <label>64.</label>
        <mixed-citation publication-type="journal"><name><surname>Lizio</surname><given-names>M</given-names></name>, <name><surname>Harshbarger</surname><given-names>J</given-names></name>, <name><surname>Shimoji</surname><given-names>H</given-names></name>, <name><surname>Severin</surname><given-names>J</given-names></name>, <name><surname>Kasukawa</surname><given-names>T</given-names></name>, <name><surname>Sahin</surname><given-names>S</given-names></name>, <name><surname>Abugessaisa</surname><given-names>I</given-names></name>, <name><surname>Fukuda</surname><given-names>S</given-names></name>, <name><surname>Hori</surname><given-names>F</given-names></name>, <name><surname>Ishikawa-Kato</surname><given-names>S</given-names></name>, <etal/> (<year>2015</year>). <article-title>Gateways to the FANTOM5 promoter level mammalian expression atlas</article-title>. <source>Genome Biol</source>
<volume>16</volume>, <fpage>22</fpage>. <pub-id pub-id-type="doi">10.1186/s13059-014-0560-6</pub-id>.<pub-id pub-id-type="pmid">25723102</pub-id>
</mixed-citation>
      </ref>
      <ref id="R65">
        <label>65.</label>
        <mixed-citation publication-type="journal"><name><surname>Bohlen</surname><given-names>J</given-names></name>, <name><surname>Fenzl</surname><given-names>K</given-names></name>, <name><surname>Kramer</surname><given-names>G</given-names></name>, <name><surname>Bukau</surname><given-names>B</given-names></name>, and <name><surname>Teleman</surname><given-names>AA</given-names></name> (<year>2020</year>). <article-title>Selective 40S Footprinting Reveals Cap-Tethered Ribosome Scanning in Human Cells</article-title>. <source>Mol Cell</source>
<volume>79</volume>, <fpage>561</fpage>&#x2013;<lpage>574 e565</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2020.06.005</pub-id>.<pub-id pub-id-type="pmid">32589966</pub-id>
</mixed-citation>
      </ref>
      <ref id="R66">
        <label>66.</label>
        <mixed-citation publication-type="journal"><name><surname>Wagner</surname><given-names>S</given-names></name>, <name><surname>Bohlen</surname><given-names>J</given-names></name>, <name><surname>Herrmannova</surname><given-names>A</given-names></name>, <name><surname>Jelinek</surname><given-names>J</given-names></name>, <name><surname>Preiss</surname><given-names>T</given-names></name>, <name><surname>Valasek</surname><given-names>LS</given-names></name>, and <name><surname>Teleman</surname><given-names>AA</given-names></name> (<year>2022</year>). <article-title>Selective footprinting of 40S and 80S ribosome subpopulations (Sel-TCP-seq) to study translation and its control</article-title>. <source>Nat Protoc</source>. <pub-id pub-id-type="doi">10.1038/s41596-022-00708-4</pub-id>.</mixed-citation>
      </ref>
      <ref id="R67">
        <label>67.</label>
        <mixed-citation publication-type="journal"><name><surname>Young</surname><given-names>DJ</given-names></name>, <name><surname>Makeeva</surname><given-names>DS</given-names></name>, <name><surname>Zhang</surname><given-names>F</given-names></name>, <name><surname>Anisimova</surname><given-names>AS</given-names></name>, <name><surname>Stolboushkina</surname><given-names>EA</given-names></name>, <name><surname>Ghobakhlou</surname><given-names>F</given-names></name>, <name><surname>Shatsky</surname><given-names>IN</given-names></name>, <name><surname>Dmitriev</surname><given-names>SE</given-names></name>, <name><surname>Hinnebusch</surname><given-names>AG</given-names></name>, and <name><surname>Guydosh</surname><given-names>NR</given-names></name> (<year>2018</year>). <article-title>Tma64/eIF2D, Tma20/MCT-1, and Tma22/DENR Recycle Post-termination 40S Subunits In Vivo</article-title>. <source>Mol Cell</source>
<volume>71</volume>, <fpage>761</fpage>&#x2013;<lpage>774 e765</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2018.07.028</pub-id>.<pub-id pub-id-type="pmid">30146315</pub-id>
</mixed-citation>
      </ref>
      <ref id="R68">
        <label>68.</label>
        <mixed-citation publication-type="journal"><name><surname>Xiao</surname><given-names>Z</given-names></name>, <name><surname>Zou</surname><given-names>Q</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, and <name><surname>Yang</surname><given-names>X</given-names></name> (<year>2016</year>). <article-title>Genome-wide assessment of differential translations with ribosome profiling data</article-title>. <source>Nat Commun</source>
<volume>7</volume>, <fpage>11194</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms11194</pub-id>.<pub-id pub-id-type="pmid">27041671</pub-id>
</mixed-citation>
      </ref>
      <ref id="R69">
        <label>69.</label>
        <mixed-citation publication-type="journal"><name><surname>Clemm von Hohenberg</surname><given-names>K</given-names></name>, <name><surname>Muller</surname><given-names>S</given-names></name>, <name><surname>Schleich</surname><given-names>S</given-names></name>, <name><surname>Meister</surname><given-names>M</given-names></name>, <name><surname>Bohlen</surname><given-names>J</given-names></name>, <name><surname>Hofmann</surname><given-names>TG</given-names></name>, and <name><surname>Teleman</surname><given-names>AA</given-names></name> (<year>2022</year>). <article-title>Cyclin B/CDK1 and Cyclin A/CDK2 phosphorylate DENR to promote mitotic protein translation and faithful cell division</article-title>. <source>Nat Commun</source>
<volume>13</volume>, <fpage>668</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-022-28265-0</pub-id>.<pub-id pub-id-type="pmid">35115540</pub-id>
</mixed-citation>
      </ref>
      <ref id="R70">
        <label>70.</label>
        <mixed-citation publication-type="journal"><name><surname>Neubauer</surname><given-names>H</given-names></name>, <name><surname>Cumano</surname><given-names>A</given-names></name>, <name><surname>Muller</surname><given-names>M</given-names></name>, <name><surname>Wu</surname><given-names>H</given-names></name>, <name><surname>Huffstadt</surname><given-names>U</given-names></name>, and <name><surname>Pfeffer</surname><given-names>K</given-names></name> (<year>1998</year>). <article-title>Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis</article-title>. <source>Cell</source>
<volume>93</volume>, <fpage>397</fpage>&#x2013;<lpage>409</lpage>. <pub-id pub-id-type="doi">10.1016/s0092-8674(00)81168-x</pub-id>.<pub-id pub-id-type="pmid">9590174</pub-id>
</mixed-citation>
      </ref>
      <ref id="R71">
        <label>71.</label>
        <mixed-citation publication-type="journal"><name><surname>Morris</surname><given-names>R</given-names></name>, <name><surname>Kershaw</surname><given-names>NJ</given-names></name>, and <name><surname>Babon</surname><given-names>JJ</given-names></name> (<year>2018</year>). <article-title>The molecular details of cytokine signaling via the JAK/STAT pathway</article-title>. <source>Protein Sci</source>
<volume>27</volume>, <fpage>1984</fpage>&#x2013;<lpage>2009</lpage>. <pub-id pub-id-type="doi">10.1002/pro.3519</pub-id>.<pub-id pub-id-type="pmid">30267440</pub-id>
</mixed-citation>
      </ref>
      <ref id="R72">
        <label>72.</label>
        <mixed-citation publication-type="journal"><name><surname>Macchi</surname><given-names>P</given-names></name>, <name><surname>Villa</surname><given-names>A</given-names></name>, <name><surname>Giliani</surname><given-names>S</given-names></name>, <name><surname>Sacco</surname><given-names>MG</given-names></name>, <name><surname>Frattini</surname><given-names>A</given-names></name>, <name><surname>Porta</surname><given-names>F</given-names></name>, <name><surname>Ugazio</surname><given-names>AG</given-names></name>, <name><surname>Johnston</surname><given-names>JA</given-names></name>, <name><surname>Candotti</surname><given-names>F</given-names></name>, <name><surname>O&#x2019;Shea</surname><given-names>JJ</given-names></name>, and <etal/> (<year>1995</year>). <article-title>Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)</article-title>. <source>Nature</source>
<volume>377</volume>, <fpage>65</fpage>&#x2013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1038/377065a0</pub-id>.<pub-id pub-id-type="pmid">7659163</pub-id>
</mixed-citation>
      </ref>
      <ref id="R73">
        <label>73.</label>
        <mixed-citation publication-type="journal"><name><surname>Teng</surname><given-names>MW</given-names></name>, <name><surname>Bowman</surname><given-names>EP</given-names></name>, <name><surname>McElwee</surname><given-names>JJ</given-names></name>, <name><surname>Smyth</surname><given-names>MJ</given-names></name>, <name><surname>Casanova</surname><given-names>JL</given-names></name>, <name><surname>Cooper</surname><given-names>AM</given-names></name>, and <name><surname>Cua</surname><given-names>DJ</given-names></name> (<year>2015</year>). <article-title>IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases</article-title>. <source>Nat Med</source>
<volume>21</volume>, <fpage>719</fpage>&#x2013;<lpage>729</lpage>. <pub-id pub-id-type="doi">10.1038/nm.3895</pub-id>.<pub-id pub-id-type="pmid">26121196</pub-id>
</mixed-citation>
      </ref>
      <ref id="R74">
        <label>74.</label>
        <mixed-citation publication-type="journal"><name><surname>Igarashi</surname><given-names>K</given-names></name>, <name><surname>Garotta</surname><given-names>G</given-names></name>, <name><surname>Ozmen</surname><given-names>L</given-names></name>, <name><surname>Ziemiecki</surname><given-names>A</given-names></name>, <name><surname>Wilks</surname><given-names>AF</given-names></name>, <name><surname>Harpur</surname><given-names>AG</given-names></name>, <name><surname>Larner</surname><given-names>AC</given-names></name>, and <name><surname>Finbloom</surname><given-names>DS</given-names></name> (<year>1994</year>). <article-title>Interferon-gamma induces tyrosine phosphorylation of interferon-gamma receptor and regulated association of protein tyrosine kinases, Jak1 and Jak2, with its receptor</article-title>. <source>J Biol Chem</source>
<volume>269</volume>, <fpage>14333</fpage>&#x2013;<lpage>14336</lpage>.<pub-id pub-id-type="pmid">7514165</pub-id>
</mixed-citation>
      </ref>
      <ref id="R75">
        <label>75.</label>
        <mixed-citation publication-type="journal"><name><surname>Silva</surname><given-names>CM</given-names></name>, <name><surname>Lu</surname><given-names>H</given-names></name>, <name><surname>Weber</surname><given-names>MJ</given-names></name>, and <name><surname>Thorner</surname><given-names>MO</given-names></name> (<year>1994</year>). <article-title>Differential tyrosine phosphorylation of JAK1, JAK2, and STAT1 by growth hormone and interferon-gamma in IM-9 cells</article-title>. <source>J Biol Chem</source>
<volume>269</volume>, <fpage>27532</fpage>&#x2013;<lpage>27539</lpage>.<pub-id pub-id-type="pmid">7525556</pub-id>
</mixed-citation>
      </ref>
      <ref id="R76">
        <label>76.</label>
        <mixed-citation publication-type="journal"><name><surname>Sun</surname><given-names>R</given-names></name>, and <name><surname>Abraham</surname><given-names>C</given-names></name> (<year>2020</year>). <article-title>IL23 Promotes Antimicrobial Pathways in Human Macrophages, Which Are Reduced With the IBD-Protective IL23R R381Q Variant</article-title>. <source>Cell Mol Gastroenterol Hepatol</source>
<volume>10</volume>, <fpage>673</fpage>&#x2013;<lpage>697</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcmgh.2020.05.007</pub-id>.<pub-id pub-id-type="pmid">32474165</pub-id>
</mixed-citation>
      </ref>
      <ref id="R77">
        <label>77.</label>
        <mixed-citation publication-type="journal"><name><surname>Hammaren</surname><given-names>HM</given-names></name>, <name><surname>Virtanen</surname><given-names>AT</given-names></name>, <name><surname>Raivola</surname><given-names>J</given-names></name>, and <name><surname>Silvennoinen</surname><given-names>O</given-names></name> (<year>2019</year>). <article-title>The regulation of JAKs in cytokine signaling and its breakdown in disease</article-title>. <source>Cytokine</source>
<volume>118</volume>, <fpage>48</fpage>&#x2013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.cyto.2018.03.041</pub-id>.<pub-id pub-id-type="pmid">29685781</pub-id>
</mixed-citation>
      </ref>
      <ref id="R78">
        <label>78.</label>
        <mixed-citation publication-type="journal"><name><surname>Ma</surname><given-names>L</given-names></name>, <name><surname>Clayton</surname><given-names>JR</given-names></name>, <name><surname>Walgren</surname><given-names>RA</given-names></name>, <name><surname>Zhao</surname><given-names>B</given-names></name>, <name><surname>Evans</surname><given-names>RJ</given-names></name>, <name><surname>Smith</surname><given-names>MC</given-names></name>, <name><surname>Heinz-Taheny</surname><given-names>KM</given-names></name>, <name><surname>Kreklau</surname><given-names>EL</given-names></name>, <name><surname>Bloem</surname><given-names>L</given-names></name>, <name><surname>Pitou</surname><given-names>C</given-names></name>, <etal/> (<year>2013</year>). <article-title>Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F</article-title>. <source>Blood Cancer J</source>
<volume>3</volume>, <fpage>e109</fpage>. <pub-id pub-id-type="doi">10.1038/bcj.2013.6</pub-id>.<pub-id pub-id-type="pmid">23584399</pub-id>
</mixed-citation>
      </ref>
      <ref id="R79">
        <label>79.</label>
        <mixed-citation publication-type="journal"><name><surname>Fieschi</surname><given-names>C</given-names></name>, <name><surname>Dupuis</surname><given-names>S</given-names></name>, <name><surname>Picard</surname><given-names>C</given-names></name>, <name><surname>Smith</surname><given-names>CI</given-names></name>, <name><surname>Holland</surname><given-names>SM</given-names></name>, and <name><surname>Casanova</surname><given-names>JL</given-names></name> (<year>2001</year>). <article-title>High levels of interferon gamma in the plasma of children with complete interferon gamma receptor deficiency</article-title>. <source>Pediatrics</source>
<volume>107</volume>, <fpage>E48</fpage>. <pub-id pub-id-type="doi">10.1542/peds.107.4.e48</pub-id>.<pub-id pub-id-type="pmid">11335769</pub-id>
</mixed-citation>
      </ref>
      <ref id="R80">
        <label>80.</label>
        <mixed-citation publication-type="journal"><name><surname>Suzuki</surname><given-names>T</given-names></name>, <name><surname>Sakagami</surname><given-names>T</given-names></name>, <name><surname>Rubin</surname><given-names>BK</given-names></name>, <name><surname>Nogee</surname><given-names>LM</given-names></name>, <name><surname>Wood</surname><given-names>RE</given-names></name>, <name><surname>Zimmerman</surname><given-names>SL</given-names></name>, <name><surname>Smolarek</surname><given-names>T</given-names></name>, <name><surname>Dishop</surname><given-names>MK</given-names></name>, <name><surname>Wert</surname><given-names>SE</given-names></name>, <name><surname>Whitsett</surname><given-names>JA</given-names></name>, <etal/> (<year>2008</year>). <article-title>Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA</article-title>. <source>J Exp Med</source>
<volume>205</volume>, <fpage>2703</fpage>&#x2013;<lpage>2710</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20080990</pub-id>.<pub-id pub-id-type="pmid">18955570</pub-id>
</mixed-citation>
      </ref>
      <ref id="R81">
        <label>81.</label>
        <mixed-citation publication-type="journal"><name><surname>Suzuki</surname><given-names>T</given-names></name>, <name><surname>Sakagami</surname><given-names>T</given-names></name>, <name><surname>Young</surname><given-names>LR</given-names></name>, <name><surname>Carey</surname><given-names>BC</given-names></name>, <name><surname>Wood</surname><given-names>RE</given-names></name>, <name><surname>Luisetti</surname><given-names>M</given-names></name>, <name><surname>Wert</surname><given-names>SE</given-names></name>, <name><surname>Rubin</surname><given-names>BK</given-names></name>, <name><surname>Kevill</surname><given-names>K</given-names></name>, <name><surname>Chalk</surname><given-names>C</given-names></name>, <etal/> (<year>2010</year>). <article-title>Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy</article-title>. <source>Am J Respir Crit Care Med</source>
<volume>182</volume>, <fpage>1292</fpage>&#x2013;<lpage>1304</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201002-0271OC</pub-id>.<pub-id pub-id-type="pmid">20622029</pub-id>
</mixed-citation>
      </ref>
      <ref id="R82">
        <label>82.</label>
        <mixed-citation publication-type="journal"><name><surname>Altman</surname><given-names>MC</given-names></name>, <name><surname>Rinchai</surname><given-names>D</given-names></name>, <name><surname>Baldwin</surname><given-names>N</given-names></name>, <name><surname>Toufiq</surname><given-names>M</given-names></name>, <name><surname>Whalen</surname><given-names>E</given-names></name>, <name><surname>Garand</surname><given-names>M</given-names></name>, <name><surname>Syed Ahamed Kabeer</surname><given-names>B</given-names></name>, <name><surname>Alfaki</surname><given-names>M</given-names></name>, <name><surname>Presnell</surname><given-names>SR</given-names></name>, <name><surname>Khaenam</surname><given-names>P</given-names></name>, <etal/> (<year>2021</year>). <article-title>Development of a fixed module repertoire for the analysis and interpretation of blood transcriptome data</article-title>. <source>Nat Commun</source>
<volume>12</volume>, <fpage>4385</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-021-24584-w</pub-id>.<pub-id pub-id-type="pmid">34282143</pub-id>
</mixed-citation>
      </ref>
      <ref id="R83">
        <label>83.</label>
        <mixed-citation publication-type="journal"><name><surname>Rinchai</surname><given-names>D</given-names></name>, <name><surname>Roelands</surname><given-names>J</given-names></name>, <name><surname>Toufiq</surname><given-names>M</given-names></name>, <name><surname>Hendrickx</surname><given-names>W</given-names></name>, <name><surname>Altman</surname><given-names>MC</given-names></name>, <name><surname>Bedognetti</surname><given-names>D</given-names></name>, and <name><surname>Chaussabel</surname><given-names>D</given-names></name> (<year>2021</year>). <article-title>BloodGen3Module: Blood transcriptional module repertoire analysis and visualization using R</article-title>. <source>Bioinformatics</source>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btab121</pub-id>.</mixed-citation>
      </ref>
      <ref id="R84">
        <label>84.</label>
        <mixed-citation publication-type="journal"><name><surname>Schoenborn</surname><given-names>JR</given-names></name>, and <name><surname>Wilson</surname><given-names>CB</given-names></name> (<year>2007</year>). <article-title>Regulation of interferon-gamma during innate and adaptive immune responses</article-title>. <source>Adv Immunol</source>
<volume>96</volume>, <fpage>41</fpage>&#x2013;<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1016/S0065-2776(07)96002-2</pub-id>.<pub-id pub-id-type="pmid">17981204</pub-id>
</mixed-citation>
      </ref>
      <ref id="R85">
        <label>85.</label>
        <mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>B</given-names></name>, <name><surname>Hu</surname><given-names>J</given-names></name>, <name><surname>Hu</surname><given-names>X</given-names></name>, <name><surname>Chen</surname><given-names>H</given-names></name>, <name><surname>Bao</surname><given-names>R</given-names></name>, <name><surname>Zhou</surname><given-names>Y</given-names></name>, <name><surname>Ye</surname><given-names>Y</given-names></name>, <name><surname>Zhan</surname><given-names>M</given-names></name>, <name><surname>Cai</surname><given-names>W</given-names></name>, <name><surname>Li</surname><given-names>H</given-names></name>, and <name><surname>Li</surname><given-names>HB</given-names></name> (<year>2022</year>). <article-title>DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion</article-title>. <source>Nat Commun</source>
<volume>13</volume>, <fpage>2059</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-022-29754-y</pub-id>.<pub-id pub-id-type="pmid">35440133</pub-id>
</mixed-citation>
      </ref>
      <ref id="R86">
        <label>86.</label>
        <mixed-citation publication-type="journal"><name><surname>Glassman</surname><given-names>CR</given-names></name>, <name><surname>Mathiharan</surname><given-names>YK</given-names></name>, <name><surname>Jude</surname><given-names>KM</given-names></name>, <name><surname>Su</surname><given-names>L</given-names></name>, <name><surname>Panova</surname><given-names>O</given-names></name>, <name><surname>Lupardus</surname><given-names>PJ</given-names></name>, <name><surname>Spangler</surname><given-names>JB</given-names></name>, <name><surname>Ely</surname><given-names>LK</given-names></name>, <name><surname>Thomas</surname><given-names>C</given-names></name>, <name><surname>Skiniotis</surname><given-names>G</given-names></name>, and <name><surname>Garcia</surname><given-names>KC</given-names></name> (<year>2021</year>). <article-title>Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells</article-title>. <source>Cell</source>
<volume>184</volume>, <fpage>983</fpage>&#x2013;<lpage>999 e924</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2021.01.018</pub-id>.<pub-id pub-id-type="pmid">33606986</pub-id>
</mixed-citation>
      </ref>
      <ref id="R87">
        <label>87.</label>
        <mixed-citation publication-type="journal"><name><surname>Hummel</surname><given-names>TM</given-names></name>, <name><surname>Ackfeld</surname><given-names>T</given-names></name>, <name><surname>Schonberg</surname><given-names>M</given-names></name>, <name><surname>Ciupka</surname><given-names>G</given-names></name>, <name><surname>Schulz</surname><given-names>F</given-names></name>, <name><surname>Oberdoerster</surname><given-names>A</given-names></name>, <name><surname>Grotzinger</surname><given-names>J</given-names></name>, <name><surname>Scheller</surname><given-names>J</given-names></name>, and <name><surname>Floss</surname><given-names>DM</given-names></name> (<year>2017</year>). <article-title>Synthetic Deletion of the Interleukin 23 Receptor (IL-23R) Stalk Region Led to Autonomous IL-23R Homodimerization and Activation</article-title>. <source>Mol Cell Biol</source>
<volume>37</volume>. <pub-id pub-id-type="doi">10.1128/MCB.00014-17</pub-id>.</mixed-citation>
      </ref>
      <ref id="R88">
        <label>88.</label>
        <mixed-citation publication-type="journal"><name><surname>Cua</surname><given-names>DJ</given-names></name>, <name><surname>Sherlock</surname><given-names>J</given-names></name>, <name><surname>Chen</surname><given-names>Y</given-names></name>, <name><surname>Murphy</surname><given-names>CA</given-names></name>, <name><surname>Joyce</surname><given-names>B</given-names></name>, <name><surname>Seymour</surname><given-names>B</given-names></name>, <name><surname>Lucian</surname><given-names>L</given-names></name>, <name><surname>To</surname><given-names>W</given-names></name>, <name><surname>Kwan</surname><given-names>S</given-names></name>, <name><surname>Churakova</surname><given-names>T</given-names></name>, <etal/> (<year>2003</year>). <article-title>Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain</article-title>. <source>Nature</source>
<volume>421</volume>, <fpage>744</fpage>&#x2013;<lpage>748</lpage>. <pub-id pub-id-type="doi">10.1038/nature01355</pub-id>.<pub-id pub-id-type="pmid">12610626</pub-id>
</mixed-citation>
      </ref>
      <ref id="R89">
        <label>89.</label>
        <mixed-citation publication-type="journal"><name><surname>Gaffen</surname><given-names>SL</given-names></name>, <name><surname>Jain</surname><given-names>R</given-names></name>, <name><surname>Garg</surname><given-names>AV</given-names></name>, and <name><surname>Cua</surname><given-names>DJ</given-names></name> (<year>2014</year>). <article-title>The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing</article-title>. <source>Nat Rev Immunol</source>
<volume>14</volume>, <fpage>585</fpage>&#x2013;<lpage>600</lpage>. <pub-id pub-id-type="doi">10.1038/nri3707</pub-id>.<pub-id pub-id-type="pmid">25145755</pub-id>
</mixed-citation>
      </ref>
      <ref id="R90">
        <label>90.</label>
        <mixed-citation publication-type="journal"><name><surname>Steinman</surname><given-names>L</given-names></name> (<year>2007</year>). <article-title>A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage</article-title>. <source>Nat Med</source>
<volume>13</volume>, <fpage>139</fpage>&#x2013;<lpage>145</lpage>. <pub-id pub-id-type="doi">10.1038/nm1551</pub-id>.<pub-id pub-id-type="pmid">17290272</pub-id>
</mixed-citation>
      </ref>
      <ref id="R91">
        <label>91.</label>
        <mixed-citation publication-type="journal"><name><surname>Fieschi</surname><given-names>C</given-names></name>, and <name><surname>Casanova</surname><given-names>JL</given-names></name> (<year>2003</year>). <article-title>The role of interleukin-12 in human infectious diseases: only a faint signature</article-title>. <source>Eur J Immunol</source>
<volume>33</volume>, <fpage>1461</fpage>&#x2013;<lpage>1464</lpage>. <pub-id pub-id-type="doi">10.1002/eji.200324038</pub-id>.<pub-id pub-id-type="pmid">12778462</pub-id>
</mixed-citation>
      </ref>
      <ref id="R92">
        <label>92.</label>
        <mixed-citation publication-type="journal"><name><surname>Acosta-Rodriguez</surname><given-names>EV</given-names></name>, <name><surname>Rivino</surname><given-names>L</given-names></name>, <name><surname>Geginat</surname><given-names>J</given-names></name>, <name><surname>Jarrossay</surname><given-names>D</given-names></name>, <name><surname>Gattorno</surname><given-names>M</given-names></name>, <name><surname>Lanzavecchia</surname><given-names>A</given-names></name>, <name><surname>Sallusto</surname><given-names>F</given-names></name>, and <name><surname>Napolitani</surname><given-names>G</given-names></name> (<year>2007</year>). <article-title>Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells</article-title>. <source>Nat Immunol</source>
<volume>8</volume>, <fpage>639</fpage>&#x2013;<lpage>646</lpage>. <pub-id pub-id-type="doi">10.1038/ni1467</pub-id>.<pub-id pub-id-type="pmid">17486092</pub-id>
</mixed-citation>
      </ref>
      <ref id="R93">
        <label>93.</label>
        <mixed-citation publication-type="journal"><name><surname>Zielinski</surname><given-names>CE</given-names></name>, <name><surname>Corti</surname><given-names>D</given-names></name>, <name><surname>Mele</surname><given-names>F</given-names></name>, <name><surname>Pinto</surname><given-names>D</given-names></name>, <name><surname>Lanzavecchia</surname><given-names>A</given-names></name>, and <name><surname>Sallusto</surname><given-names>F</given-names></name> (<year>2011</year>). <article-title>Dissecting the human immunologic memory for pathogens</article-title>. <source>Immunol Rev</source>
<volume>240</volume>, <fpage>40</fpage>&#x2013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-065X.2010.01000.x</pub-id>.<pub-id pub-id-type="pmid">21349085</pub-id>
</mixed-citation>
      </ref>
      <ref id="R94">
        <label>94.</label>
        <mixed-citation publication-type="journal"><name><surname>Lindestam Arlehamn</surname><given-names>CS</given-names></name>, <name><surname>Gerasimova</surname><given-names>A</given-names></name>, <name><surname>Mele</surname><given-names>F</given-names></name>, <name><surname>Henderson</surname><given-names>R</given-names></name>, <name><surname>Swann</surname><given-names>J</given-names></name>, <name><surname>Greenbaum</surname><given-names>JA</given-names></name>, <name><surname>Kim</surname><given-names>Y</given-names></name>, <name><surname>Sidney</surname><given-names>J</given-names></name>, <name><surname>James</surname><given-names>EA</given-names></name>, <name><surname>Taplitz</surname><given-names>R</given-names></name>, <etal/> (<year>2013</year>). <article-title>Memory T cells in latent Mycobacterium tuberculosis infection are directed against three antigenic islands and largely contained in a CXCR3+CCR6+ Th1 subset</article-title>. <source>PLoS Pathog</source>
<volume>9</volume>, <fpage>e1003130</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1003130</pub-id>.<pub-id pub-id-type="pmid">23358848</pub-id>
</mixed-citation>
      </ref>
      <ref id="R95">
        <label>95.</label>
        <mixed-citation publication-type="journal"><name><surname>Lander</surname><given-names>ES</given-names></name>, <name><surname>Linton</surname><given-names>LM</given-names></name>, <name><surname>Birren</surname><given-names>B</given-names></name>, <name><surname>Nusbaum</surname><given-names>C</given-names></name>, <name><surname>Zody</surname><given-names>MC</given-names></name>, <name><surname>Baldwin</surname><given-names>J</given-names></name>, <name><surname>Devon</surname><given-names>K</given-names></name>, <name><surname>Dewar</surname><given-names>K</given-names></name>, <name><surname>Doyle</surname><given-names>M</given-names></name>, <name><surname>FitzHugh</surname><given-names>W</given-names></name>, <etal/> (<year>2001</year>). <article-title>Initial sequencing and analysis of the human genome</article-title>. <source>Nature</source>
<volume>409</volume>, <fpage>860</fpage>&#x2013;<lpage>921</lpage>. <pub-id pub-id-type="doi">10.1038/35057062</pub-id>.<pub-id pub-id-type="pmid">11237011</pub-id>
</mixed-citation>
      </ref>
      <ref id="R96">
        <label>96.</label>
        <mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>H</given-names></name>, and <name><surname>Durbin</surname><given-names>R</given-names></name> (<year>2009</year>). <article-title>Fast and accurate short read alignment with Burrows-Wheeler transform</article-title>. <source>Bioinformatics</source>
<volume>25</volume>, <fpage>1754</fpage>&#x2013;<lpage>1760</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btp324</pub-id>.<pub-id pub-id-type="pmid">19451168</pub-id>
</mixed-citation>
      </ref>
      <ref id="R97">
        <label>97.</label>
        <mixed-citation publication-type="book"><name><surname>Van der</surname><given-names>Auwera</given-names></name>, <name><surname>G.O.C.</surname><given-names>B</given-names></name>, (<year>2020</year>). <source>Genomics in the Cloud: Using Docker, GATK, and WDL in Terra</source> (<edition>1st Edition</edition>). <publisher-name>O&#x2019;Reilly Media</publisher-name>.</mixed-citation>
      </ref>
      <ref id="R98">
        <label>98.</label>
        <mixed-citation publication-type="journal"><name><surname>Cingolani</surname><given-names>P</given-names></name>, <name><surname>Platts</surname><given-names>A</given-names></name>, <name><surname>Wang le</surname><given-names>L</given-names></name>, <name><surname>Coon</surname><given-names>M</given-names></name>, <name><surname>Nguyen</surname><given-names>T</given-names></name>, <name><surname>Wang</surname><given-names>L</given-names></name>, <name><surname>Land</surname><given-names>SJ</given-names></name>, <name><surname>Lu</surname><given-names>X</given-names></name>, and <name><surname>Ruden</surname><given-names>DM</given-names></name> (<year>2012</year>). <article-title>A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3</article-title>. <source>Fly (Austin)</source>
<volume>6</volume>, <fpage>80</fpage>&#x2013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.4161/fly.19695</pub-id>.<pub-id pub-id-type="pmid">22728672</pub-id>
</mixed-citation>
      </ref>
      <ref id="R99">
        <label>99.</label>
        <mixed-citation publication-type="journal"><name><surname>D.</surname><given-names>F</given-names></name>, (<year>1993</year>). <source>Bias reduction of maximum likelihood estimates Biometrika</source>, <fpage>27</fpage>&#x2013;<lpage>38</lpage>.</mixed-citation>
      </ref>
      <ref id="R100">
        <label>100.</label>
        <mixed-citation publication-type="book"><collab>Team, R.C.</collab> (<year>2022</year>). <source>R: A language and environment for statistical computing</source>. . <publisher-name>R Foundation for Statistical Computing</publisher-name>, <publisher-loc>Vienna, Austria</publisher-loc>.</mixed-citation>
      </ref>
      <ref id="R101">
        <label>101.</label>
        <mixed-citation publication-type="journal"><name><surname>Wagner</surname><given-names>S</given-names></name>, <name><surname>Bohlen</surname><given-names>J</given-names></name>, <name><surname>Herrmannova</surname><given-names>A</given-names></name>, <name><surname>Jelinek</surname><given-names>J</given-names></name>, <name><surname>Preiss</surname><given-names>T</given-names></name>, <name><surname>Valasek</surname><given-names>LS</given-names></name>, and <name><surname>Teleman</surname><given-names>AA</given-names></name> (<year>2022</year>). <article-title>Selective footprinting of 40S and 80S ribosome subpopulations (Sel-TCP-seq) to study translation and its control</article-title>. <source>Nat Protoc</source>
<volume>17</volume>, <fpage>2139</fpage>&#x2013;<lpage>2187</lpage>. <pub-id pub-id-type="doi">10.1038/s41596-022-00708-4</pub-id>.<pub-id pub-id-type="pmid">35869369</pub-id>
</mixed-citation>
      </ref>
      <ref id="R102">
        <label>102.</label>
        <mixed-citation publication-type="journal"><name><surname>Langmead</surname><given-names>B</given-names></name>, and <name><surname>Salzberg</surname><given-names>SL</given-names></name> (<year>2012</year>). <article-title>Fast gapped-read alignment with Bowtie 2</article-title>. <source>Nature methods</source>
<volume>9</volume>, <fpage>357</fpage>&#x2013;<lpage>359</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.1923</pub-id>.<pub-id pub-id-type="pmid">22388286</pub-id>
</mixed-citation>
      </ref>
      <ref id="R103">
        <label>103.</label>
        <mixed-citation publication-type="journal"><name><surname>Drutman</surname><given-names>SB</given-names></name>, <name><surname>Mansouri</surname><given-names>D</given-names></name>, <name><surname>Mahdaviani</surname><given-names>SA</given-names></name>, <name><surname>Neehus</surname><given-names>AL</given-names></name>, <name><surname>Hum</surname><given-names>D</given-names></name>, <name><surname>Bryk</surname><given-names>R</given-names></name>, <name><surname>Hernandez</surname><given-names>N</given-names></name>, <name><surname>Belkaya</surname><given-names>S</given-names></name>, <name><surname>Rapaport</surname><given-names>F</given-names></name>, <name><surname>Bigio</surname><given-names>B</given-names></name>, <etal/> (<year>2020</year>). <article-title>Fatal Cytomegalovirus Infection in an Adult with Inherited NOS2 Deficiency</article-title>. <source>N Engl J Med</source>
<volume>382</volume>, <fpage>437</fpage>&#x2013;<lpage>445</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1910640</pub-id>.<pub-id pub-id-type="pmid">31995689</pub-id>
</mixed-citation>
      </ref>
      <ref id="R104">
        <label>104.</label>
        <mixed-citation publication-type="journal"><name><surname>Mina</surname><given-names>MJ</given-names></name>, <name><surname>Kula</surname><given-names>T</given-names></name>, <name><surname>Leng</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>M</given-names></name>, <name><surname>de Vries</surname><given-names>RD</given-names></name>, <name><surname>Knip</surname><given-names>M</given-names></name>, <name><surname>Siljander</surname><given-names>H</given-names></name>, <name><surname>Rewers</surname><given-names>M</given-names></name>, <name><surname>Choy</surname><given-names>DF</given-names></name>, <name><surname>Wilson</surname><given-names>MS</given-names></name>, <etal/> (<year>2019</year>). <article-title>Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens</article-title>. <source>Science</source>
<volume>366</volume>, <fpage>599</fpage>&#x2013;<lpage>606</lpage>. <pub-id pub-id-type="doi">10.1126/science.aay6485</pub-id>.<pub-id pub-id-type="pmid">31672891</pub-id>
</mixed-citation>
      </ref>
      <ref id="R105">
        <label>105.</label>
        <mixed-citation publication-type="journal"><name><surname>Mohan</surname><given-names>D</given-names></name>, <name><surname>Wansley</surname><given-names>DL</given-names></name>, <name><surname>Sie</surname><given-names>BM</given-names></name>, <name><surname>Noon</surname><given-names>MS</given-names></name>, <name><surname>Baer</surname><given-names>AN</given-names></name>, <name><surname>Laserson</surname><given-names>U</given-names></name>, and <name><surname>Larman</surname><given-names>HB</given-names></name> (<year>2019</year>). <article-title>Publisher Correction: PhIP-Seq characterization of serum antibodies using oligonucleotide-encoded peptidomes</article-title>. <source>Nat Protoc</source>
<volume>14</volume>, <fpage>2596</fpage>. <pub-id pub-id-type="doi">10.1038/s41596-018-0088-4</pub-id>.</mixed-citation>
      </ref>
      <ref id="R106">
        <label>106.</label>
        <mixed-citation publication-type="journal"><name><surname>Hasan</surname><given-names>MR</given-names></name>, <name><surname>Rahman</surname><given-names>M</given-names></name>, <name><surname>Khan</surname><given-names>T</given-names></name>, <name><surname>Saeed</surname><given-names>A</given-names></name>, <name><surname>Sundararaju</surname><given-names>S</given-names></name>, <name><surname>Flores</surname><given-names>A</given-names></name>, <name><surname>Hawken</surname><given-names>P</given-names></name>, <name><surname>Rawat</surname><given-names>A</given-names></name>, <name><surname>Elkum</surname><given-names>N</given-names></name>, <name><surname>Hussain</surname><given-names>K</given-names></name>, <etal/> (<year>2021</year>). <article-title>Virome-wide serological profiling reveals association of herpesviruses with obesity</article-title>. <source>Sci Rep</source>
<volume>11</volume>, <fpage>2562</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-021-82213-4</pub-id>.<pub-id pub-id-type="pmid">33510449</pub-id>
</mixed-citation>
      </ref>
      <ref id="R107">
        <label>107.</label>
        <mixed-citation publication-type="journal"><name><surname>Khan</surname><given-names>T</given-names></name>, <name><surname>Rahman</surname><given-names>M</given-names></name>, <name><surname>Ali</surname><given-names>FA</given-names></name>, <name><surname>Huang</surname><given-names>SSY</given-names></name>, <name><surname>Ata</surname><given-names>M</given-names></name>, <name><surname>Zhang</surname><given-names>Q</given-names></name>, <name><surname>Bastard</surname><given-names>P</given-names></name>, <name><surname>Liu</surname><given-names>Z</given-names></name>, <name><surname>Jouanguy</surname><given-names>E</given-names></name>, <name><surname>Beziat</surname><given-names>V</given-names></name>, <etal/> (<year>2021</year>). <article-title>Distinct antibody repertoires against endemic human coronaviruses in children and adults</article-title>. <source>JCI Insight</source>
<volume>6</volume>. <pub-id pub-id-type="doi">10.1172/jci.insight.144499</pub-id>.</mixed-citation>
      </ref>
      <ref id="R108">
        <label>108.</label>
        <mixed-citation publication-type="journal"><name><surname>Korsunsky</surname><given-names>I</given-names></name>, <name><surname>Millard</surname><given-names>N</given-names></name>, <name><surname>Fan</surname><given-names>J</given-names></name>, <name><surname>Slowikowski</surname><given-names>K</given-names></name>, <name><surname>Zhang</surname><given-names>F</given-names></name>, <name><surname>Wei</surname><given-names>K</given-names></name>, <name><surname>Baglaenko</surname><given-names>Y</given-names></name>, <name><surname>Brenner</surname><given-names>M</given-names></name>, <name><surname>Loh</surname><given-names>PR</given-names></name>, and <name><surname>Raychaudhuri</surname><given-names>S</given-names></name> (<year>2019</year>). <article-title>Fast, sensitive and accurate integration of single-cell data with Harmony</article-title>. <source>Nat Methods</source>
<volume>16</volume>, <fpage>1289</fpage>&#x2013;<lpage>1296</lpage>. <pub-id pub-id-type="doi">10.1038/s41592-019-0619-0</pub-id>.<pub-id pub-id-type="pmid">31740819</pub-id>
</mixed-citation>
      </ref>
      <ref id="R109">
        <label>109.</label>
        <mixed-citation publication-type="journal"><name><surname>Aran</surname><given-names>D</given-names></name>, <name><surname>Looney</surname><given-names>AP</given-names></name>, <name><surname>Liu</surname><given-names>L</given-names></name>, <name><surname>Wu</surname><given-names>E</given-names></name>, <name><surname>Fong</surname><given-names>V</given-names></name>, <name><surname>Hsu</surname><given-names>A</given-names></name>, <name><surname>Chak</surname><given-names>S</given-names></name>, <name><surname>Naikawadi</surname><given-names>RP</given-names></name>, <name><surname>Wolters</surname><given-names>PJ</given-names></name>, <name><surname>Abate</surname><given-names>AR</given-names></name>, <etal/> (<year>2019</year>). <article-title>Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage</article-title>. <source>Nat Immunol</source>
<volume>20</volume>, <fpage>163</fpage>&#x2013;<lpage>172</lpage>. <pub-id pub-id-type="doi">10.1038/s41590-018-0276-y</pub-id>.<pub-id pub-id-type="pmid">30643263</pub-id>
</mixed-citation>
      </ref>
      <ref id="R110">
        <label>110.</label>
        <mixed-citation publication-type="journal"><name><surname>Monaco</surname><given-names>G</given-names></name>, <name><surname>Lee</surname><given-names>B</given-names></name>, <name><surname>Xu</surname><given-names>W</given-names></name>, <name><surname>Mustafah</surname><given-names>S</given-names></name>, <name><surname>Hwang</surname><given-names>YY</given-names></name>, <name><surname>Carre</surname><given-names>C</given-names></name>, <name><surname>Burdin</surname><given-names>N</given-names></name>, <name><surname>Visan</surname><given-names>L</given-names></name>, <name><surname>Ceccarelli</surname><given-names>M</given-names></name>, <name><surname>Poidinger</surname><given-names>M</given-names></name>, <etal/> (<year>2019</year>). <article-title>RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types</article-title>. <source>Cell Rep</source>
<volume>26</volume>, <fpage>1627</fpage>&#x2013;<lpage>1640 e1627</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2019.01.041</pub-id>.<pub-id pub-id-type="pmid">30726743</pub-id>
</mixed-citation>
      </ref>
      <ref id="R111">
        <label>111.</label>
        <mixed-citation publication-type="journal"><name><surname>Hao</surname><given-names>Y</given-names></name>, <name><surname>Hao</surname><given-names>S</given-names></name>, <name><surname>Andersen-Nissen</surname><given-names>E</given-names></name>, <name><surname>Mauck</surname><given-names>WM</given-names><suffix>3rd</suffix></name>, <name><surname>Zheng</surname><given-names>S</given-names></name>, <name><surname>Butler</surname><given-names>A</given-names></name>, <name><surname>Lee</surname><given-names>MJ</given-names></name>, <name><surname>Wilk</surname><given-names>AJ</given-names></name>, <name><surname>Darby</surname><given-names>C</given-names></name>, <name><surname>Zager</surname><given-names>M</given-names></name>, <etal/> (<year>2021</year>). <article-title>Integrated analysis of multimodal single-cell data</article-title>. <source>Cell</source>
<volume>184</volume>, <fpage>3573</fpage>&#x2013;<lpage>3587 e3529</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2021.04.048</pub-id>.<pub-id pub-id-type="pmid">34062119</pub-id>
</mixed-citation>
      </ref>
      <ref id="R112">
        <label>112.</label>
        <mixed-citation publication-type="journal"><name><surname>Crowell</surname><given-names>HL</given-names></name>, <name><surname>Soneson</surname><given-names>C</given-names></name>, <name><surname>Germain</surname><given-names>PL</given-names></name>, <name><surname>Calini</surname><given-names>D</given-names></name>, <name><surname>Collin</surname><given-names>L</given-names></name>, <name><surname>Raposo</surname><given-names>C</given-names></name>, <name><surname>Malhotra</surname><given-names>D</given-names></name>, and <name><surname>Robinson</surname><given-names>MD</given-names></name> (<year>2020</year>). <article-title>muscat detects subpopulation-specific state transitions from multi-sample multi-condition single-cell transcriptomics data</article-title>. <source>Nat Commun</source>
<volume>11</volume>, <fpage>6077</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-19894-4</pub-id>.<pub-id pub-id-type="pmid">33257685</pub-id>
</mixed-citation>
      </ref>
      <ref id="R113">
        <label>113.</label>
        <mixed-citation publication-type="journal"><name><surname>Love</surname><given-names>MI</given-names></name>, <name><surname>Huber</surname><given-names>W</given-names></name>, and <name><surname>Anders</surname><given-names>S</given-names></name> (<year>2014</year>). <article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>. <source>Genome Biol</source>
<volume>15</volume>, <fpage>550</fpage>. <pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id>.<pub-id pub-id-type="pmid">25516281</pub-id>
</mixed-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig position="float" id="F1">
      <label>Figure 1:</label>
      <caption>
        <title>Hemizygous <italic toggle="yes">MCTS1</italic> mutations in patients with MSMD from five unrelated families.</title>
        <p id="P91"><bold>(A)</bold> Family pedigrees with allele segregation. The patients in black suffer from MSMD and are hemizygous for the indicated <italic toggle="yes">MCTS1</italic> alleles. The arrow indicates the proband. Other symbols; asymptomatic: black vertical line, heterozygous: blackdots, unknown genotype: &#x201C;E?&#x201D;, wild-type: WT. <bold>(B)</bold> Schematic representation of the MCTS1 mRNA (top) and protein (middle) structure. (Bottom) Predicted protein products of the <italic toggle="yes">MCTS1</italic> variants found in MSMD patients. <bold>(C)</bold> CADD MAF plot of all the nonsynonymous, hemizygous <italic toggle="yes">MCTS1</italic> variants of the gnomAD database (in black, splicing in blue), and the five <italic toggle="yes">MCTS1</italic> pLOF variants of patients with MSMD (in red). <bold>(D)</bold> Schematic representation of the known molecular function of MCTS1 and its binding partner, DENR.</p>
      </caption>
      <graphic xlink:href="nihms-1935775-f0001" position="float"/>
    </fig>
    <fig position="float" id="F2">
      <label>Figure 2:</label>
      <caption>
        <title>The <italic toggle="yes">MCTS1</italic> mutations found in MSMD patients are loss-of-expression and loss-of-function.</title>
        <p id="P92"><bold>(A)</bold> Western blot of wild-type (WT) and MCTS1<sup>KO</sup> HeLa cells transiently transfected with MCTS1 variants; Red: patients; blue: synthetic LOF variant; purple: gnomAD missense variants; EV: empty vector. Bold variants: hemizygous in gnomAD. Representative data from three independent experiments are shown. <bold>(B-D)</bold> Levels of MCTS1 protein in <bold>(B)</bold> primary fibroblasts from P2 and healthy controls, <bold>(C)</bold> T-cell blasts from P2, P4, P5 and P7 and healthy WT controls, and <bold>(D)</bold> neutrophils of P2, his relatives (M = mother, F= father, S = sister) and two healthy WT controls (C1, C2) as determined by western blotting. <bold>(E)</bold> Schematic representation of the reporter constructs used for the MCTS1 activity assay in <bold>(F)</bold> Activity of the MCTS1 variants used for the transient transfection of MCTS1<sup>KO</sup> HeLa cells, as assessed by the luciferase translation reinitiation assay. Bars: mean and SD of five biological replicates. Statistical significance was assessed in unpaired Welch&#x2019;s <italic toggle="yes">t</italic>-tests corrected for multiple testing. *<italic toggle="yes">p</italic>&lt;0.05</p>
      </caption>
      <graphic xlink:href="nihms-1935775-f0002" position="float"/>
    </fig>
    <fig position="float" id="F3">
      <label>Figure 3:</label>
      <caption>
        <title>Defective ribosome recycling and translation reinitiation in the patients&#x2019; cells</title>
        <p id="P93"><bold>(A-D)</bold> Metagene profiles for 40S <bold>(A, C)</bold> and 80S <bold>(B, D)</bold> ribosome footprinting showing the position of the 5&#x2019; end of the ribosome footprints relative to the stop codons of all proteins (coding ORFs) in HeLa cells <bold>(A, B)</bold> and SV40-fibroblasts <bold>(C, D). (A, B)</bold> Read counts normalized against the area indicated on the plot; <bold>(C, D)</bold> Read counts normalized by sequencing depth. <bold>(E)</bold> Penultimate codon enrichments for mORFs in the top quartile for 40S accumulation (<italic toggle="yes">n</italic> = 1034) relative to all detected mORF stop codons (<italic toggle="yes">n</italic> = 4222). Significance was assessed in binomial tests, with correction for multiple testing. <bold>(F)</bold> Volcano plot of changes in translation efficiency from 80S footprinting data for P2 SV40-fibroblasts +/&#x2212; MCTS1. The <italic toggle="yes">p</italic>-values adjusted for multiple testing in X-tail analysis are shown on the <italic toggle="yes">y</italic>-axis. <bold>(G)</bold> Volcano plot of changes in translation efficiency from the 80S footprinting data of T-cell blasts from P2, P4, P5, P7 relative to four healthy controls. The <italic toggle="yes">p</italic>-values adjusted for multiple testing by X-tail analysis are shown on the <italic toggle="yes">y</italic>-axis. <bold>(H)</bold> Levels of mRNA, ribosome footprints on mRNA and translation efficiency for the <italic toggle="yes">JAK2</italic> endogenous mRNA from <bold>(G)</bold>.</p>
      </caption>
      <graphic xlink:href="nihms-1935775-f0003" position="float"/>
    </fig>
    <fig position="float" id="F4">
      <label>Figure 4:</label>
      <caption>
        <title>JAK2 translation depends on MCTS1-mediated reinitiation.</title>
        <p id="P94"><bold>(A)</bold> The 5&#x2019;UTR translation reporters indicated were assessed in WT (black) and MCTS1<sup>KO</sup> (red) HeLa cells. Number &#x2212;1, &#x2212;2 indicate distinct 5&#x2019;UTR isoforms. Results are shown for 3-5 biological replicates per reporter. Statistical significance was assessed in multiple, two-tailed, unpaired <italic toggle="yes">t</italic>-tests with correction for multiple testing (**<italic toggle="yes">p</italic>&lt;0.005). <bold>(B-C)</bold> Efficiency of JAK2 reporter translation in WT and MCTS1<sup>KO</sup> cells transfected with the indicated constructs, as assessed in dual-luciferase assays. Results for three biological replicates are shown. Statistical significance was assessed in multiple, two-tailed, unpaired <italic toggle="yes">t</italic>-tests with correction for multiple testing (*<italic toggle="yes">p</italic>&lt;0.05, **<italic toggle="yes">p</italic>&lt;0.005). <bold>(D)</bold> Trace of the 40S ribosome footprints on the endogenous <italic toggle="yes">JAK2</italic> 5&#x2019;UTR. Red: MCTS1-dependent stuORFs, pink: MCTS1-independent uORF, blue: JAK2 main ORF.</p>
      </caption>
      <graphic xlink:href="nihms-1935775-f0004" position="float"/>
    </fig>
    <fig position="float" id="F5">
      <label>Figure 5:</label>
      <caption>
        <title>JAK2 is poorly expressed in cells derived from MCTS1-deficient patients.</title>
        <p id="P95"><bold>(A-D)</bold> Western blot for JAK2, MCTS1, DENR and vinculin on total lysate from <bold>(A)</bold> MCTS1<sup>KO</sup> THP-1 clones (1 to 5) and wild-type (WT) THP-1 cells, <bold>(B)</bold> SV40-fibroblasts from P2 and a healthy control stably transduced with the indicated overexpression constructs, <bold>(C)</bold> HSV-T cells from P2, healthy controls and an IL-12R&#x3B2;1-deficient patient and <bold>(D)</bold> T-cell blasts from P2, P5 and healthy controls (C1, C2 and C3). The data shown are representative of three (A, C, D), or (B) two independent experiments.) <bold>(E)</bold> Quantification of JAK2 protein levels relative to a loading control from (A-D) <bold>(F)</bold> Gene set enrichment analysis of RNA-seq analysis of T-cell blasts from heathy controls (<italic toggle="yes">n</italic> = 9), MCTS1-deficient (<italic toggle="yes">n</italic> = 4), TYK2-deficient (<italic toggle="yes">n</italic> = 1), IL-12R&#x3B2;1-deficient (<italic toggle="yes">n</italic> = 1), IRAK4-deficient (<italic toggle="yes">n</italic> = 1) and TYK2 P1104A-homozygous (<italic toggle="yes">n</italic> = 2) patients were stimulated with IL-1&#x3B2; (24 h) and with IL-12 and IL-23 (6 h). Dot heatmaps are shown for the 10 gene sets for the healthy controls most strongly affected by stimulation with IL-23 + IL-1&#x3B2; relative to IL-1&#x3B2; alone. <bold>(G, I)</bold> Western blots of the indicated HEK-Blue cell lines stably transduced with the indicated lentiviral vectors. The data shown are representative of three biological replicates. <bold>(H, J)</bold> HEK-Blue colorimetric activity of the indicated cell lines stimulated with the indicated cytokines for 20 hours. Data are shown for three biological replicates and statistical significance was assessed in unpaired, two-tailed <italic toggle="yes">t</italic>-tests, *<italic toggle="yes">p</italic>&lt;0.05, **<italic toggle="yes">p</italic>&lt;0.005. <bold>(K)</bold> The effect of gandotinib on the response to IL-23 + IL1-&#x3B2; or IL-12 in NK cells and to IFN-&#x3B3; or IFN-&#x3B1; in monocytes. Summary plot, see <xref rid="SD7" ref-type="supplementary-material">Figure S7O</xref>&#x2013;<xref rid="SD7" ref-type="supplementary-material">R</xref> for details. The data shown are the means of six biological replicates performed on NK cells and monocytes from two heathy donors each.</p>
      </caption>
      <graphic xlink:href="nihms-1935775-f0005" position="float"/>
    </fig>
    <fig position="float" id="F6">
      <label>Figure 6:</label>
      <caption>
        <title>Defective IL-23-dependent IFN-&#x3B3; induction in the patients&#x2019; primary immune cells</title>
        <p id="P96"><bold>(A-B)</bold> Fresh PBMCs were stimulated with 50 ng/ml IL-12 or 100 ng/ml IL-23 for 48 hours or with PMA plus ionomycin for 24 hours. IFN-&#x3B3; levels in the supernatant were assessed by LEGENDplex multiplex ELISA <bold>(A)</bold> and <italic toggle="yes">IFNG</italic> mRNA induction was assessed by qPCR <bold>(B)</bold>. Statistical significance was assessed in unpaired Mann-Whitney <italic toggle="yes">U</italic> tests (*<italic toggle="yes">p</italic>&lt;0.05). <bold>(C)</bold> RNA-seq analysis. Log<sub>2</sub> fold-change in mRNA levels upon stimulation with IL-23 (100 ng/ml IL-23 for 48 hours) for transcripts differentially expressed in healthy controls, for the healthy controls and patients. <bold>(D)</bold> Heatmap showing the proportions of transcripts with changes in expression for indicated modules for the various individuals compared (controls versus P2, P4, P5) relative to baseline values in the absence of stimulation. Red: transcripts at higher levels than baseline, blue: decrease in transcript levels relative to baseline. <bold>(E)</bold> Cryopreserved PBMCs of the indicated genotypes were stimulated with 50 ng/ml IL-12, 100 ng/ml IL-23, 2.5 ng/ml IL-1&#x3B2;, or a combination of these cytokines for 48 hours, or with PMA + ionomycin for 24 hours. IFN-&#x3B3; levels in the supernatant were assessed by LEGENDplex multiplex ELISA. Bars indicate the mean and SD.</p>
      </caption>
      <graphic xlink:href="nihms-1935775-f0006" position="float"/>
    </fig>
    <fig position="float" id="F7">
      <label>Figure 7:</label>
      <caption>
        <title>Patients&#x2019; V&#x3B4;2<sup>+</sup> &#x3B3;&#x3B4; T and MAIT cells have impaired <italic toggle="yes">IFNG</italic> induction upon IL-23 stimulation and BCG infection.</title>
        <p id="P97"><bold>(A-D)</bold> Single-cell RNA sequencing (scRNA-seq) analysis. PBMCs were either left non-stimulated or were stimulated with IL-23 for 6 hours, and single-cell capture was then performed. <bold>(A)</bold> Clustering analysis identifying 17 major leukocyte subsets. <bold>(B)</bold> The fold-change in <italic toggle="yes">IFNG</italic> mRNA levels following stimulation in MCTS1 patients relative to controls is shown on the <italic toggle="yes">x</italic>-axis. The <italic toggle="yes">y</italic>-axis shows the same parameter for IL-23R<sup>&#x2212;/&#x2212;</sup> patients as a comparison. The size of the circles indicates the median change (IL-23 versus NS) in normalized <italic toggle="yes">IFNG</italic> mRNA levels in controls for the corresponding subset. <bold>(C)</bold> Pathway analysis of the transcriptional response to IL-23 in IL-12R&#x3B2;1<sup>&#x2212;/&#x2212;</sup>, IL-23R<sup>&#x2212;/&#x2212;</sup> and MCTS1-deficient PBMCs relative to healthy control PBMCs, using the 50 Hallmark gene sets. Results are shown for selected immune-related gene sets. NES, normalized enrichment score. <bold>(D)</bold> Leading-edge genes for the Hallmark IFN-&#x3B3; response gene set common to IL-12R&#x3B2;1-, IL-23R-and MCTS1-deficient patients relative to controls are shown. <bold>(E-G)</bold> Induction of IFN-&#x3B3; in MCTS1-deficient V&#x3B4;2<sup>+</sup> &#x3B3;&#x3B4; T <bold>(E),</bold> MAIT <bold>(F)</bold> and NK <bold>(G)</bold> cells upon IL-23 stimulation and mycobacterial infection. Frequency of IFN-&#x3B2;-positive V&#x3B4;2<sup>+</sup> &#x3B3;&#x3B4; T cells following stimulation with cytokine, BCG or PMA plus ionomycin.</p>
      </caption>
      <graphic xlink:href="nihms-1935775-f0007" position="float"/>
    </fig>
    <table-wrap position="float" id="T1">
      <caption>
        <p id="P98">Key resources table</p>
      </caption>
      <table frame="box" rules="all">
        <colgroup span="1">
          <col align="left" valign="middle" span="1"/>
          <col align="left" valign="middle" span="1"/>
          <col align="left" valign="middle" span="1"/>
        </colgroup>
        <thead>
          <tr>
            <th align="left" valign="middle" rowspan="1" colspan="1">REAGENT or RESOURCE</th>
            <th align="left" valign="middle" rowspan="1" colspan="1">SOURCE</th>
            <th align="left" valign="middle" rowspan="1" colspan="1">IDENTIFIER</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td colspan="3" align="left" valign="top" rowspan="1">
<bold>Antibodies</bold>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">human MCTS1</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Teleman Lab</td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">human Tubulin</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Sigma Aldrich</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# T9026, RRID:AB_477593</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">human DENR</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Teleman Lab</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">human GAPDH</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Santa Cruz</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# sc-47724 HRP, RRID:AB_627678</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">human Vinculin</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Santa Cruz</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# sc-73614 HRP, RRID:AB_1131294</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">human JAK2</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cell Signaling Technology</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 3230, RRID:AB_2128522</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">human JAK1</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cell Signaling Technology</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 3332, RRID:AB_2128499</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">human TYK2</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Santa Cruz</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# sc-5271, RRID:AB_628419</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">human pSTAT1</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BD</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 612133, RRID:AB_399504</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Human pSTAT3</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cell Signaling Technology</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 9134S, RRID:AB_331589</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Human pSTAT1-PE (pY701)</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BD</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 612564, RRID:AB_399855</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Human pSTAT4-PE (pY693)</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BD</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 562073, RRID:AB_10895804</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Human pSTAT3-PE (pY705)</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BD</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 612569, RRID:AB_399860</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Anti-Human gamma delta TCR &#x2013; Alexa 647</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BioLegend</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 331214, RRID:AB_1089210</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Anti-human CD3 &#x2013; V450</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BD Biosciences</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 560365, RRID:AB_1645570</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Brilliant Violet 605 anti-human CD56 (NCAM) (Clone 5.1H11)</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BioLegend</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 362538, RRID:AB_2565856</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BUV563 Mouse Anti-Human CD4 Clone SK3 (also known as Leu3a)</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BD Biosciences</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 612912, RRID:AB_2870197</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Anti-TCR V&#x3B4;1-FITC, human</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Miltenyi Biotec</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 130-118-362, RRID:AB_2751495</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BUV737 Mouse Anti-Human CD8 Clone SK1</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BD Biosciences</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 612754, RRID:AB_2870085</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">APC/Fire 750 anti-human TCR V&#x3B4;2 Antibody</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BioLegend</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 331420, RRID:AB_2687326</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Brilliant Violet 785 anti-human CD20 [2H7]</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BioLegend</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 302356, RRID:AB_2566316</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Alexa Fluor 700 anti-human TCR V&#x3B1;7.2 [3C10]</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BioLegend</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 351728, RRID:AB_2566337</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MR1-5-OP-RU-tetramer tetramer</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">NIH tetramer core facility</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Anti-TCR V&#x3B2;11-APC, human (clone REA559)</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Miltenyi Biotec</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 130-108-733, RRID:AB_2653741</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BV480 Mouse Anti-Human Invariant NK T Cell</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BD Biosciences</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 746788, RRID:AB_2744044</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Anti-T-bet Mouse Monoclonal Antibody (PE/Cy7) [clone: 4B10]</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BioLegend</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 644823, RRID:AB_2561760</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Brilliant Violet 711 anti-human IFN-&#x3B3; (Clone 4S.B3)</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BioLegend</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 502540, RRID:AB_2563506</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Brilliant Violet 510 anti-human TNF-&#x3B1; (Clone MAb11)</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BioLegend</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 502950, RRID:AB_2565860</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">PerCP/Cy5.5 anti-human IL-17A [BL168]</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BioLegend</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 512313, RRID:AB_961397</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Ror&#x3B3;t Mouse anti Human, PE, Clone: Q21 559</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BD Biosciences</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 563081, RRID:AB_2686896</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Anti-human CD3 &#x2013; V450</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BD Biosciences</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 560365, RRID:AB_1645570</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BUV563 Mouse Anti-Human CD4 Clone SK3 (also known as Leu3a)</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BD Biosciences</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 612912, RRID:AB_2870197</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BUV737 Mouse Anti-Human CD8 Clone SK1</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">BD Biosciences</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 612754, RRID:AB_2870085</td>
          </tr>
          <tr>
            <td colspan="3" align="left" valign="bottom" rowspan="1">
<bold>Bacterial and virus strains</bold>
</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1"><italic toggle="yes">Mycobacterium bovis</italic> BCG</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">(Vogt and Nathan, 2011, PMID: 21911939)</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Stellar<sup>&#x2122;</sup> cells</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Takara</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 636763</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Biological samples</bold>
</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1"/>
            <td align="left" valign="bottom" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Peripheral blood mononuclear cells from indicated individuals</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">This manuscript</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasma from indicated individuals</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td colspan="3" align="left" valign="top" rowspan="1">
<bold>Chemicals, peptides, and recombinant proteins</bold>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Recombinant human Interleukin-12</td>
            <td align="left" valign="top" rowspan="1" colspan="1">R&amp;D Systems</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# 219-IL-025</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Recombinant human Interleukin-23</td>
            <td align="left" valign="top" rowspan="1" colspan="1">R&amp;D Systems</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# 1290-IL-010</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Recombinant human Interleukin-2</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Gibco,</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# PHC0023</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Recombinant human Interleukin-4</td>
            <td align="left" valign="top" rowspan="1" colspan="1">R&amp;D Systems</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# 204-IL</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Recombinant human M-CSF</td>
            <td align="left" valign="top" rowspan="1" colspan="1">R&amp;D Systems</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# 216-MC</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Recombinant human GM-CSF</td>
            <td align="left" valign="top" rowspan="1" colspan="1">R&amp;D Systems</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# 215-GM</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Recombinant human RANKL</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Peprotech</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# 310-01</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">FcBlock</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Miltenyi Biotec</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# 130-059-901</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Phorbol 12-myristate 13-acetate</td>
            <td align="left" valign="top" rowspan="1" colspan="1">MedChem Express</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# HY-18739</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Lymphoprep</td>
            <td align="left" valign="top" rowspan="1" colspan="1">StemCell</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# 07801</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Cycloheximide</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Santa-Cruz</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# sc-3508</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">DNase I, RNase-free</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">EN0521</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">RNase I</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Ambion</td>
            <td align="left" valign="top" rowspan="1" colspan="1">AM2294</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">GlycoBlue</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Ambion</td>
            <td align="left" valign="top" rowspan="1" colspan="1">AM9515</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Acid phenol&#x2013;chloroform</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Ambion</td>
            <td align="left" valign="top" rowspan="1" colspan="1">AM9722</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Formaldehyde 16%</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# 28908</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">DSP</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# A35393</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Nonidet P40 Substitute</td>
            <td align="left" valign="top" rowspan="1" colspan="1">AppliChem</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# A1694</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Ionomycin calcium salt</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# I3909-1ML</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Live/Dead Aqua</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher</td>
            <td align="left" valign="top" rowspan="1" colspan="1">L34966</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Protamine sulfate</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Merck</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# P3369-10G</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Aqua Dead Cell Stain kit</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# L34957</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">HEK-BlueTM Selection</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Invivogen</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# hb-sel</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">QUANTI-Blue Solution</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Invivogen</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# rep-qbs3</td>
          </tr>
          <tr>
            <td colspan="3" align="left" valign="top" rowspan="1">
<bold>Critical commercial assays</bold>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">SureSelect Human All Exon V6</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Agilent</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# 5190-8864</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">RiboZero TruSeq Stranded Total RNA Library Prep Kit</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Illumina</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# 20020596</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">10X Genomics Chromium chip</td>
            <td align="left" valign="top" rowspan="1" colspan="1">10X Genomics</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Chromium Single Cell 3&#x2019; Reagent Kit (v3 Chemistry)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">10X Genomics</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# CG000183 Rev</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Quick-RNA Micro-Prep Kit</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Zymo</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# R1051</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Super-Script II Reverse Transcriptase</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 18064014</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Agilent RNA 6000 Nano Kit</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Agilent</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# 5067-1511</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">CD14 MicroBeads</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Miltenyi</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# 130-050-201</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Agilent Small RNA Kit</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Agilent</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# 5067-1548</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">SMARTer smRNA-Seq Kit for Illumina</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Takara</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# 635031</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">TruSeq Stranded mRNA</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Illumina</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# 20020594</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Maxpar Direct Immune Profiling Assay</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Fluidigm</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# 201334</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">TruSeq RNA single indexes</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Illumina</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# 20020492</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Superscript II reverse transcriptase</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# 18064022</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Qubit dsDNA HS Assay Kit</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Invitrogen</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# Q32851</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Agilent High Sensitivity DNA Kit</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Agilent</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# 5067-4626</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">pCR<sup>&#x2122;</sup>4-T0P0<sup>&#xAE;</sup> vector</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Invitrogen</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# K457502</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Dual-Luciferase<sup>&#xAE;</sup> Reporter Assay System</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Promega</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# E1910</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Qiagen blood mini kit</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Qiagen</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# 51104</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Lipofectamine 2000</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# 11668019</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">SureSelect Human All Exon 50 Mb kit</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Agilent Technologies</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# 5190-6213</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Big Dye Terminator v3.1 cycle sequencing kit</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Applied Biosystems</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# 4337455</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">iPrep PureLink gDNA Blood Kit and iPrep Instruments</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Life Technologies, Thermo Fisher Scientific</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 10552894</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">TaqMan Fast Universal PCR Master Mix (2X), no AmpErase UNG</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# 4352042</td>
          </tr>
          <tr>
            <td colspan="3" align="left" valign="top" rowspan="1">Deposited data</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">RNA-seq, single-cell RNA-seq, and RIBO-seq</td>
            <td align="left" valign="top" rowspan="1" colspan="1">SRA</td>
            <td align="left" valign="top" rowspan="1" colspan="1">PRJNA1004232</td>
          </tr>
          <tr>
            <td colspan="3" align="left" valign="top" rowspan="1">Experimental models: Cell lines</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">HEK293T cells</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">ATCC</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# CRL-11268, RRID:CVCL_1926</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">HEK-Blue IL-23 sensitive cells</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Invivogen</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat# hkb-il23</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">HeLa Cells</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">ATCC</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cat# CRM-CCL-2, RRID:CVCL_0030</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">THP1 WT Cells</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">ATCC</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">ATCC Cat# TIB-202, RRID:CVCL_0006</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">THP1 MCTS1 KO Cells</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">This manuscript</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cos-7</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">ATCC</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">ATCC Cat# CRL-1651, RRID:CVCL_0224</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">HT1080</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">ATCC</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">ATCC Cat# CCL-121, RRID:CVCL_0317</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">&#x3B3;2A- fibrosarcoma cells</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Boisson-Dupuis et al. PMID: 30578352</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td colspan="3" align="left" valign="bottom" rowspan="1">Experimental models: Organisms/strains</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">NA</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">NA</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td colspan="3" align="left" valign="top" rowspan="1">Oligonucleotides</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1 Exon2+3 Exon trapping Forward</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">gatc gaattcCTCATATTCCTCCCCCTAACC</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1 Exon2+3 Exon trapping Reverse</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">gatc ggatccCCCATTGTATTCTCAGCACC</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Exon Trapping SPL3_MCTS1_Locus Sequencing primer</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">aattggttgtagcaggtaata</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1 Site directed mutagenesis of P3 splicing variant forward</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">CCTGTCAAAATAGTCCGATGgtctttgtttttgtctgtgt</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1 Site directed mutagenesis of P3 splicing variant forward</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">acacagacaaaaacaaagacCATCGGACTATTTTGACAGG</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1 sgRNA1 F</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">CACCGGCCTGGGAAGGATACAACAA</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1 sgRNA1 R</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">AAACTTGTTGTATCCTTCCCAGGC C</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">JAK2 Cloning primer F BamH1</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">GAGAACCCTGGACCTatgggaatggcctgccttacg</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">JAK2 Cloning primer R Xho1</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">TTTTCTAGGTCTCGAtcatccagccatgttatccc</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_1-1F</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">ggcaacctccaacttttattttg</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_1-1R</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">tgagacaagatcgtgccact</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_2-1F</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">tgtgtaccctgaatcttgactt</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_2-1R</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">gcctcctgagttcaagcaat</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_3-1F</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">ctgctaggtctctgctctca</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_3-1R</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">ggcacatgggttcttttcagt</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_4-1F</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">ctgcacctggtcattactgc</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_4-1R</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">gcccaagtgcattccttctg</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_5-1F</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">ctcaattatttctccccacccc</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_5-1R</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">ttgggaggctgatcacttga</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_6-1F</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">gggacatggacctgctttag</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_6-1R</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">cttcctttgctcatacctgtgt</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_7-1F</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">agactgcctatggagtattagca</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_7-1R</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">agacacactgcctgagagaa</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_8-1F</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">tgggtagtcatgaacatttcca</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_8-1R</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">tgatctcgtggagttgtggt</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_9-1F</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">tgttctcagaactctaccacct</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_9-1R</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">tccagactaagacgtgcataca</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_10-1F</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">tcctcattagcttctgggtgt</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_10-1R</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">ccttccctcttactcatctgga</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_11-1F</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">agtcactttcaagccaggtg</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_11-1R</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">ctcccgggttcatgccac</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_12-1F</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">aagtcatgcaaggagatggc</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_12-1R</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">cctcggtctctcaaagtgct</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_13-1F</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">gtctgtcactcattaaaggcagt</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_13-1R</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">gcacggtcttggctcacc</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_14-1F</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">gtgcatcaaagtcagcccat</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_14-1R</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">gggtgttcttaaagcagggc</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_15-1F</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">tcatgagtggggttagggtt</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_15-1R</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">gtttcgctcttgttgccca</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_16-1F</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">acactctatgcggactcaca</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_16-1R</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">gcacaatctcggctcactg</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_17-1F</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">tggaacttggggaggcttag</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_17-1R</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">tgcatgtgatgatgtatgggg</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_1-1F</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">ggcaacctccaacttttattttg</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1_EXON5+6_P5,7_1-1R</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">tgagacaagatcgtgccact</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1 exon2 genomic locus for knockout forward</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">GACATTGGTTTTGTGCTGGACAGA</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">MCTS1 exon2 genomic locus for knockout reverse</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">ACCGAGCTTTACACAGACAAAAACA</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cloning-MCTS2 F (BamH1 EcoR1 digest)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">TTGGTACCGAGCTCGGACCTATGTTCAAGAAGTTT</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cloning MCTS2 R( BamH1 EcoR1 digest)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">ATGGATATCTGCAGAATCATTTATATGTCTTCATG</td>
          </tr>
          <tr>
            <td colspan="3" align="left" valign="top" rowspan="1">Recombinant DNA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">pCDNA3.1 EV</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher</td>
            <td align="left" valign="top" rowspan="1" colspan="1">V79020</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">pCDNA3.1 MCTS1</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">pcDNA3.1 MCTS1 P77AFs</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">pCDNA3.1 MCTS1 R72*</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">pCDNA3.1 MCTS1 K4-C55</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">pCDNA3.1 MCTS1 A133-K181</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">pCDNA3.1 MCTS1 A109D</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">pCDNA3.1 MCTS1 G24C</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">pCDNA3.1 MCTS1 I30M</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">pCDNA3.1 MCTS1 E37D</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">pCDNA3.1 MCTS1 K46R</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">pCDNA3.1 MCTS1 C55S</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">pCDNA3.1 MCTS1 R72K</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">pCDNA3.1 MCTS1 R83K</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">pCDNA3.1 MCTS1 I102V</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">pCDNA3.1 MCTS1 S107G</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">pCDNA3.1 MCTS1 P119S</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">pCDNA3.1 MCTS1 E137K</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">pCDNA3.1 MCTS1 Q140P</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">pCDNA3.1 MCTS1 A142T</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">pCDNA3.1 MCTS1 D154H</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">IFNG 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">IL12A-1 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">IL12A-2 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">IL12B-1 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">IL12B-2 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">IL23A-1 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">ISG15 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">IFNGR1-1 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">IFNGR2-1 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">IFNGR2-2 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">IFNGR2-3 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">IL12RB1-1 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">IL12RB1-2 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">IL12RB2-1 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">IL12RB2-2 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">IL12RB2-3 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">IL23R 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">CD40-1 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">CD40-2 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">CD40LG-1 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">CD40LG-2 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">ITGB2-2 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">ITGB2-3 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">PDCD1 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">JAK1-2 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">JAK1-3 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">JAK2-1 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">TYK2-1 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">TYK2-2 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">TYK2-3 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">IRF1-1 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">IRF1-2 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">IRF4 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">IRF8-1 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">STAT1-1 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">STAT1-2 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">STAT1-3 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">ZNFX1-1 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">ZNFX1-2 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">ZNFX1-3 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">REL-1 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">REL-2 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">RORC-1 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">RORC-2 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">CYBB-1 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">IKBKG-1 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">IKBKG-2 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">SPPL2A-1 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">TKB21-1 5&#x2019;UTR Reporter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This Manuscript</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td colspan="3" align="left" valign="bottom" rowspan="1">
<bold>Software and algorithms</bold>
</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">R</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">The R Project for Statistical Computing</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">
<ext-link xlink:href="https://www.r-project.org" ext-link-type="uri">https://www.r-project.org</ext-link>
</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Custom software for sequencing analysis</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Aurelio Teleman (github)</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">
<ext-link xlink:href="https://github.com/aurelioteleman/Teleman-Lab" ext-link-type="uri">https://github.com/aurelioteleman/Teleman-Lab</ext-link>
</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Uni-form Mani-fold Approximation and Projection (UMAP)</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Becht et al. (PMID 30531897)</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">v.0.3.5</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Burrows-Wheeler aligner</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Li et al. PMID: 19451168</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">V0.7.12</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">GATK</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Van der Auwera, G. &amp; O&#x2019;Connor, B. Genomics in the Cloud: Using Docker, GATK, and WDL in Terra (1st Edition). (O&#x2019;Reilly Media, 2020).</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">VEP (Variant Effect Predictor, Ensemble 37)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Wang et al. PMID: 20601685</td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">SnpEff-4.1a tools</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cingolani et al. PMID: 22728672</td>
            <td align="left" valign="top" rowspan="1" colspan="1">V4.1a</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Fastqc</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Babraham Bioinformatics</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<ext-link xlink:href="https://www.bioinformatics.babraham.ac.uk/projects/fastqc/" ext-link-type="uri">https://www.bioinformatics.babraham.ac.uk/projects/fastqc/</ext-link>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Cutadapt</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet.journal 17, 10&#x2013;12 (2011).</td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Bowtie 2</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Langmead &amp; Salzberg PMID: 22388286</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Version 2</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">SAMtools</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Li et al. PMID: 19505943</td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">BEDtools</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Quinlan &amp; Hall PMID: 20110278</td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">BBmap</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<ext-link xlink:href="http://sourceforge.net/projects/bbmap/" ext-link-type="uri">sourceforge.net/projects/bbmap/</ext-link>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">DESeq2</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Love et al., 2014 PMID: 25516281</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<ext-link xlink:href="https://bioconductor.org/packages/release/bioc/html/DESeq2.html" ext-link-type="uri">https://bioconductor.org/packages/release/bioc/html/DESeq2.html</ext-link>
</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Cell Ranger</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">10X Genomics</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">
<ext-link xlink:href="https://support.10xgenomics.com/single-cell-gene-expression/software/pipelines/latest/what-is-cell-ranger" ext-link-type="uri">https://support.10xgenomics.com/single-cell-gene-expression/software/pipelines/latest/what-is-cell-ranger</ext-link>
</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">STAR (2.6.1d)</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Dobin et al. PMID: 23104886</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">
<ext-link xlink:href="https://github.com/alexdobin/STAR" ext-link-type="uri">https://github.com/alexdobin/STAR</ext-link>
</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Seurat R package</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Stuart et al., 2019 PMID: 31178118</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">
<ext-link xlink:href="https://cran.r-project.org/web/packages/Seurat/index.html" ext-link-type="uri">https://cran.r-project.org/web/packages/Seurat/index.html</ext-link>
</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Uniform Manifold Approximation and Projection (UMAP)</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Becht et al., 2018 PMID: 30531897</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">
<ext-link xlink:href="https://cran.r-project.org/web/packages/uwot/index.html" ext-link-type="uri">https://cran.r-project.org/web/packages/uwot/index.html</ext-link>
</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">SingleCellExperiment</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1"/>
            <td align="justify" valign="bottom" rowspan="1" colspan="1">
<ext-link xlink:href="https://bioconductor.org/packages/release/bioc/html/SingleCellExperiment.html" ext-link-type="uri">https://bioconductor.org/packages/release/bioc/html/SingleCellExperiment.html</ext-link>
</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">SingleR</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1"/>
            <td align="left" valign="bottom" rowspan="1" colspan="1">
<ext-link xlink:href="https://bioconductor.org/packages/release/bioc/html/SingleR.html" ext-link-type="uri">https://bioconductor.org/packages/release/bioc/html/SingleR.html</ext-link>
</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">muscat</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Crowell et al. PMID: 33257685</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1"><ext-link xlink:href="https://bioconductor.org/packages/release/bioc/html/muscat.html" ext-link-type="uri">https://bioconductor.org/packages/release/bioc/html/muscat.html)</ext-link>)</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">PLINK</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Purcell et al. PMID: 17701901</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">logistf</td>
            <td align="left" valign="bottom" rowspan="1" colspan="1"/>
            <td align="left" valign="bottom" rowspan="1" colspan="1">
<ext-link xlink:href="https://cran.r-project.org/web/packages/logistf/index.html" ext-link-type="uri">https://cran.r-project.org/web/packages/logistf/index.html</ext-link>
</td>
          </tr>
          <tr>
            <td colspan="3" align="left" valign="top" rowspan="1">
<bold>Other</bold>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <boxed-text id="BX1" position="float">
      <caption>
        <title>Highlights</title>
      </caption>
      <list list-type="bullet" id="L2">
        <list-item>
          <p id="P99">X-linked recessive complete human MCTS1 deficiency underlies mycobacterial disease</p>
        </list-item>
        <list-item>
          <p id="P100">A lack of MCTS1 inhibits JAK2 translation by impairing ribosome recycling at two uORFs</p>
        </list-item>
        <list-item>
          <p id="P101">Decreases in JAK2 protein levels impair the responses of NK and T lymphocytes to IL-23</p>
        </list-item>
        <list-item>
          <p id="P102">Innate-like T cells from patients produce low levels of IFN-&#x3B3; upon IL-23 stimulation</p>
        </list-item>
      </list>
    </boxed-text>
  </floats-group>
</article>
</pmc-articleset>